

FOR OFFICIAL USE ONLY

U.S. DEPARTMENT OF COMMERCE
Patent and Trademark Office19 16
SEARCH REQUEST FORM

Examiner # (Mandatory): _____ Requester's Full Name: _____

Art Unit _____ Location (Bldg/Room#): 10 D 11 Phone (circle 305 306 308) _____

Serial Number: _____ Results Format Preferred (circle): PAPER DISK E-MAIL

Title of Invention _____

Inventors (please provide full names): _____

Earliest Priority Date: _____

Keywords (include any known synonyms registry numbers, explanation of initialisms): _____

Search Topic:

Please write detailed statement of the search topic, and the concept of the invention. Describe as specifically as possible the subject matter to be searched. Define any terms that may have a special meaning. Give examples of relevant citations, authors, etc., if known. You may include a copy of the abstract and the broadcast or most relevant claim(s).

STAFF USE ONLYSearcher: StephensonSearcher Phone #: 305-4449

Searcher Location: _____

Date Picked Up: _____

Date Completed: 9/22/95

Clerical Prep Time: _____

Terminal Time: _____

Number of Databases: _____

Type of Search

_____ N.A. Sequence

_____ A.A. Sequence

_____ Structure (#)

_____ Bibliographic

_____ Litigation I

_____ Fulltext

_____ Procurement

_____ Other

Vendors (include cost where applicable)

_____ STN

_____ Questel/Orbit

_____ Lexis/Nexis

_____ WWW/Internet

_____ In-house sequence systems (list)

_____ Dialog

_____ Dr. Link

_____ Westlaw

_____ Other (specify)

file copy

Best Available Copy

* 8316	8332:	gap of unknown length
* 8333	10032:	contig of 1700 bp in length
* 10033	10049:	gap of unknown length
* 10050	11755:	contig of 1706 bp in length
* 11756	11772:	gap of unknown length
* 11773	20315:	contig of 8543 bp in length
* 20316	20332:	gap of unknown length
* 20333	38250:	contig of 17918 bp in length
* 38251	38267:	gap of unknown length
* 38268	115442:	contig of 77175 bp in length
* 115443	115459:	gap of unknown length
* 115460	198605:	contig of 83146 bp in length.
Location/Qualifiers		
1..198605		
/organism="Homo sapiens"		
/db_xref="taxon:9606"		
/clone="DJ400N23"		
BASE COUNT	53938 a	46957 c 46811 g 50746 t 153 others
ORIGIN		
Query Match	68.3%;	Score 1590; DB 19; Length 198605;
Best Local Similarity	99.7%;	Pred. No. 0.00e+00;
Matches 1605; Conservative	0;	Mismatches 3; Indels 2; Gaps 2;
Db	125463	TATAGAGAAATGCCCTTTATAGAAAAGTAGAAACCAACGATTAATATTCTTCTTCAGCATCAC 125522
Cp	2316	TATAGAGAAATGCCCTTTATAGAAAAGTAGAAACCAACGATTAATATTCTTCTCAGCATCAC 2257
Db	125523	TAAACCAAGAGACCACCTGAGGTCTAGTCCCAAAGCAGATGCTCCATAGAAGCCC 125582
Cp	2256	TAAACCAAGAGACCACCTGAGGTCTAGTCCCAAAGCAGATGCTCCATAGAAGCCC 2197
Db	125583	CACTAACCCCTGCTCCACATTGGCAGTGGAAGGGTCTCGAAAGGAGCTCTATGGCT 125642
Cp	2196	CACTAACCCCTGCTCCACATTGGGCAGTGGGAAGGGTCTCGAAGGAGCTCTATGGCT 2137
Db	125643	AGGAGTGCCAAGGCTCTTGAGTGTGACATCACAGGTTAGAGGCCCTGCTGAGCTGCTA 125702
Cp	2136	AGGAGTGCCAAGGCTCTTGAGTGTGACATCACAGGTTAGAGGCCCTGCTGAGCTGCTA 2077
Db	125703	GCACAGTCAGTGGAGAAATGTTGGCTCCGTCAGGAAGCTGGGCTCTTGCCATGCCAGT 125762
Cp	2076	GCACAGTCAGTGGAGAAATGTTGGCTCCGTCAGGAAGCTGGGCTCTTGCCATGCCAGT 2017
Db	125763	AGCTTGCTTACGACCTTGGGCAAGTCACATTTTTCTCTCTGGGGTCTCTGTGCCAAAAGG 125822
Cp	2016	AGCTTGCTTACGACCTTGGGCAAGTCACATTTTTCTCTCTGGGGTCTCTGTGCCAAAAGG 1957
Db	125823	CTTAATGAGCCCTTTCTAATGGTCTTTTGATTGCTTTATGAGTTAGGGCTGTGACCCTA 125882
Cp	1956	CTTAATGAGCCCTTTCTAATGGTCTTTTGATTGCTTTATGAGTTAGGGCTGTGACCCTA 1897
Db	125883	GCCCCAGTGCCTTACAGGAAGTGTGACCTGGACGCCGAGGACCACCTGCTAAATCA 125942
Cp	1896	GCCCCAGTGCCTTACAGGAAGTGTGACCTGGACGCCGCGAG - ACCACTGCTAAATCA 1838
Db	125943	GGCCCACTGGGGAGCAAGCCCTGAAGTGCCTTTATFACCTTGCCTGAGCTTAGTTTCC 126002
Cp	1837	GGCCCACTGGGGAGCAAGCCCTGAAGTGCCTTTATFACCTTGCCTGAGCTTAGTTTCC 1778
Db	126003	AGGTAGCCTTTAGGAAGCAGCTCAAGAGCCCCACAGTATAATTCCTATAGTTAGCTA 126062
Cp	1777	AGGTAGCCTTTAGGAAGCAGCTCAAGAGCCCCACAGTATAATTCCTATAGTTAGCTA 1718
Db	126063	ACTACTCTCTTACTGTGCAAAATGAAGACAGGTCACTATCCATCCCTGAAGAGAACTG 126122
Cp	1717	ACTACTCTCTTACTGTGCAAAATGAAGACAGGTCACTATCCATCCCTGAAGAGAACTG 1658
Db	126123	GGGCATCCCAAGTCTGCCTCTGCTGTGGCCAAAGGGGAGCAGATCCTTCTCTATCC 126182
Cp	1657	GGGCATCCCAAGTCTGCCTCTGCTGTGGCCAAAGGGGAGCAGATCCTTCTCTATCC 1598
126183	TCCTTCCTAAGTGGAAATGCTCAGTCGAAATCTCTCTTATTAAGAACAGGAAGTCC 126242	

AUTHORS Du,Z, Scheet,P and Harper,M.
TITLE The sequence of H. sapiens PAC clone DJ515N1
JOURNAL Unpublished (1997)
REFERENCE 2 (bases 1 to 128978)
AUTHORS Waterston,R.
TITLE Direct Submission
JOURNAL Submitted (12-MAY-1997)
COMMENT SUBMITTED BY: Genome Sequencing Center
Department of Genetics
Washington University
St. Louis MO 63108, USA
http://genome.wustl.edu/gsc
mailto:sapiens@watson.wustl.edu

NOTICE: This sequence may not represent the entire insert of this clone. It may be shorter because we only sequence overlapping clone sections once, or longer because we provide a small overlap between neighboring data submissions.

This sequence was finished as follows unless otherwise noted: all regions were double stranded or sequenced with an alternate chemistry; an attempt was made to resolve all sequencing problems, such as compressions and repeats; all regions were covered by sequence from more than one subclone; and the assembly was confirmed by restriction digest.

MAPPING INFORMATION:

This sequence was generated from part of bacterial clone contigs of human chromosome 22, constructed by the Sanger Centre chromosome 22 mapping group. Further information can be found at <http://www.sanger.ac.uk/HGP/Chr22/>

SOURCE INFORMATION:

This clone was derived from human PAC library RPCI-3 prepared by Pieter de Jong and coworkers at Roswell Park Cancer Institute, using the method described by Ioannou et al., Nature Genetics 6:84-9 (1994). The library is from one male donor. For further details, see <http://bacpac.med.buffalo.edu/>. The clone is available from Genome Systems, Inc. (<http://www.genomesystems.com>). VECTOR: pCVPAC2

NEIGHBORING SEQUENCE INFORMATION:

The clone sequenced to the left is H_DJ400N23; the clone sequenced to the right is H_DJ412A9. Actual start of this clone is at base position 1 of H_DJ515N1.

This clone contains STS WI-12936 (NID:g1344756) and A006121 (NID:g1341182).

FEATURES

source

Location/Qualifiers
1..128978
/organism="Homo sapiens"
/db_xref="taxon:9606"
/chromosome="22"
/clone="DJ515N1"
/clone_lib="RPCI-3"
/map="22q11.2-q22"
7..131
/rpt_family="L1"
223..526
/rpt_family="ALU"
528..944
/rpt_family="L1"
989..1266
/rpt_family="ALU"
1485..1576
/rpt_family="L1"
complement(1599..1626)
/rpt_family="MER"
1620..1939
/rpt_family="MER"
complement(1959..2201)
/rpt_family="MER"

repeat_region complement(3813..3101)
/rpt_family="ALU"
repeat_region complement(3383..3639)
/rpt_family="ALU"
repeat_region 5560..5648
/rpt_family="ALU"
repeat_region complement(6859..7148)
/rpt_family="ALU"
repeat_region 8165..8447
/rpt_family="ALU"
repeat_region complement(8453..8742)
/rpt_family="ALU"
repeat_region 9147..9438
/rpt_family="ALU"
repeat_region 11741..12034
/rpt_family="ALU"
repeat_region complement(12037..12313)
/rpt_family="ALU"
repeat_region 12643..12925
/rpt_family="ALU"
repeat_region 13532..13693
/rpt_family="ALU"
repeat_region 13889..14009
/rpt_family="ALU"
misc_feature 14446..14613
/note="match to human EST AAL22029 (NID:g1678048)
zm25f10.r1"
misc_feature 14452..14613
/note="match to human EST D31562 (NID:g644442)"
gene 14543..23803
/gene="WUGSC:DJ515N1.2"
CDS join(14543..14612,15591..15707,15803..15922,17188..17388,
17494..17572,23599..23803)
/gene="WUGSC:DJ515N1.2"
/note="Putative gene. Genscan predictions confirmed by EST
splicing: coded for by human CDNAS AAL22029
(NID:g1678048), D31562 (NID:g644442), AAL158721
(NID:g1733515), RS9640 (NID:g830335) and F13082
(NID:g709111)."
/codon_start=1
/protein_id="AAB54054.1"
/db_xref="PID:g2078470"
/db_xref="GI:2078470"
/translation="MLLAWQAFIVNMLLAAYGSGCFWNGHLYREDOTSPAPGL
RCNLWLDQAQSLASAPVSGAGNSYCRNPDEDPGWCYVSGAGVPEKPCEDLRCP
ETTSQALPFTTEIOEASEGDEVOVFAPANLPARSEAAVOPVIGISQVRMNS
KEKDLGTLGVLTGMVILIIAGILIGISTKRGKLEQHDQKVCEREMQRTIL
PLSAFTNPCEIVDEKTVVVTQTPVDPQEGTTPLMGQAGTFGA"
misc_feature 14544..14613
/gene="WUGSC:DJ515N1.2"
/note="match to human EST AAL158721 (NID:g1733515)
zo78g11.r1"
misc_feature 15589..15641
/gene="WUGSC:DJ515N1.2"
/note="match to human EST D31562 (NID:g644442)"
misc_feature 15589..15708
/gene="WUGSC:DJ515N1.2"
/note="match to human EST AAL158721 (NID:g1733515)
zo78g11.r1"
misc_feature 15589..15706
/gene="WUGSC:DJ515N1.2"
/note="match to human EST AAL22029 (NID:g1678048)
zm25f10.r1"
repeat_region complement(16489..16778)
/rpt_family="ALU"
repeat_region complement(18503..18758)
/rpt_family="ALU"
repeat_region 19258..19548
/rpt_family="ALU"
repeat_region 19569..19858
/rpt_family="ALU"
repeat_region complement(20735..20996)
/rpt_family="ALU"

```

repeat_region 22684..22975
/rpt_family="ALU"
repeat_region 23163..23289
/rpt_family="ALU"
misc_feature 23942..24240
/note="match to human EST 244818 (NID:g573984)"
complement(25449..25740)
/rpt_family="ALU"
complement(28446..58170)
/gene="LIMK-2"
complement(28446..94478)
/gene="LIMK-2"
complement(join(28446..28590,31579..31736,33380..33435,
34183..34357,35686..35751,36687..38743,38980..39111,
39817..39903,40755..40941,44096..44292,44648..44753,
46810..46998,47657..47766,48461..48596,81068..81167,
94463..94478))
/gene="LIMK-2"
/note="DJ515N1.1b; match to D45906 (NID:g1136921); coded
for by human cDNA D45906 (NID:g1805593)"
/codon_start=1
/product="Lim Kinase"
/protein_id="AAB54056.1"
/db_xref="PIR:g2078472"
/db_xref="GI:2078472"
/translation="MSALAGEDVRCPCGDHIAIPSOIWIYVTHWGSFCRSECO
DSLNIWYKDGKLYCPKDYKGFGEFCHGCSLLMTGPFVAGFKYHPECFACMSCK
VIEEDGAYALVQHATYCYGKNEVLAPEFLRSTESVOELPYSVTLISMPEATTE
GRGFSVSSEACSNYATTVQVKEVNRHISPNNRNATHPGDRILEINGTVPRTLRVE
EVEDAISOTLOLLIHDHPVSORLDQRLREARLHPMGNAGHPHALSTLDTKLE
GTLRRSLRRSNSISKSPSPKPELIFSRSLSRSCSSYSQOIFRPNCLIHG
EVLGKFGGQAIKVTHTKATKVYMKELIRDEDETKFTLEVKVMSLHPNVLKFI
GLYKDKKLNLLEYIEGGLKDFLRSMDPPFMOOKVRFKFIAGSMAYLHSMCIIR
DLNSHNLKILKDTVYVDFGLSRLIYEKRRKPMKATTKKRLKNDKRRKTVVG
NPTWAPMUNGSKSYDETVIDFSFIVLCRIIGOVYADPLCLRLDFGLNVLFWFK
FVPTDCPPAPFPFLAAICCRPEPSPAFSKLESFELSFLYLGLPFLPAELFELDH
TVSNQGLTRDSDP"
complement(join(28446..28590,29751..30098,31579..31736,
33380..33435,34183..34357,35686..35751,36687..38743,
39880..39911,39817..39903,40755..40941,44096..44292,
44648..44753,46810..46998,47657..47766,48461..48596,
58118..58170))

```

... Note: remainder of annotations omitted.

```

Query Match 67.7%; Score 1576; DB 30; Length 128978;
Best Local Similarity 99.6%; Pred. No. 0.00e+00;
Matches 1603; Conservative 0; Mismatches 3; Indels 4; Gaps 3;

```

Db	23597	AGGGGAAGGATTGAAACACAGCATGATCAGAAAGTATGTGAGAGGGAGATGCAGCGA	23656
QY	709	AGGGGAAGGATTGAAACACAGCATGATCAGAAAGTATGTGAGAGGGAGATGCAGCGA	768
Db	23657	ATCACTGCCCCTGTCTGCCCTTACCACCCACCTGTGAGATTGTGGATGAGAAGACT	23716
QY	769	ATCACTGCCCCTGTCTGCCCTTACCACCCACCTGTGAGATTGTGGATGAGAAGACT	828
Db	23717	GTCGTGTCCACACAGCAGCAGCTCCAGTTCACCTCTAGGAGGGCACCACCCCTTATG	23776
QY	829	GTCGTGTCCACACAGCAGCAGCTCCAGTTCACCTCTAGGAGGGCACCACCCCTTATG	888
Db	23777	GGCCAGGCGGGACTCTCTGGGCTTGAGCCGCCCTGAGGAGGGCAGACCCCTTATG	23836
QY	889	GGCCAGGCGGGACTCTCTGGGCTTGAGCCGCCCTGAGGAGGGCAGACCCCTTATG	948
Db	23837	TGTCAGGAGCAGCCACCTCTACAGCTAGGAGGAACCTACCACTTTGTCTGGTTA	23896
QY	949	TGTCAGGAGCAGCCACCTCTACAGCTAGGAGGAACCTACCACTTTGTCTGGTTA	1008
Db	23897	AAACCCATACCTCCCGCTTTTGGCGAATCCTAGTAGAGTGACAGAGCAGGTGG	23956
QY	1009	AAACCCATACCTCCCGCTTTTGGCGAATCCTAGTAGAGTGACAGAGCAGGTGG	1068
Db	23957	CCCTGTGGCTGAGGGTAAGGCTAGGCTCTTAACAGTCTCTTGTCCATCCCTTG	24016
QY	1069	CCCTGTGGCTGAGGGTAAGGCTAGGCTCTTAACAGTCTCTTGTCCATCCCTTG	1128
Db	24017	GAGCAGATTTTGTCTGTGGATGGAGACAGTGGCAGCTCCACAGTGTGCTGCTTAAG	24076
QY	1129	GAGCAGATTTTGTCTGTGGATGGAGACAGTGGCAGCTCCACAGTGTGCTGCTTAAG	1188
Db	24077	GGCTTCCAAACATTTGCTGCACCCCTGGAACCTGAACAGGGATAGAGGGAGCTCCCC	24136
QY	1189	GGCTTCCAAACATTTGCTGCACCCCTGGAACCTGAACAGGGATAGAGGGAGCTCCCC	1248
Db	24137	AGGCTCTCTGTCTTACTAAGATGGCTCAGTCTCCACTGTGGGCTTGAGTGGCATAC	24196
QY	1249	AGGCTCTCTGTCTTACTAAGATGGCTCAGTCTCCACTGTGGGCTTGAGTGGCATAC	1307
Db	24197	ACTGTTATTCATGGTTAAGTAAGCAGGTCAAGGGATGGCATTTGAAAATAATATTAG	24256
QY	1308	ACTGTTATTCATGGTTAAGTAAGCAGGTCAAGGGATGGCATTTGAAAATAATATTAG	1367
Db	24257	TTTTTAAATATTTGGGATGGAACTCCCTACTGACCTCTGACAACCTGGAACGAGTTGT	24316
QY	1368	TTTTTAAATATTTGGGATGGAACTCCCTACTGACCTCTGACAACCTGGAACGAGTTGT	1427
Db	24317	ACAGAAGTCAGAACTTTGGGTTGGGAATGAGATCTAGTTGTGGCTGTGCTTCTCA	24376
QY	1428	ACTGAAGTCAGAACTTTGGGTTGGGAATGAGATCTAGTTGTGGCTGTGCTTCTCA	1487
Db	24377	GCTTCTGGCAATGATGCTTGTGACACCTGGGCCAGGCTGGGCCAGGAGCTCTTC	24436
QY	1488	GCTTCTGGCAATGATGCTTGTGACACCTGGGCCAGGCTGGGCCAGGAGCTCTTC	1547
Db	24437	CTGTTTCAATAAGGAAGAAATTTGACTGAGCATTCCTTAGGAAGAGATAGAGAA	24496
QY	1548	CTGTTTCAATAAGGAAGAAATTTGACTGAGCATTCCTTAGGAAGAGATAGAGAA	1607
Db	24497	GGATCTGCTCGCCCTTTGGCCACAGGAGCAGACCTGGATGGATGCCAGTTCTCT	24556
QY	1608	GGATCTGCTCGCCCTTTGGCCACAGGAGCAGACCTGGATGGATGCCAGTTCTCT	1667
Db	24557	TCAGGGATGATGATGACCTGTCTTCAATTTGCACAGTAAAGAGATAGTAACT	24616
QY	1668	TCAGGGATGATGATGACCTGTCTTCAATTTGCACAGTAAAGAGATAGTAACT	1727
Db	24617	ATGGGAATATATCTGTGGGCTTGTGAGCTGCTTCAAGAGGCTAACCTGGAACCTAG	24676
QY	1728	ATGGGAATATATCTGTGGGCTTGTGAGCTGCTTCAAGAGGCTAACCTGGAACCTAG	1787
Db	24677	CTCAGAGCAAGGTAATAAGCACTTCAGGGCTTGCTCCCCAAGTGGGCTGATTAGCA	24736
QY	1788	CTCAGAGCAAGGTAATAAGCACTTCAGGGCTTGCTCCCCAAGTGGGCTGATTAGCA	1847
Db	24737	GCTGTCTGCGGGCTTCAGGTCAGACCTTCTGTAGGGCCTGGGGCTAGGGTCACA	24796
QY	1848	GCTGTCTGCGGGCTTCAGGTCAGACCTTCTGTAGGGCCTGGGGCTAGGGTCACA	1906
Db	24797	GCCCTTACTCATAAAGCAATCAAGAACCACTTAAAGAGGCTCATTAAGGCTTTGGAC	24856
QY	1907	GCCCTTACTCATAAAGCAATCAAGAACCACTTAAAGAGGCTCATTAAGGCTTTGGAC	1966
Db	24857	ACAGACCCAGAGAGGAAAGTACTTGCCCAAGGTTCGTAAGCAAGCTACTGGCATGG	24916
QY	1967	ACAGACCCAGAGAGGAAAGTACTTGCCCAAGGTTCGTAAGCAAGCTACTGGCATGG	2026
Db	24917	CAAGAGCCAGCTTCTTCAGGAGCGCAACATTTCTCCACTGCACCTGCTAGCAGTCA	24976
QY	2027	CAAGAGCCAGCTTCTTCAGGAGCGCAACATTTCTCCACTGCACCTGCTAGCAGTCA	2086
Db	24977	GCAGGGCTCTAACCTGTGATGTCACACTCAAGAGGCTGGGAGCTCTAGGCATAGAG	25036
QY	2087	GCAGGGCTCTAACCTGTGATGTCACACTCAAGAGGCTGGGAGCTCTAGGCATAGAG	2146
Db	25037	CTTCTTTTCCAGAACCTTCCACTGCCCCAATGTGGAGAC--GGGTAGTGGGGCTTCTA	25094

||||| 2147 CTTCCTTCCAGAACCTTCCACATGTCACATGTCGAGACAGGGGTAGTGGGGCTTTCTA 2206
Db 25095 TGGAGCATCTGCTTTGGGACCTAGACCTCAGGTGGTCTCTTGGTGTAGTGTGCTGG 25154
QY 2207 TGGAGCATCTGCTTTGGGACCTAGACCTCAGGTGGTCTCTTGGTGTAGTGTGCTGG 2266
Db 25155 AGAAGAGAAATTAATCTGCTTCTACTTTCTATATAAGGCAATTTCTCTATA 25204
QY 2267 AGAAGAGAAATTAATCTGCTTCTACTTTCTATATAAGGCAATTTCTCTATA 2316

3
RESULT AC005478 150140 bp DNA HTG 14-AUG-1998
LOCUS Homo sapiens clone DJ0425102, WORKING DRAFT SEQUENCE, 5 unordered
DEFINITION pieces.
ACCESSION AC005478
NID 93419864
VERSION AC005478.1 GI:3419864
KEYWORDS HTG; HTGS_PHASE1.
SOURCE human.
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Vertebrata; Mammalia; Eutheria;
Primates; Catarrhini; Homnidae; Homo.
REFERENCE Waterston, R.H.
AUTHORS The sequence of Homo sapiens clone
TITLE Unpublished
JOURNAL 2 (bases 1 to 150140)
REFERENCE Waterston, R.H.
AUTHORS Direct Submission
TITLE Submitted (14-AUG-1998) Genome Sequencing Center, Washington
JOURNAL University School of Medicine, 4444 Forest Park Parkway, St. Louis,
MO 63108, USA

COMMENT
* NOTE: This is a 'working draft' sequence. It currently
* consists of 5 contigs. The true order of the pieces
* is not known and their order in this sequence record is
* arbitrary. Gaps between the contigs are represented as
* runs of N, but the exact sizes of the gaps are unknown.
* This record will be updated with the finished sequence
* as soon as it is available and the accession number will
* be preserved.
* 1 1987: contig of 1987 bp in length
* 1988 2005: gap of unknown length
* 2006 4759: contig of 2754 bp in length
* 4760 4777: gap of unknown length
* 4778 12352: contig of 7575 bp in length
* 12353 12370: gap of unknown length
* 12371 46730: contig of 34360 bp in length
* 46731 46748: gap of unknown length
* 46749 150140: contig of 103392 bp in length.

FEATURES
Location/Qualifiers
1..150140
/organism="Homo sapiens"
/db_xref="taxon:9606"
/clone="DJ0425102"

BASE COUNT 38079 a 35586 c 35793 g 40610 t 72 others
ORIGIN

Query Match 67.7% Score 1576; DB 19; Length 150140;
Best Local Similarity 99.6%; Pred. No. 0.00e+00;
Matches 1603; Conservative 0; Mismatches 3; Indels 4; Gaps 3;

Db 76991 TATAGAGAAATGCTTTATAGAAAAGTAGAACACAGTAATTTCTCTCCAGCATCAC 77050
Cp 2316 TATAGAGAAATGCTTTATAGAAAAGTAGAACACAGTAATTTCTCTCCAGCATCAC 2257
Db 77051 TAACACAGAGACCACTGAGGTCTAGTCCCAAGAGAGATGGTCCATAGAAAGCCC 77110
Cp 2256 TAACACAGAGACCACTGAGGTCTAGTCCCAAGAGAGATGGTCCATAGAAAGCCC 2197
Db 77111 CACTAACCC- -GTCCTCACATTTGGGCGAGTGGAGGGTCTTGGAAAGGAGCTCTATGGCT 77168
|||||

Cp 2196 CACTAACCCCTGCTCTCCACATTTGGGCACTGGAGGGTCTTGAAAGGAGCTCTATGGCT 2137
Db 77169 AGGAGCTGCCAAGGCTCTTGGTGTGACATCAGAGGTAGAGGGCTCTGCTGAGCTGCTA 77228
Cp 2136 AGGAGCTGCCAAGGCTCTTGGTGTGACATCAGAGGTAGAGGGCTCTGCTGAGCTGCTA 2077
Db 77229 GCACAGTGCAGTGGAGAAATGTTGGCTCCGTCAGGAAAGTGGGCTTGGCATCCAGT 77288
Cp 2076 GCACAGTGCAGTGGAGAAATGTTGGCTCCGTCAGGAAAGTGGGCTTGGCATCCAGT 2017
Db 77289 AGCTTGCTTACGACCTTGGGCAAGTCACTTTTCTCTCTGGGGTCTCTGTCGAAAGG 77348
Cp 2016 AGCTTGCTTACGACCTTGGGCAAGTCACTTTTCTCTCTGGGGTCTCTGTCGAAAGG 1957
Db 77349 CTTAATGAGCCCTTTCTAATGTTCTTTGATTGCTTTTATGAGTTAGGGCTGTGACCCCTA 77408
Cp 1956 CTTAATGAGCCCTTTCTAATGTTCTTTGATTGCTTTTATGAGTTAGGGCTGTGACCCCTA 1897
Db 77409 GCGGAGTGCCTTACAGGAAGTGTGACCTGGAGCGCCGCGAGGACCACTGCTAAATCA 77468
Cp 1896 GCGGAGTGCCTTACAGGAAGTGTGACCTGGAGCGCCGCGAG - ACCACCTGCTAAATCA 1838
Db 77469 GCGGAGTGCCTTACAGGAAGTGTGACCTGGAGCGCCGCGAGGACCACTGCTAAATCA 77528
Cp 1837 GCGGAGTGCCTTACAGGAAGTGTGACCTGGAGCGCCGCGAG - ACCACCTGCTAAATCA 1778
Db 77529 AGGTAGCTCTTAAAGCAGCTCACAAGGCGCCGCGAGGACCACTGCTAAATCA 77588
Cp 1777 AGGTAGCTCTTAAAGCAGCTCACAAGGCGCCGCGAGGACCACTGCTAAATCA 1718
Db 77589 ACTACTCTTCTTACCTGTGCAAAATGAAGCAGGTCACATCATCCCTGGAAGAAACTG 77648
Cp 1717 ACTACTCTTCTTACCTGTGCAAAATGAAGCAGGTCACATCATCCCTGGAAGAAACTG 1658
Db 77649 GGGCATCCAGGCTGCTGCTCTGCTGTCCTGTCGCAAGGCGGAGCAGATCTCTCTATCC 77708
Cp 1657 GGGCATCCAGGCTGCTGCTCTGCTGTCCTGTCGCAAGGCGGAGCAGATCTCTCTATCC 1598
Db 77709 TCTTCTTAAGTGGAAATGCTCAGTGCATTTCTCTTCTTATGAAAGCAGGAGTCCC 77768
Cp 1597 TCTTCTTAAGTGGAAATGCTCAGTGCATTTCTCTTCTTATGAAAGCAGGAGTCCC 1538
Db 77769 TGGGCCAGGCTGCGCCAGGTTGTCAGGCACATCATTCGCCAGCAGCTGAGGATAC 77828
Cp 1537 TGGGCCAGGCTGCGCCAGGTTGTCAGGCACATCATTCGCCAGCAGCTGAGGATAC 1478
Db 77829 CAGCAGCACAACCTAGATCTCATTCCCAACCCAAAGTTCTGACTTCTGTACAACCTCGT 77888
Cp 1477 CAGCAGCACAACCTAGATCTCATTCCCAACCCAAAGTTCTGACTTCTGACTACAACCTCGT 1418
Db 77889 TCCAGTTCTCAGAGTGCAGTGGAGTTCCATCCCAAAATATTTTAAATAATATAT 77948
Cp 1417 TCCAGTTCTCAGAGTGCAGTGGAGTTCCATCCCAAAATATTTTAAATAATATAT 1358
Db 77949 TTTTTCATGCCATCCCTTACCTGCTTACCTTAACCATGAATAACAGTGTATGCCACT 78008
Cp 1357 TTTTTCATGCCATCCCTTACCTGCTTACCTTAACCATGAATAACAGTGTATGCCACT 1298
Db 78009 CAAGCCACAGTGGAGCTGAGGCTGAGGCTAGTAAAGCAGAGGAGCTGGGGAGCTC 78068
Cp 1297 CAAGCCACAGTGGAGCTGAGGCTAGTAAAGCAGAGGAGCTGGGGAGCTC 1239
Db 78069 CCGGTCTATCCCTGGTTTCACTTCCAGGGGTGAGGCAATTTTGGAGAGCCCTTAGCAGCA 78128
Cp 1238 CCGGTCTATCCCTGGTTTCACTTCCAGGGGTGAGGCAATTTTGGAGAGCCCTTAGCAGCA 1179
Db 78129 GCATCACTGGGAGCTGCCACTGTCTCCATCCACAGACAAAATCTGCTCCAAAGGATGG 78188
Cp 1178 GCATCACTGGGAGCTGCCACTGTCTCCATCCACAGACAAAATCTGCTCCAAAGGATGG 1119
Db 78189 ACAAGGAGCACTCTTAGGAGCCCTTACCCAGCTTACCTCAGCCACAGGCGCCACCTGCTT 78248
Cp 1118 ACAAGGAGCACTCTTAGGAGCCCTTACCCAGCTTACCTCAGCCACAGGCGCCACCTGCTT 1059

Db 78249 CTGCTCTCTTACTAGGATTCGCAAAAGCGGGAGTGGTAGGTTTAAACCAAG 78308
 Cp 1058 CTGCTACTCTTACTAGGATTCGCAAAAGCGGGAGTGGTAGGTTTAAACCAAG 999
 Db 78309 ACAAGTGGTAGTCTCTCTAGTGTAGGAGGTGGGCTCTCTGACACAGTGTCTGCAT 78368
 Cp 998 ACAAGTGGTAGTCTCTCTAGTGTAGGAGGTGGGCTCTCTGACACAGTGTCTGCAT 939
 Db 78369 GGGCTCTGCTCCACTGGGGGGCTCAGGCCAGGAGTCCGGCTGGCCATTAAGGGG 78428
 Cp 938 GGGCTCTGCTCCACTGGGGGGCTCAGGCCAGGAGTCCGGCTGGCCATTAAGGGG 879
 Db 78429 GTGCTGCTCTCTGAGGTCAACTGGAGTGTGGTGGACACGACAGTCTTCTCA 78488
 Cp 878 GTGCTGCTCTCTGAGGTCAACTGGAGTGTGGTGGACACGACAGTCTTCTCA 819
 Db 78489 TCCAAATCTCAGAGTGGGGTGGTGAAGGACAGACAGGACAGTGTCTGCTGCATC 78548
 Cp 818 TCCAAATCTCAGAGTGGGGTGGTGAAGGACAGACAGGACAGTGTCTGCTGCATC 759
 Db 78549 TCCCTCTCACAATCTCTCATCATGCTGTTCTTCAATCCTTCCCTT 78598
 Cp 758 TCCCTCTCACAATCTCTCATCATGCTGTTCTTCAATCCTTCCCTT 709

RESULT 4
 LOCUS G24591 464 bp DNA STS 31-MAY-1996
 DEFINITION human STS WI-14622.
 ACCESSION G24591
 NID G1344917
 VERSION G24591.1 GI:1344917
 KEYWORDS STS sequence; primer; sequence tagged site.
 SOURCE human STSs derived from sequences in dbEST and the Unigene collection.

ORGANISM Homo sapiens
 Eukaryotes; Mitochondrial eukaryotes; Metazoa; Chordata;
 Vertebrata; Euthera; Primates; Catarrhini; Hominoidea; Homo.

REFERENCE 1 (bases 1 to 464)
 AUTHORS Hudson, T.
 TITLE Whitehead Institute/MIT Center for Genome Research; Physically Mapped STS
 JOURNAL Unpublished (1995)

COMMENT Contact: Thomas Hudson
 Whitehead Institute/MIT Center for Genome Research
 9 Cambridge Center, Cambridge MA 02142 USA
 Tel: 617 252 1900
 Fax: 617 252 1902
 Email: thudson@genome.wi.mit.edu

Primer A: CCAGTAATATCTCTCTCTCCAGCA
 Primer B: ACCCTTCCACTGCCAAT
 STS size: 125
 PCR Profile:

Presoak:
 Denaturation:
 Annealing: 56 degrees C
 Polymerization:
 PCR Cycles: 35
 Thermal Cycler:

Protocol:
 Template: 10 ng
 Primer: each 5 pM
 dNTPs: each 4 mM
 Taq Polymerase: 0.025 units/ul
 Total Vol: 20 ul

Buffer:
 MgCl2: 1.5 mM
 KCl: 50 mM
 Tris-HCl: 10 mM

pH: 9.3

Derived from dbEST (genbank accession R59582).

FEATURES
 source
 Location/Qualifiers
 1..464

primer_bind
 primer_bind
 complement(150..167)
 125 nt 3 others

STS
 primer_bind
 primer_bind
 complement(150..167)
 125 nt 3 others

BASE COUNT 109 a 108 c 119 g 125 t
 ORIGIN

Query Match 17.3%; Score 403; DB 34; Length 464;
 Best Local Similarity 96.5%; Pred. No. 0.00e+00;
 Matches 447; Conservative 0; Mismatches 10; Indels 6; Gaps 6;

Db 1 TTTTATTTTATAGAGAAATGCTTTATAGAAAAGTAGAAACAGTAATATCTCTCT 60
 Cp 2326 TTTTATTTTATAGAGAAATGCTTTATAGAAAAGTAGAAACAGTAATATCTCTCT 2367

Db 61 CCAGCATCCTACACCAAGAGACCTGAGGTCTAGGTCCCAAGAGAGATGGCTCCA 120
 Cp 2266 CCAGCATCCTACACCAAGAGACCTGAGGTCTAGGTCCCAAGAGAGATGGCTCCA 2207

Db 121 TAGAAAGCCCACTAACCCCTGCTCCACATTTGGGCAAGTGGAGGTTCTGGAAGGAAG 180
 Cp 2206 TAGAAAGCCCACTAACCCCTGCTCCACATTTGGGCAAGTGGAGGTTCTGGAAGGAAG 2147

Db 181 CTCTATGGCTAGGAGTGGCAAGGCCCTCTTGGTGTGACATCAGAGTGTAGAGGCCCTGC 240
 Cp 2146 CTCTATGGCTAGGAGTGGCAAGGCCCTCTTGGTGTGACATCAGAGTGTAGAGGCCCTGC 2087

Db 241 TGAGCTCTAGCACAGTGCAGTGGAGAAATGTTGGCTCCGCTCAG-AAGCTGGGCTCTTG 299
 Cp 2086 TGAGCTCTAGCACAGTGCAGTGGAGAAATGTTGGCTCCGCTCAG-AAGCTGGGCTCTTG 2027

Db 300 CCATGCCAGTGTGCTTACGACCTTGGCAAGTACTTTTCTCTCTCTGGGGCTCTG 359
 Cp 2026 CCATGCCAGTGTGCTTACGACCTTGGCAAGTACTTTTCTCTCTCTGGGGCTCTG 1968

Db 360 TGTTCCTTCTTATAGAGGCCCTTTTATAGTGTCTTGTATGTTTATGAGTTAG 419
 Cp 1967 TGT-CCAAAGGCTTATAGAG-CCCTTCT-ATGGTCTTGTATGTTTATGAGTTAG 1911

Db 420 GGCTT-TGACCTAGGCCCCAGTGCCTTACAGGAAGTGTCTGAC 461
 Cp 1910 GGGCTGTGACCTAGCCCCAGTGCCTTACAGGAAGTGTCTGAC 1868

RESULT 5
 LOCUS G20845 239 bp DNA STS 24-JUL-1996
 DEFINITION human STS A006121, sequence tagged site.
 ACCESSION G20845
 NID G1341182
 VERSION G20845.1 GI:1341182
 KEYWORDS STS; STS sequence; primer; sequence tagged site.
 SOURCE human.
 ORGANISM Homo sapiens
 Eukaryotes; Mitochondrial eukaryotes; Metazoa; Chordata;
 Vertebrata; Euthera; Primates; Catarrhini; Hominoidea; Homo.

REFERENCE 1 (bases 1 to 239)
 AUTHORS Adams, M.D.
 JOURNAL Unpublished (1996)

COMMENT Contact: Mark Adams
 The Institute for Genomic Research
 9712 Medical Center Dr., Rockville, MD 20850
 Email: mdadams@tigr.org

Primer A: CTCAGATGAGGTATATAACA
 Primer B: GTGATGTCACACTCAAGA

STS size: 239
PCR Profile:

Denaturation: 96C 5min
Anneal: 54C 30sec
Extend: 72C 30sec
Denature: 95C 30sec
FinalExtend: 72C 5min
Cycles: 30

Protocol:

GenomicDNA: 25 ng
Primer: 0.43 uM each
dNTPs: 230 uM each
AmpliTaq: 0.5 units
TagStart Ab: 0.5 units
Total Volume: 10 ul

Buffer:

Tris-HCl pH 8: 100 mM
KCl: 500 mM
MgCl2: 20 mM
Tris-HCl: 10 mM
Concentration: 10X

Prepared with primer pairs derived from TH85933: GenBank Accession
Numbers- H27162, H27370, R59582, F03785, F10676, Z40604, N31943,
N42779.

FEATURES

Source

Location/Qualifiers

1..239

/organism="Homo sapiens"

/db_xref="taxon:9606"

1..239

1..239

complement(222..239)

77 a 56 c 54 g 52 t

BASE COUNT

ORIGIN

Query Match

Best Local Similarity 8.6%; Score 200; DB 34; Length 239;

Matches 212; Conservative 0; Mismatches 0; Indels 2; Gaps 1;

Db 28 TATAGAAATGCTTTATAGAAAGTAGAAACCAAGTAAATATCTCTCCAGCATCAC 87

Cp 2316 TATAGAAATGCTTTATAGAAAGTAGAAACCAAGTAAATATCTCTCCAGCATCAC 87

Db 88 TATAGAAATGCTTTATAGAAAGTAGAAACCAAGTAAATATCTCTCCAGCATCAC 2257

Cp 2256 TATAGAAATGCTTTATAGAAAGTAGAAACCAAGTAAATATCTCTCCAGCATCAC 147

Db 148 TATAGAAATGCTTTATAGAAAGTAGAAACCAAGTAAATATCTCTCCAGCATCAC 2197

Cp 2196 TATAGAAATGCTTTATAGAAAGTAGAAACCAAGTAAATATCTCTCCAGCATCAC 205

Db 206 TATAGAAATGCTTTATAGAAAGTAGAAACCAAGTAAATATCTCTCCAGCATCAC 2137

Cp 2136 TATAGAAATGCTTTATAGAAAGTAGAAACCAAGTAAATATCTCTCCAGCATCAC 2103

RESULT 6

LOCUS G24430 284 bp DNA STS 31-MAY-1996

DEFINITION human STS WI-12936.

ACCESSION G24430

NID G1344756

VERSION G24430.1 GI:1344756

KEYWORDS STS sequence; primer; sequence tagged site.

SOURCE human STSs derived from sequences in dbEST and the Unigene

ORGANISM Homo sapiens

REFERENCE Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;

1 (bases 1 to 284)

Vertebrata; Eutheria; Primates; Catarrhini; Homnidae; Homo.

Hudson.T.

Whitehead Institute/MIT Center for Genome Research; Physically

Maped STSs

JOURNAL COMMENT

Unpublished (1995)

Contact: Thomas Hudson
Whitehead Institute/MIT Center for Genome Research
9 Cambridge Center, Cambridge MA 02142 USA
Tel: 617 252 1900
Fax: 617 252 1902
Email: thudson@genome.wi.mit.edu

Primer A: CTATATGACAGTGTCTCAGAAATGAGG

Primer B: TTTCAGAACCTTCCACTG

STS size: 204

PCR Profile:

Presoak:

Denaturation:

Annealing: 56 degrees C

Polymerization:

PCR Cycles: 35

Thermal Cycler:

Protocol:

Template: 10 ng

Primer: each 5 pM

dNTPs: each 4 nM

Taq Polymerase: 0.025 units/ul

Total Vol: 20 ul

Buffer:

MgCl2: 1.5 mM

KCl: 50 mM

Tris-HCl: 10 mM

pH: 9.3

Derived from dbEST (genbank accession Z40604).

Location/Qualifiers

1..284

/organism="Homo sapiens"

/db_xref="taxon:9606"

/map="101.4 CR from top of Chr22 linkage group"

49..252

49..72

complement(233..252)

90 a 61 c 59 g 71 t 3 others

BASE COUNT

ORIGIN

Query Match

Best Local Similarity 8.3%; Score 194; DB 34; Length 284;

Matches 194; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Db 88 TATAGAAATGCTTTATAGAAAGTAGAAACCAAGTAAATATCTCTCCAGCATCAC 147

Cp 2316 TATAGAAATGCTTTATAGAAAGTAGAAACCAAGTAAATATCTCTCCAGCATCAC 2257

Db 148 TATAGAAATGCTTTATAGAAAGTAGAAACCAAGTAAATATCTCTCCAGCATCAC 207

Cp 2256 TATAGAAATGCTTTATAGAAAGTAGAAACCAAGTAAATATCTCTCCAGCATCAC 2197

Db 208 TATAGAAATGCTTTATAGAAAGTAGAAACCAAGTAAATATCTCTCCAGCATCAC 267

Cp 2196 TATAGAAATGCTTTATAGAAAGTAGAAACCAAGTAAATATCTCTCCAGCATCAC 2137

Db 268 TATAGAAATGCTTTATAGAAAGTAGAAACCAAGTAAATATCTCTCCAGCATCAC 284

Cp 2136 TATAGAAATGCTTTATAGAAAGTAGAAACCAAGTAAATATCTCTCCAGCATCAC 2120

RESULT 7

LOCUS I66494 7218 bp DNA

DEFINITION Sequence 14 from patent US 5670367.

ACCESSION I66494

NID 92724471

VERSION I66494.1

KEYWORDS GI:2724471

23-DEC-1997

Db	1	GGCTGAGGGTAAGGCTGGGTAGGGTCCTTAACAGTGTCTCTGTCCATCCCTTGGAGCAGA	60
QY	1076	GGCTGAGGGTAAGGCTGGGTAGGGTCCTTAACAGTGTCTCTGTCCATCCCTTGGAGCAGA	1135
Db	61	TTTTGTCTGTGGATGGAGACAGTGGCGAGCTCCACAGTGATGCTGCTAGTAGGGCTTCC	120
QY	1136	TTTTGTCTGTGGATGGAGACAGTGGCGAGCTCCACAGTGATGCTGCTAGTAGGGCTTCC	1195
Db	121	AAACATTGCCTGCACCCCTGGAACTGAACCCAGGATAGACGGGGAGCTCCCCAGGCTCC	180
QY	1196	AAACATTGCCTGCACCCCTGGAACTGAACCCAGGATAGACGGGGAGCTCCCCAGGCTCC	1255
Db	181	TCGTGCTTTTACTAAGATGGCCTCAGTCTCACTCTGGGCTTGAGTGGCATACACTGTTA	240
QY	1256	TCGTGCTTTTACTAAGATGGC-TCAGTCTCACTCTGGGCTTGAGTGGCATACACTGTTA	1314
Db	241	TTCATGGTTAAGGTAAGCAGGCTCAAGGAGTGGCAATGAAAAATATATTTAGTTTTAA	300
QY	1315	TTCATGGTTAAGGTAAGCAGGCTCAAGGAGTGGCAATGAAAAATATATTTAGTTTTAA	1374

AGGCTGGGTAGGGTGCTTAACAGTGTCTCTTGTCCTCATCCCTTGGAGCAGA 60
|||||
|||||
AGGCTGGGTAGGGTGCTTAACAGTGTCTCTTGTCCTCATCCCTTGGAGCAGA 1135
|||||
|||||
GATGGAGACAGTGGCAGCTCCCCACAGTGATGCTGTGCTTAAGGGGTCC 120
|||||
|||||
GATGGAGACAGTGGCAGCTCCCCACAGTGATGCTGTGCTTAAGGGGTCC 1195
|||||
|||||
GCACCCCTGGAACTGAAACACAGGGATAGACGGGGAGCTCCCCACAGGCTCC 180
|||||
|||||
GCACCCCTGGAACTGAAACACAGGGATAGACGGGGAGCTCCCCACAGGCTCC 1255
|||||
|||||
CTAAGATGGGCTCAGTCTCCACTGTGGGCTTGAGTGGGCATACACTGTGA 240
|||||
|||||
CTAAGATGGC-TCAGTCTCCACTGTGGGCTTGAGTGGGCATACACTGTGA 1314
|||||
|||||
GGTAAACAGCGCTCAAGGGATGGCATTGAAAAATATATTAGTTTTTAA 300
|||||
|||||
GGTAAACAGCGCTCAAGGGATGGCATTGAAAAATATATTAGTTTTTAA 1374

Db 301 AATATTGGATGGAACTCCCTACTGACCTCTGAGAACTGGAAACGAGTTTGTACAGAG 360
 QY 1375 AATATTGGATGGAACTCCCTACTGACCTCTGAGAACTGGAAACGAGTTTGTACTGAAG 1434
 Db 361 TCAGAACTTTGGTTGGGAATGAGATCTAGGTGTGGCTGCTGATGCTTACGTTGCT 420
 QY 1435 TCAGAACTTTGGTTGGGAATGAGATCTAGGTGTGGCTGCTGATGCTTACGTTGCT 1494
 Db 421 GCGAATGATGCTTGGCAACCTGGGCGGAGGCTGGGCGGAGGACTTCTCTGTTTC 480
 QY 1495 GCGAATGATGCTTGGCAACCTGGGCGGAGGCTGGGCGGAGGACTTCTCTGTTTC 1554
 Db 481 AT 482
 QY 1555 AT 1556

RESULT 3
 LOCUS N56924 597 bp mRNA EST 22-FEB-1996
 DEFINITION Y782403.s1 Soares_multiple_sclerosis_2NBHSP Homo sapiens cDNA
 clone IMAGE:280037 3', mRNA sequence.

ACCESSION N56924
 VERSION N56924.1 GI:1200814
 KEYWORDS EST.
 SOURCE human.

ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Mammalia;
 Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1 (bases 1 to 597)
 Hillier, L., Clark, N., Duboue, T., Elliston, K., Hawkins, M.,
 Holman, M., Hultman, M., Kucaba, T., Le, M., Lennon, G., Marra, M.,
 Parsons, J., Rifkin, L., Rohlfing, T., Soares, M., Tan, F.,
 Trevaskis, E., Waterston, R., Williamson, A., Wohlmann, P. and
 Wilson, R.

LABORATORY The WashU-Merck EST Project

UNPUBLISHED (1995)

On Apr 14, 1993 this sequence version replaced gi:692843.

Contact: Wilson RK
 Washington University School of Medicine
 4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108
 Tel: 314 286 1800
 Fax: 314 286 1810
 Email: est@wustl.edu

This clone is available royalty-free through LLNL; contact the
 IMAGE Consortium (info@image.llnl.gov) for further information.
 Seq primer: m13 -40 forward
 High quality sequence stop: 358.

FEATURES
 source


1. 597
 /organism="Homo sapiens"
 /note="Vector: pT73D (Pharmacia) with a modified
 polylinker V-type; phagemid; Site_1: Not I; Site_2: Eco
 RI; 1st strand cDNA was primed with a Not I - oligo(dT)
 primer [5']
 TGTTACCAATCTGAAGTGGGAGCGCGCGGATTTTTTTTTTTTTTTT 3']
 double-stranded cDNA was size selected, ligated to Eco RI
 adaptors (Pharmacia), digested with Not I and cloned into
 the Not I and Eco RI sites of a modified pT73 vector
 (Pharmacia). Library went through one round of
 normalization to a Cot - 5. Library constructed by Bento
 Soares and M. Fatima Bonaldo. RNA from 4 multiple sclerosis
 lesions from one patient was kindly provided by Dr. Kevin
 G. Becker (NINDS/NIH).
 /db_xref="GDB:3898413"
 /db_xref="taxon:9606"
 /clone="IMAGE:280037"
 /clone_lib="Soares_multiple_sclerosis_2NBHSP"
 /sex="male"
 /tissue_type="multiple sclerosis lesions"
 /dev_stage="Age 46"
 /lab_host="DH10B (ampicillin resistant)"

BASE COUNT 151 a 139 c 147 g 159 t 1 others
 ORIGIN
 Query Match 19.9%; Score 464; DB 33; Length 597;
 Best Local Similarity 97.6%; Pred. No. 0.00e+00;
 Matches 490; Conservative 0; Mismatches 9; Indels 3; Gaps 3;

Db 99 TATAGAGAAATGCTTTATAGAAAAGTAGAACACAGTAATATCTCTTCCAGCATCAC 158
 Cp 2316 TATAGAGAAATGCTTTATAGAAAAGTAGAACACAGTAATATCTCTTCCAGCATCAC 2257
 Db 159 TAACACCAAGAGACCACTGAGGTCTAGGTCCCAAGCAGATGCTCCATAGAAAGCCC 218
 Cp 2256 TAACACCAAGAGACCACTGAGGTCTAGGTCCCAAGCAGATGCTCCATAGAAAGCCC 2197
 Db 219 CACTAACCCCTGTCTCCACATTTGGGCAAGTGGGAGGTTCTGGAAGAGAGCTCTATGGCT 278
 Cp 2196 CACTAACCCCTGTCTCCACATTTGGGCAAGTGGGAGGTTCTGGAAGAGAGCTCTATGGCT 2137
 Db 279 AGAGCTGCCAAGCCCTCTTGGTGTGACATCAGAGCTTAGAGCCCTCTGTGAGCTGCTA 338
 Cp 2136 AGAGCTGCCAAGCCCTCTTGGTGTGACATCAGAGCTTAGAGCCCTCTGTGAGCTGCTA 2077
 Db 339 GCACAGTGCAGTGGAGAAATGTTGGCTCGCTCAGAAAGCTGGGCTCTTCCCATGCCAGT 398
 Cp 2076 GCACAGTGCAGTGGAGAAATGTTGGCTCGCTCAGAAAGCTGGGCTCTTCCCATGCCAGT 2017
 Db 399 AGCTTCTTACGACCTTGGGCAAGTGCATCTTCTCTCTGGGGTCTGTGTCCAAAGG 458
 Cp 2016 AGCTTCTTACGACCTTGGGCAAGTGCATCTTCTCTCTGGGGTCTGTGTCCAAAGG 1957
 Db 459 CTTAATGAGCCCTTTCTAATGTTCTTCTGATGCTTTATGAGTTAGGGGCTGTGACC-TA 517
 Cp 1956 CTTAATGAGCCCTTTCTAATGTTCTTCTGATGCTTTATGAGTTAGGGGCTGTGACCCTA 1897
 Db 518 GCCCAGTGNCTACAGGAAGTGTGCTGGAGCCCGCCGACGACCTGCTAAATCAG 577
 Cp 1896 GCCCAGTGNCTACAGGAAGTGTGCTGGAGCCCGCCGACGACCTGCTAAATCAG 1837
 Db 578 GCC-A-TTGGGGAGCAAGCCCT 597
 Cp 1836 GCCCAGTGGGAGCAAGCCCT 1815

RESULT 4
 LOCUS AI299416 461 bp mRNA EST 03-DEC-1998
 DEFINITION cm89409.x1 NCI_CGAP_Lu5 Homo sapiens cDNA clone IMAGE:1895921 3',
 mRNA sequence.
 ACCESSION AI299416
 NID G3959070
 VERSION AI299416.1 GI:3959070
 KEYWORDS EST.
 SOURCE human.
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Mammalia;
 Eutheria; Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1 (bases 1 to 461)
 NCI-CGAP <http://www.ncbi.nlm.nih.gov/ncicgap>.
 AUTHORS National Cancer Institute, Cancer Genome Anatomy Project (CGAP),
 Tumor Gene Index
 TITLE Unpublished (1997)
 JOURNAL On Aug 21, 1998 this sequence version replaced.
 COMMENT

Contact: Robert Strausberg, Ph.D.
 Tel: (301) 496-1550
 Email: Robert.Strausberg@nih.gov
 Tissue Procurement: Christopher Moskaluk, M.D., Ph.D., Michael R.
 Emmert-Buck, M.D., Ph.D.
 CDNA Library Preparation: M. Bento Soares, Ph.D.
 CDNA Library Arrayed by: Greg Lennon, Ph.D.
 DNA Sequencing by: Washington University Genome Sequencing Center
 Clone distribution: NCI-CGAP clone distribution information can be
 found through the I.M.A.G.E. Consortium/LLNL at:



Release 3.1A John F. Collins, Biocomputing Research Unit.
Copyright (c) 1993-1998 University of Edinburgh, U.K.
Distribution rights by Oxford Molecular Ltd

MPSrch_nn n.a. - n.a. database search, using Smith-Waterman algorithm
Run on: Mon Sep 20 20:55:46 1999; MasPar time 140.28 Seconds
Tabular output not generated. 1177.638 Million cell updates/sec

Title: >US-09-084-491A-1
Description: (1-2329) from US09084491A.seq
N.A. Sequence: 2329 1 TTACGACAGCATACAA.....CTCTATATAAAAAA 2329
Comp: AATGCTCTGCTATTGTT.....GAGATATTTTTTTTTTTT

Scoring table: TABLE default
Gap 6
Nmatch STD : Dbase 0; Query 0
Searched: 137044 seqs, 35465580 bases x 2
Post-processing: Minimum Match 0%
Listing first 45 summaries
Database: n-issued
1:5A_COMB 2:5B_COMB 3:5C_COMB 4: PCT9_COMB 5:backfiles1
Statistics: Mean 9.355; Variance 5.013; scale 1.866

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description	Pred. No.
C 1	64	2.7	7218	2	US-08-232-Sequence 14, Applicati	8.57e-27
C 2	43	1.8	965	3	US-08-388-Sequence 22, Applicati	1.40e-12
C 3	41	1.8	965	3	US-08-388-Sequence 22, Applicati	1.40e-12
C 4	40	1.7	215	1	US-08-238-Sequence 5, Applicatio	1.17e-10
C 5	34	1.5	7218	2	US-08-232-Sequence 14, Applicati	6.19e-07
C 6	32	1.4	215	1	US-08-238-Sequence 5, Applicatio	9.74e-06
C 7	28	1.2	2184	1	US-07-815-Sequence 1, Applicatio	1.99e-03
C 8	28	1.2	2288	2	US-08-290-Sequence 4, Applicatio	1.99e-03
C 9	28	1.2	2289	1	US-07-838-Sequence 2, Applicatio	1.99e-03
C 10	28	1.2	2679	5	5200340-7 Patent No. 5200340.	1.99e-03
C 11	25	1.1	66	1	US-08-471-Sequence 144, Applicat	8.77e-02
C 12	25	1.1	69	1	US-08-471-Sequence 142, Applicat	8.77e-02
C 13	26	1.1	74	4	PCT-US95-1 Sequence 100, Applicat	2.54e-02
C 14	25	1.1	74	4	PCT-US95-1 Sequence 94, Applicati	8.77e-02
C 15	25	1.1	74	4	PCT-US95-1 Sequence 94, Applicati	8.77e-02
C 16	25	1.1	75	4	PCT-US95-1 Sequence 99, Applicati	8.77e-02
C 17	26	1.1	81	4	PCT-US95-1 Sequence 98, Applicati	2.54e-02
C 18	25	1.1	81	4	PCT-US95-1 Sequence 92, Applicati	8.77e-02
C 19	25	1.1	81	4	PCT-US95-1 Sequence 97, Applicati	8.77e-02
C 20	25	1.1	82	4	PCT-US95-1 Sequence 97, Applicati	8.77e-02

21	26	1.1	2296	1	US-07-750-Sequence 18, Applicati	2.54e-02
22	26	1.1	2497	3	US-08-643-Sequence 12, Applicati	2.54e-02
23	26	1.1	2753	1	US-07-854-Sequence 1, Applicati	2.54e-02
24	23	1.0	65	1	US-08-471-Sequence 145, Applicat	9.71e-01
25	23	1.0	65	1	US-08-471-Sequence 145, Applicat	9.71e-01
26	23	1.0	68	1	US-08-471-Sequence 143, Applicat	9.71e-01
27	23	1.0	68	1	US-08-471-Sequence 143, Applicat	9.71e-01
28	23	1.0	69	1	US-08-471-Sequence 142, Applicat	9.71e-01
29	24	1.0	74	4	PCT-US95-1 Sequence 100, Applicat	2.96e-01
30	24	1.0	81	4	PCT-US95-1 Sequence 98, Applicati	2.96e-01
31	24	1.0	82	4	PCT-US95-1 Sequence 97, Applicati	2.96e-01
32	24	1.0	242	2	US-08-273-Sequence 1, Applicati	2.96e-01
33	23	1.0	2033	2	US-08-448-Sequence 14, Applicati	9.71e-01
34	23	1.0	2033	1	US-08-148-Sequence 14, Applicati	9.71e-01
35	23	1.0	2219	1	US-07-882-Sequence 1, Applicatio	9.71e-01
36	23	1.0	2219	1	US-08-184-Sequence 2, Applicatio	9.71e-01
37	23	1.0	2219	1	US-08-184-Sequence 1, Applicatio	9.71e-01
38	23	1.0	2232	2	US-08-334-Sequence 1, Applicatio	9.71e-01
39	23	1.0	2232	4	PCT-US95-1 Sequence 1, Applicatio	9.71e-01
40	23	1.0	2282	1	US-07-882-Sequence 7, Applicatio	9.71e-01
41	24	1.0	2380	3	US-08-572-Sequence 3, Applicatio	2.96e-01
42	24	1.0	3603	1	US-08-646-Sequence 15, Applicati	2.96e-01
43	24	1.0	3603	1	US-08-188-Sequence 15, Applicati	2.96e-01
44	23	1.0	4673	1	US-07-638-Sequence 1, Applicatio	9.71e-01
45	23	1.0	6100	1	US-08-184-Sequence 6, Applicatio	9.71e-01

ALIGNMENTS

RESULT 1
ID US-08-232-463-14 STANDARD; DNA; UNC; 7218 BP.
AC xxxxxx
DT
Sequence 14, Application US/08232463
Sequence 14, Application US/08232463
Patent No. 5670367
GENERAL INFORMATION:
APPLICANT: DORNER, F.
APPLICANT: SCHEIFLINGER, F.
APPLICANT: FALKNER, F. G.
TITLE OF INVENTION: RECOMBINANT FOWLPOX VIRUS
NUMBER OF SEQUENCES: 52
CORRESPONDENCE ADDRESSES:
ADDRESSEE: Foley & Lardner
STREET: 1800 Diagonal Road, Suite 500
CITY: Alexandria
STATE: VA
COUNTRY: USA
ZIP: 22313-0299
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/232,463
FILING DATE:
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/07/935,313
FILING DATE:
APPLICATION NUMBER: EP 91 114 300.6
FILING DATE: 26-AUG-1991
ATTORNEY/AGENT INFORMATION:
NAME: BENT, Stephen A.
REGISTRATION NUMBER: 29,768
REFERENCE/DOCKET NUMBER: 30472/114 IMMU
TELECOMMUNICATION INFORMATION:
TELEPHONE: (703)836-9300
TELEFAX: (703)683-4109
INFORMATION FOR SEQ ID NO: 14:
SEQUENCE CHARACTERISTICS:

CC	REFERENCE/DOCKET NUMBER:	LUD 5409
CC	TELECOMMUNICATION INFORMATION:	
CC	TELEPHONE:	212-688-9200
CC	TELEFAX:	212-838-3884
CC	INFORMATION FOR SEQ ID NO:	22:
CC	SEQUENCE CHARACTERISTICS:	
CC	LENGTH:	965 base pairs
CC	TYPE:	nucleic acid
CC	STRANDEDNESS:	unknown
CC	TOPOLOGY:	unknown
CC	MOLECULE TYPE:	DNA (genomic)
CC	SEQUENCE	965 BP; 192 A; 170 C; 226 G; 200 T; 177 OTHER.
Query Match 1.8%; Score 43; DB 3; Length 965;		
Best Local Similarity 18.1%; Pred. No. 1.40e-12;		
Matches 33; Conservative 84; Mismatches 62; Indels 3; Gaps 3;		
Db	774	TGGTGGKURHUVHVGVSRTSTCTASDYTTXWGVVRGWGDYGGGYTNYNKGKRGV 833 : :::: : :::: : :::: : :::: :
Qy	1381	TGGGATGGACCTCCTACTGACCTCT-CACAACGTGAACAGAGTTGTACTCAAGTCAGA 1439 : :::: : :::: : :::: : :::: :
Db	834	TMADTSSNSRSVTAADTAVYYCYGRSISDSDGDYWGTTVTYSSHUVKDWTSSSAHV 893 : : : : : : : : : : :
Qy	1440	ACTTGCGTGGGAATGAGATCTAGGTGTGCCTGGT-ATGCTCAGCTTGCTGGCA 1498 : : : : : : : : : : :
Db	894	GDRVYTCRSTHGNGNTYWKAKARYNVRNSRVSRSGSGSTDYTTSSDAYYYCGTH 953 : : : : : : : : : : :
Qy	1499	ATGATGTGCCTT-CACAACCGTGGGCCAGGCGCTGGGCCAGGACTCTCTCTGTTTCATA 1557 : : : : : : : : : : :
Db	954	AR 955 :
Qy	1558	AG 1559 :

RESULT 3
 ID US-08-388-672A-22 STANDARD; DNA; UNC; 965 BP.
 AC xxxxxx
 DT
 Sequence 22, Application US/08388672A
 CC Sequence 22, Application US/08388672A
 CC Patent No. 5795961
 CC GENERAL INFORMATION:
 CC APPLICANT: Wallace, T. Paul
 CC APPLICANT: Harris, William J.
 CC APPLICANT: Carr, Frank J.
 CC APPLICANT: Old, Lloyd J.
 CC APPLICANT: Welt, Sydney
 CC APPLICANT: Kitamura, Kunio
 CC TITLE OF INVENTION: Recombinant Human Anti-Lewis B
 CC TITLE OF INVENTION: Antibodies
 CC NUMBER OF SEQUENCES: 25
 CC CORRESPONDENCE ADDRESS:
 CC ADDRESSEE: Felfe and Lynch
 CC STREET: 805 Third Avenue
 CC CITY: New York
 CC STATE: New York
 CC COUNTRY: U.S.A.
 CC ZIP: 10022
 CC COMPUTER READABLE FORM:
 CC MEDIUM TYPE: Floppy disk
 CC COMPUTER: IBM PC compatible
 CC OPERATING SYSTEM: PC-DOS/MS-DOS
 CC SOFTWARE: PatentIn Release #1.0, Version #1.30
 CC CURRENT APPLICATION DATA:
 CC APPLICATION NUMBER: US/08/388,672A
 CC FILING DATE: 14-FEB-1995
 CC CLASSIFICATION:
 CC ATTORNEY/AGENT INFORMATION:
 CC NAME: Hanson, No. 5795961man D.
 CC REGISTRATION NUMBER: 30,946
 CC REFERENCE/DOCKET NUMBER: LUD 5409
 CC TELECOMMUNICATION INFORMATION:
 CC TELEPHONE: 212-688-9200

[illegible]

```

CC STRANDEDNESS: single
CC TOPOLOGY: linear
CC IMMEDIATE SOURCE:
CC CLONE: ptzqpt-Fls
CC SQ SEQUENCE 7218 BP; 1944 A; 1491 C; 1486 G; 1929 T; 368 OTHER.

Query Match 1.5%; Score 34; DB 2; Length 7218;
Best Local Similarity 1.5%; Pred. No. 6.19e-07;
Matches 4; Conservative 148; Mismatches 118; Indels 0; Gaps 0;

Db 1062 GCGATYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYY 1121
QY 765 GCGAATCACTTGCCTTGCTGCTCCACCAACCCACCTGTGAGATTGTGATGAGAA 824
Db 1122 YYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYY 1181
QY 825 GACTGTGCTGTCACACAGCAGACTCCAGTTCACCTCAGGAGGGCAGACCCCT 884
Db 1182 YYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYY 1241
QY 885 TATGGGCCAGCGCGGACTCTGGGGCTCAGCCCCCAGTGGCAGGAGCCATGCAG 944
Db 1242 YYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYY 1301
QY 945 ACATGTGTGAGGACGCCACCTCTCTACAGTAGGAGGAACCTACCACTTTGTGTCG 1004
Db 1302 YYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYY 1331
QY 1005 GTTAAACCTACCACCTCCCGCTTTT 1034

RESULT 6
ID JS-08-238-163-5 STANDARD; DNA; UNC; 215 BP.
AC xxxxxx
DT
DE Sequence 5, Application US/08238163
CC Sequence 5, Application US/08238163
CC Patent No. 5569830
CC GENERAL INFORMATION:
CC APPLICANT: BENNETT, Alan
CC APPLICANT: LABAVITCH, John M.
CC APPLICANT: POWELL, Ann
CC APPLICANT: STOTZ, Henrik
CC TITLE OF INVENTION: PLANT INHIBITORS OF FUNGAL
CC TITLE OF INVENTION: POLYCALACTUONASES AND THEIR USE TO CONTROL FUNG
CC NUMBER OF SEQUENCES: 24
CC CORRESPONDENCE ADDRESS:
CC ADDRESSEE: Townsend and Townsend Khourie and Crew
CC STREET: Steuart Street Tower, One Market Plaza
CC CITY: San Francisco
CC STATE: California
CC COUNTRY: US
CC ZIP: 94105-1493
CC COMPUTER READABLE FORM:
CC MEDIUM TYPE: Floppy disk
CC COMPUTER: IBM PC compatible
CC OPERATING SYSTEM: PC-DOS/MS-DOS
CC SOFTWARE: PatentIn Release #1.0, Version #1.25
CC CURRENT APPLICATION DATA:
CC APPLICATION NUMBER: US/08/238,163
CC FILING DATE: 03-MAY-1994
CC CLASSIFICATION: 800
CC ATTORNEY/AGENT INFORMATION:
CC NAME: Bastian, Kevin L.
CC REGISTRATION NUMBER: 34,774
CC REFERENCE/DOCKET NUMBER: 2307E-540
CC TELECOMMUNICATION INFORMATION:
CC TELEPHONE: (415) 543-9600
CC TELEFAX: (415) 543-5043
CC INFORMATION FOR SEQ ID NO: 5:
CC SEQUENCE CHARACTERISTICS:
CC LENGTH: 215 base pairs
CC TYPE: nucleic acid

```

```

CC STRANDEDNESS: single
CC TOPOLOGY: unknown
CC MOLECULE TYPE: protein
CC FEATURE:
CC NAME/KEY: misc_feature
CC LOCATION: 1..215
CC OTHER INFORMATION: /standard_name= "Deduced amino acid
CC OTHER INFORMATION: sequence of PGIP from bean."
SQ SEQUENCE 215 BP; 15 A; 8 C; 25 G; 26 T; 141 OTHER.

Query Match 1.4%; Score 32; DB 1; Length 215;
Best Local Similarity 15.5%; Pred. No. 9.74e-06;
Matches 22; Conservative 57; Mismatches 62; Indels 1; Gaps

Db 41 WGVCDTDTTVRVNDSGHNYSSANYNGNNGVGAATHYTHTN-VSGADSKTVDTSN 99
Qy 629 TGGCTACGTGCTGGGCAATACCATGATGGTGATCATCTGCCATCGGAGCTGGCATCA 688
Db 100 ASGTSSNGGTDGRRSGADSYGSKTAMTSNRRTGTANNVDSRNMGDASVGSNDKTKK 159
Qy 689 TCTTGGGCTACTCCTACAAGAGGGGAAGATTGTGAAGAAGACAGCATGATCAGAAAGTAT 748
Db 160 HAKNSADGKVGSKNNGDRNNRY 181
Qy 749 GTGAGAGGAGATGCACCGAAT 770

RESULT 7
ID US-07-815-333A-1 STANDARD; DNA; UNC; 2184 BP.
AC xxxxxx
DT
DE Sequence 1, Application US/07815333A
CC Sequence 1, Application US/07815333A
CC Patent No. 5342831
CC GENERAL INFORMATION:
CC APPLICANT: Nakamura, Toshikazu
CC APPLICANT: Matsumoto, Kunio
CC TITLE OF INVENTION: EPIHELIOCYTE GROWTH ACCELERATOR
CC NUMBER OF SEQUENCES: 2
CC CORRESPONDENCE ADDRESS:
CC ADDRESSEE: Leydig, Voit & Mayer
CC STREET: Two Prudential Plaza, Suite 4900
CC CITY: Chicago
CC STATE: Illinois
CC COUNTRY: United States of America
CC ZIP: 60601
CC COMPUTER READABLE FORM:
CC MEDIUM TYPE: Floppy disk
CC COMPUTER: IBM PC compatible
CC OPERATING SYSTEM: PC-DOS/MS-DOS
CC SOFTWARE: PatentIn Release #1.0, Version #1.25
CC CURRENT APPLICATION DATA:
CC APPLICATION NUMBER: US/07/815,333A
CC FILING DATE: 19911227
CC CLASSIFICATION: 530
CC ATTORNEY/AGENT INFORMATION:
CC NAME: Green, Robert F.
CC REGISTRATION NUMBER: 27555
CC REFERENCE/DOCKET NUMBER: 44069
CC TELECOMMUNICATION INFORMATION:
CC TELEPHONE: (312) 616-5600
CC TELEFAX: (312) 616-5700
CC TELEX: 25-3533
CC INFORMATION FOR SEQ ID NO: 1:
CC SEQUENCE CHARACTERISTICS:
CC LENGTH: 2184 base pairs
CC TYPE: NUCLEIC ACID
CC STRANDEDNESS: double
CC TOPOLOGY: linear
CC MOLECULE TYPE: cDNA
CC FEATURE:
CC NAME/KEY: CDS
CC LOCATION: 1..2184

```

SQ SEQUENCE 2184 BP; 673 A; 455 C; 500 G; 556 T; 0 OTHER.

 Query Match 1.2%; Score 28; DB 1; Length 2184;
 Best Local Similarity 75.9%; Pred. No. 1.99e-03;
 Matches 41; Conservative 0; Mismatches 13; Indels 0; Gaps 0;

 Db 1306 AATGAGAAATTACTGCCGAATAATCCAGATGATGCTCATGGACCCCTGGTGCTTAC 1359
 ||| | ||||| ||||| || | || | || ||||| |||||
 QY 319 AATCACAGTTTACTGCCGAACCCGAGGAGCGCGCGGCCTGGTGCTTAC 372


 RESULT 8
 ID US-08-290-937B-4 STANDARD; DNA; UNC; 2288 BP.
 AC xxxxxx
 DT
 DE Sequence 4, Application US/08290937B
 DE Sequence 4, Application US/08290937B
 CC Patent No. 5648233
 CC GENERAL INFORMATION:
 CC APPLICANT: YAMAGUCHI, KYOJI
 CC APPLICANT: SHIMA, NOBUYUKI
 CC APPLICANT: MURAKAMI, AKIHIKO
 CC APPLICANT: GOTO, MASAOKI
 CC APPLICANT: TSUDA, EISUKE
 CC APPLICANT: MASUNAGA, HIROAKI
 CC APPLICANT: TAKAHIRA, REIKO
 CC APPLICANT: OOGAKI, FUMIKO
 CC APPLICANT: UEDA, MASATSUGU
 CC APPLICANT: HIGASHIO, KANJI
 CC TITLE OF INVENTION: MODIFIED TCF
 CC NUMBER OF SEQUENCES: 13
 CC CORRESPONDENCE ADDRESS:
 CC ADDRESSEE: Testa, Hurwitz & Thibault
 CC STREET: 125 High St.
 CC CITY: Boston
 CC STATE: MA
 CC COUNTRY: USA
 CC ZIP: 02110
 CC COMPUTER READABLE FORM:
 CC MEDIUM TYPE: Floppy disk
 CC COMPUTER: IBM PC compatible
 CC OPERATING SYSTEM: PC-DOS/MS-DOS
 CC SOFTWARE: Patentin Release #1.0, Version #1.30
 CC CURRENT APPLICATION DATA:
 CC APPLICATION NUMBER: US/08/290,937B
 CC FILING DATE: 19-AUG-1994
 CC CLASSIFICATION: 530
 CC ATTORNEY/AGENT INFORMATION:
 CC NAME: CAMPBELL, PAULA A.
 CC REGISTRATION NUMBER: 32,503
 CC REFERENCE/DOCKET NUMBER: FJN-022
 CC TELECOMMUNICATION INFORMATION:
 CC TELEPHONE: (617) 248-7000
 CC TELEFAX: (617) 248-7100
 CC INFORMATION FOR SEQ ID NO: 4:
 CC SEQUENCE CHARACTERISTICS:
 CC LENGTH: 2288 base pairs
 CC TYPE: nucleic acid
 CC STRANDEDNESS: single
 CC TOPOLOGY: linear
 CC MOLECULE TYPE: cdna
 CC SEQUENCE 2288 BP; 702 A; 491 C; 524 G; 571 T; 0 OTHER.

Query Match 1.2%; Score 28; DB 2; Length 2288;
 Best Local Similarity 75.9%; Pred. No. 1.99e-03;
 Matches 41; Conservative 0; Mismatches 13; Indels 0; Gaps 0;

 Db 1367 AATGAGAAATTACTGCCGAATAATCCAGATGATGCTCATGGACCCCTGGTGCTTAC 1420
 ||| | ||||| ||||| || | || | || ||||| |||||
 QY 319 AATCACAGTTTACTGCCGAACCCGAGGAGCGCGGCCTGGTGCTTAC 372

 RESULT 9


```
CC CURRENT APPLICATION DATA:  
CC APPLICATION NUMBER: PCT/US95/11934  
CC FILING DATE: 20-SEP-1995  
CC CLASSIFICATION:  
CC ATTORNEY/AGENT INFORMATION:  
CC NAME: Misrock, S. Leslie  
CC REGISTRATION NUMBER: 18,872  
CC REFERENCE/DOCKET NUMBER: 1101-196-228  
CC TELECOMMUNICATION INFORMATION:  
CC TELEPHONE: (212) 790-9090  
CC TELEFAX: (212) 869-9741/8864  
CC TELEX: 66141 PENNIE  
CC INFORMATION FOR SEQ ID NO: 94:  
CC SEQUENCE CHARACTERISTICS:  
CC LENGTH: 74 base pairs  
CC TYPE: nucleic acid  
CC STRANDEDNESS: single  
CC TOPOLOGY: linear  
CC MOLECULE TYPE: DNA (genomic)  
CC SEQUENCE 74 BP; 3 A; 4 C; 3 G; 1 T; 63 OTHER.  
  
Query Match 1.1%; Score 25; DB 4; Length 74;  
Best Local Similarity 7.5%; Pred. No. 8.77e-02;  
Matches 5; Conservative 20; Mismatches 42; Indels 0; Gaps 0;  
  
Db 5 GNNBNNBNBNNBNBNNBNBNNBNBNNBNBNNBNBNNBNBNNBNBNNBNBNNBN 64  
QY 212 GCCACCTGTACCGGAGGACCAGACTCCCCGGCGGCCCTCCGCTGCCTCACTGGC 271  
| : : : : : : : : : : : : : : : : : : : : : : : : : : : :  
Db 65 NBNACGC 71  
.: |||||  
QY 272 TGGACGC 278  
  
RESULT 15  
ID PCT-US95-11934-94 STANDARD; DNA; UNC; 74 BP.  
AC xxxxxx  
DT  
DE Sequence 94, Application PC/TUS9511934  
CE Sequence 94, Application PC/TUS9511934  
CC GENERAL INFORMATION:  
CC APPLICANT: CytoGen Corporation  
CC TITLE OF INVENTION: Antigen Binding Peptides (Aptides) From  
CC TITLE OF INVENTION: Peptide Libraries  
CC NUMBER OF SEQUENCES: 103  
CC CORRESPONDENCE ADDRESS:  
CC ADDRESSEE: Pennie & Edmonds  
CC STREET: 1155 Avenue of the Americas  
CC CITY: New York  
CC STATE: New York  
CC COUNTRY: USA  
CC ZIP: 10036  
CC COMPUTER READABLE FORM:  
CC MEDIUM TYPE: Floppy disk  
CC COMPUTER: IBM PC compatible  
CC OPERATING SYSTEM: PC-DOS/MS-DOS  
CC SOFTWARE: PatentIn Release #1.0, Version #1.30  
CC CURRENT APPLICATION DATA:  
CC APPLICATION NUMBER: PCT/US95/11934  
CC FILING DATE: 20-SEP-1995  
CC CLASSIFICATION:  
CC ATTORNEY/AGENT INFORMATION:  
CC NAME: Misrock, S. Leslie  
CC REGISTRATION NUMBER: 18,872  
CC REFERENCE/DOCKET NUMBER: 1101-196-228  
CC TELECOMMUNICATION INFORMATION:  
CC TELEPHONE: (212) 790-9090  
CC TELEFAX: (212) 869-9741/8864  
CC TELEX: 66141 PENNIE  
CC INFORMATION FOR SEQ ID NO: 94:  
CC SEQUENCE CHARACTERISTICS:  
CC LENGTH: 74 base pairs  
CC TYPE: nucleic acid
```



(TM)

Release 3.1A John F. Collins, Biocomputing Research Unit.
Copyright (c) 1993-1998 University of Edinburgh, U.K.
Distribution rights by Oxford Molecular Ltd

MPsrch_nn n.a. - n.a. database search, using Smith-Waterman algorithm

Run on: Mon Sep 20 20:38:15 1999; MasPar time 499.24 Seconds
Tabular output not generated. 999.603 Million cell updates/sec

Title: >US-09-084-491A-1
Description: (1-2329) from US09084491A.seq
Perfect Score: 2329
N.A. Sequence: 1 TTACCAGACAGCATAACAA.....CTCTATATAAAAAA 2329
Comp: AATGGTCTGCTGATTGTT.....GAGATATTTTTTTTTTTT

Scoring table: TABLE default

Gap 6

Nmatch STD : Dbase 0; Query 0

Searched: 271905 seqs, 107135622 bases x 2

Post-processing: Minimum Match 0%
Listing first 45 summaries

Database: n-geneseq35

1:part1 2:part2 3:part3 4:part4 5:part5 6:part6 7:part7
8:part8 9:part9 10:part10 11:part11 12:part12 13:part13
14:part14 15:part15 16:part16 17:part17 18:part18
19:part19 20:part20 21:part21 22:part22 23:part23
24:part24 25:part25 26:part26 27:part27 28:part28
29:part29 30:part30 31:part31 32:part32 33:part33
34:part34 35:part35 36:part36 37:part37 38:part38
39:part39 40:part40 41:part41 42:part42 43:part43
44:part44 45:part45 46:part46 47:part47 48:part48
49:part49 50:part50 51:part51 52:part52 53:part53
54:part54 55:part55 56:part56 57:part57 58:part58
59:part59 60:part60

Statistics: Mean 9.831; Variance 6.007; scale 1.637

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description	Pred. No.
1	2329	100.0	2329	60	Human tissue plasminogen activator-like protease - useful in the	0.00e+00
2	270	11.6	399	60	Human t-PALP-related	3.38e-159
3	267	11.5	472	60	Human t-PALP-related	3.88e-157
4	238	10.2	250	60	Human t-PALP-related	2.82e-137
5	235	10.1	247	60	Human t-PALP-related	3.16e-135
6	191	8.2	461	60	Human t-PALP-related	2.63e-105
7	150	6.4	334	60	Human t-PALP-related	9.67e-78
8	74	3.2	291	60	Human t-PALP-related	2.54e-28
9	44	1.9	204	1	Base substituted E.co	2.32e-10

10	42	1.8	91	9	Q51746	Oligonucleotide probe	3.07e-09
11	43	1.8	91	9	Q51746	Oligonucleotide probe	8.48e-10
12	40	1.7	204	1	N81164	Base substituted E.co	3.94e-08
13	38	1.6	114	12	Q70468	Generic DNA sequence	4.87e-07
14	37	1.6	114	12	Q70469	Generic DNA sequence	1.69e-06
15	36	1.5	114	12	Q70468	Generic DNA sequence	5.78e-06
16	36	1.5	114	12	Q70468	Generic DNA sequence	5.78e-06
17	36	1.5	114	12	Q70467	Generic DNA sequence	5.78e-06
18	36	1.5	114	12	Q70469	Generic DNA sequence	5.78e-06
19	35	1.5	114	12	Q70470	Generic DNA sequence	1.96e-05
20	34	1.5	114	12	Q70466	Generic DNA sequence	6.56e-05
21	35	1.5	114	12	Q70467	Generic DNA sequence	1.96e-05
22	34	1.5	114	12	Q70466	Generic DNA sequence	6.56e-05
23	34	1.5	114	12	Q70470	Generic DNA sequence	6.56e-05
24	34	1.5	114	12	Q70473	Generic DNA sequence	6.56e-05
25	34	1.5	114	12	Q70465	Generic DNA sequence	6.56e-05
26	36	1.5	140	32	T76368	Human IL-8 receptor-a	5.78e-06
27	36	1.5	190	32	T76452	Chymase antisense oli	5.78e-06
28	32	1.4	114	12	Q70473	Generic DNA sequence	7.10e-04
29	32	1.4	114	12	Q70472	Generic DNA sequence	7.10e-04
30	32	1.4	114	12	Q70472	Generic DNA sequence	7.10e-04
31	32	1.4	114	12	Q70471	Generic DNA sequence	7.10e-04
32	32	1.4	130	47	V48104	Randomised Pool'oligo	7.10e-04
33	32	1.4	178	32	T76405	Human endothelin-1 an	7.10e-04
34	32	1.4	178	32	T76405	Human endothelin-1 an	7.10e-04
35	31	1.3	114	12	Q70471	Generic DNA sequence	2.29e-03
36	30	1.3	130	47	V48104	Randomised Pool'oligo	7.26e-03
37	30	1.3	160	47	V48098	Oligonucleotide Lp160	2.29e-03
38	31	1.3	160	47	V48098	Oligonucleotide Lp160	2.29e-03
39	31	1.3	190	32	T76452	Chymase antisense oli	2.29e-03
40	31	1.3	1140	1	Q02301	cPA-P2 Hybrid plasmin	2.29e-03
41	29	1.2	172	32	T76363	Degenerate Alteromona	2.27e-02
42	29	1.2	984	17	Q94336	Competative inhibitor	6.97e-02
43	28	1.2	2187	8	Q47833	Competative inhibitor	6.97e-02
44	28	1.2	2187	8	Q47832	Plasminogen encoding	6.97e-02
45	28	1.2	2679	35	T89886		

ALIGNMENTS

RESULT 1
ID V99636 standard; DNA; 2329 BP.

AC V99636;
DT 29-MAR-1999 (first entry)
DE Human tissue plasminogen activator-like protease t-PALP DNA.
KW Tissue plasminogen activator-like protease; t-PALP; human;
KW circulatory system-related disorder; blood clotting; stroke;
KW thrombosis; peripheral arterial occlusion; pulmonary embolism;
KW myocardiobrombosis; diagnosis; therapy; ss.
OS Homo sapiens.

FH Key Location/Qualifiers
FT CD5 124...915
FT sig_peptide /*tag= a
FT 124...184
FT mat_peptide /*tag= b
FT 185...912
FT /*tag= c

PN WO9854199-A1.

PD 03-DEC-1998.

PF 27-MAY-1997; U10728.

PR 28-MAY-1997; US-048000.

PA (HUMA-) HUMAN GENOME SCI INC.

PI Ebner R. Moore PA, Ruben SM,

DR WPI; 99-070207/06.

DR P-PSDB; W87769.

PT New tissue plasminogen activator-like protease - useful in the
PT diagnosis and treatment of circulatory system-related disorders

PS Claim 2; Page 54-56; 76pp; English.

CC This DNA sequence includes a coding region for a novel human tissue
CC plasminogen activator-like protease (t-PALP) polypeptide (see
CC W87769) that is a member of the serine protease family and a
CC homologue of tissue plasminogen activator (tPA, see W87770). It
CC was discovered in a cDNA library derived from activated monocytes.

CC The 2.5 kb t-PALP message has also been detected in heart, brain,
CC lung, placenta, liver, skeletal muscle, kidney, pancreas, spleen,
CC thymus, prostate, testis, ovary, small intestine, colon and
CC peripheral blood leukocytes. t-PALP cDNA that encodes mature
CC t-PALP polypeptide is deposited as ATCC 209023. Isolated nucleic
CC acids encoding amino acids -21 to 242, -20 to 242, 1-242, 4-63
CC (kringle domain) and 64-242 (protease domain) of t-PALP, or
CC encoding epitope-bearing portions of t-PALP, are also claimed as
CC are recombinant vectors, host cells, methods for producing t-PALP
CC polypeptides, and related nucleic acid molecules (see V99637-43).
CC t-PALP may be used to detect and treat disorders related to the
CC circulatory system, and to identify agonists and antagonists of
CC t-PALP activity. The homology between t-PALP and tPA indicates
CC that t-PALP may be involved in the regulation of normal and
CC abnormal clotting in e.g. stroke, deep-vein thrombosis, peripheral
CC arterial occlusion, pulmonary embolism and myocardiothrombosis.
SQ Sequence 2329 BP; 548 A; 605 C; 676 G; 500 T;

Query Match 100.0%; Score 2329; DB 60; Length 2329;
Best Local Similarity 100.0%; Pred. No. 0.00e+00;
Matches 2329; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Db 1 ttaccagaacagcataacaaggcgaggtctgaactgcaagctgggactggagcgagcgc 60
Qy 1 TTACCAGAACAGCATAAAGGGCAGGTCTGACTGCAAGCTGGGACTGGGAGGCAGAGCC 60
Db 61 gccgcgaaggggcgctcggttaaacacactggtcggtcaatcacctgcaagacaagaggca 120
Qy 61 GCCGCCAAGGGGCGCTCGGTTAAACACTGCTGCTTCAATCATCTGCAACGCAAGAGGCA 120
Db 121 aggatgtgttgccctgggttaaacagcattcctcgtcagcaaatgctcctagcagaagcc 180
Qy -121 AGGATGCTGTGGCTGGGTACAAAGCATTCCTCGTCAGCAACATGCTCTAGCAGAAGCC 180
Db 181 tatggatcgtgaggtgtttctgggacaacggccacctgtaccgggaggaaccagacctcc 240
Qy 181 TATGGATCTGAGGCGTGTTCCTGGACAAACGGCCACCTGTACCGGGAGGACCAAGCTCC 240
Db 241 cccgcgcggccctcgcgtcctaactggctgagcgagcgagcgagcggtgcctcgcc 300
Qy 241 CCCGCGCGCGCCCTCCGCTGCTCAACTGGCTGGAGCGCGAGCGGGCTGGCCTCGGCC 300
Db 301 cccgtgtcggggcgccgaatcacagttaactcgcgaaccccgagagagaccgcgcggcg 360
Qy 301 CCCGTGTCCGGGGCGCGCAATCACAGTTACTGCCGAACCCCGGACGAGGACCCGCGCG 360
Db 361 cccgtgtgctacgtcagtgaggcgccggcgctcccttgagaaacggccttgcgaggacctg 420
Qy 361 CCCTGGTGTACGTACGTGGCGAGCGCGCGCTCCCTGAGAAACGGCGCTTGCAGGACCTG 420
Db 421 cgcgtccagagaccactccaggccctgcagccttcacacagaaatccaggaaagcg 480
Qy 421 CGCTGTCCAGAGACCCTCCAGGCCCTGCCAGCCTTCACACAGAAATCCAGGAAGCG 480
Db 481 tctgaaggcgccaggtgcagatgaggtgcaggtgttcgctcctgcgaacccctgcgcgt 540
Qy 481 TCTGAAGGCCCGAGGTGCAGATGAGTGCAGGTTCCTGCTCCGCCAACCCCTGCCCGT 540
Db 541 cggagtgaggcggcagctgtgcagccagtgatgggatacagccagcggtgcggatgaac 600
Qy 541 CGGAGTGAGGCGGCGAGCTGTGCAGCCAGTGATTGGGATCAGCCAGCGGGTGCGGATGAAC 600
Db 601 tccaaggagaaaaaggaactgggaaactcgtggctacgtgctggggaattaccatgatggtg 660
Qy 601 TCCAAGGAGAAAAAGGACCTGGGAACTCTGGGCTACGTGCTGGCATTTACCATGATGGTG 660
Db 661 atcatcattgcctggagctggatcatcttggctactcctcaaaagggggaaggtat 720
Qy 661 ATCATATTGCGATCGGAGCTGGCATCATCTTGGGCTACTCTCTACAAAGGGGGGAAGGAT 720
Db 721 ttgaagaacagcatgatcagaagaagtatgtagagggagatgcagcgaatcactctgcc 780
Qy 721 TTGAAGAACAGCATGATCAGAAAGTATGTGAGAGGGAGATGCAGCGGAATCACTCTGCC 780

Db 781 ttgtctgcttcaccacccccacactgtgagattgttgatgagaagactgtctggtccac 840
Qy 781 TTGTCTGCTTCCACAAACCCACCTGTGAGATTGTGATGAGAAGACTGTCTGTTGTCAC 840
Db 841 accagccagactccagttgacctcaggaggcagacaccccccttatggccagggccggg 900
Qy 841 ACCAGCCAGACTCCAGTTGACCTCAGGAGGGCAGACCCCTTATGGGCCAGGCCGGG 900
Db 901 actcctggggcctgagccccccagtgggcagagcccatgacagacactgtgcagaca 960
Qy 901 ACTCTGGGGCCTGAGCCCCCAGTGGGAGGAGCCCATGACACACTGGTGAGGACA 960
Db 961 gccacacctctacagtaggagaaactaccactttgtgttcttggttaaacacctaccac 1020
Qy 961 GCCACACCTCTACAGCTAGGAGAACTACCACCTTTGTGTCTGTTAAACCCCTACCAC 1020
Db 1021 tccccgccttttggcgaatcctagtagagtgacagaagcagggtggccctgtgggctg 1080
Qy 1021 TCCCCGCTTTTGGCGAATCTAGTAGAGTGCAGAGAAGCAGGTGGCCCTGTGGCTG 1080
Db 1081 aggttaagctgggtaggtcctaacagtgctcctcttgcattcccttggagcagatttg 1140
Qy 1081 AGGTAAGGCTGGGTAGGGTCTTAACAGTCTCTTGTCTCCATCCCTTGGAGCAGATTG 1140
Db 1141 tctgtgtagtagacagtgagcagctccacagtgatgctgctgctaagggcttccaaaca 1200
Qy 1141 TCTGTGGATGGACAGTGGCAGCTCCACAGTGTGCTGCTTAAGGCTTCCAAACA 1200
Db 1201 ttgcctgccccctgaaactgaaccaggagatagacggggagctccccccagggctcctctg 1260
Qy 1201 TTGCCTGCACCCCTGGAACGTGAACAGGAGATAGACGGGAGCTCCCCAGGCTCCTCTG 1260
Db 1261 gcttactaagatggctcagctcctcactgtgggcttgagtgagcagacactgttattcatg 1320
Qy 1261 GCTTTACTAAGATGGCTCAGTCTCCACTGTGGCTTTGAGTGGCATACACTGTTATTCTATG 1320
Db 1321 gttaaagtaagcaggtcaaggatggtcattgaaaaataatttagtttttaaaatatt 1380
Qy 1321 GTTAAAGTAAGCAGGTCAAGGATGGCATTTGAAAAATATATTAGTTTTTAAATATT 1380
Db 1381 tgggatggaactccctactgacctgtgacaactggaacgagtttgtactgaagtcagaa 1440
Qy 1381 TGGGATGGAACCTCCCTACTGACCTCTGACAACGTGAACAGAGTTTGTACTGAAGTCAGAA 1440
Db 1441 ctttgggttgggaatagatctaggttggctgctggttatgctcagctgtgctgcaat 1500
Qy 1441 CTTTGGGTTGGGAATGAGATCTAGTTGTGGCTGCTGCTATGCTTCAGCTTGTGTGCAAT 1500
Db 1501 gatgtcccttgacaacgggtggccagcgctggcccgaggactcttctctttcataagg 1560
Qy 1501 GATGTCCCTTGACAACCGTGGCCAGCGCTGGGCCAGGGACTCTTCCTGTTTCATTAAGG 1560
Db 1561 aaaggaagaattgcactgagcattccacttaggaagagatagagaagatctgctccgc 1620
Qy 1561 AAAGGAAGAATTGCCTGAGCATTCACITAGGAAGAGGATAGAGAAGTATGCTCCGC 1620
Db 1621 ctttggccacagagcagagcgacctgggtagtccccagtttcttctcagggatggata 1680
Qy 1621 CTTTGGCCACAGAGCAGAGCGACGCTGGATGCCCGAGTTCTCTCTCAGGGATGGATA 1680
Db 1681 gtaactgtcttctattttgcacaggttaagagagtagttagtaacctatgggaattatac 1740
Qy 1681 GTACCTGTCTTCTATTTGCACAGGTAAAGAGTAGTTAGCTAACCTATGGGAATTATAC 1740
Db 1741 tgggggctctgtgagcttcttaagagagtaacctgaaactaagctcagagggcaagg 1800
Qy 1741 TGTGGGGCTTGTGAGCTGCTTCTAGAGGCTAACCTGGAACTAAGCTCAGAGGCAAGG 1800
Db 1801 taataagcacttcagggttgcctcccaagtgggcctgatttagcaggtggtctgcggg 1860
Qy 1801 TAATAAGCACTTCAGGGCTTGTCTCCCAAGTGGGCTGTATTAGCAGGTGCTGTGCGGG 1860

Db	14	gagagggaatgcagcgaaatacactctgcctctgtctgctctcaacaacccccacactgtgag	73
QY	751	GAGAGGGAGATGACGAGGAATCACTGTGCCCTTGTCTGCTCTTCCAAACCCACACTGTGAG	810
Db	74	attgtggatgagaagactcgtgtgtccacacacgacagactcagttgacctccacagag	133
QY	811	ATTGTGGATGAGAAAGACTGTGTGTCCACACACGACAGACTCCAGTTGACCTTCAGAG	870
Db	134	ggcagcaccccccttatgggacacagcgcggggactccttggggcctgagccccacagtggg	193
QY	871	GGCAGACACCCCTTATGGG-CCAGCGCGGG-ACTCCTGGGGCGCTGAGCCCCCCACAGTGG	928
Db	194	gcaggagccatggcacacactggtcaggacagcacacctctctacagctagggggaact	253
QY	929	GCAGGAGCCCATGCAGACACTGGTCAGAGACAGCCACCCCTCTACAGCTAGGAGGAAC	988
Db	254	accacttgtgttcttggtttaaaacccctaccactcccgattttttggcgattcctta	313
QY	989	ACCACCTTTGTGTT-CTGGTT-AAAACCTTACCACCTCCCCCGCTTTTGGGGAATCCT-A	1045
Db	314	gttaagatcacagaacaggtgggcctatggcttgaggggtaaggtggggtagggttcct	373
QY	1046	GTAAGAGTGCAGAGACAGGTGGCCCTGTGGGCTG-AGGGTAAGGCTGGGTAGGGT-CCT	1103
Db	374	aaaagtgggtctctgttctcctggaggaagaagtattgggttttgggtgggacagtgcca	433
QY	1104	AACAGTGC-TCCTGTGCCATCCTTGGAGCAGATTTTGTCTGTGGATGGAGACAGTGGCA	1162
Db	434	gtttccacag-gtgttg-tgtaagggggttcaaaaaattg	472
QY	1163	GCPTCCACAGTATGCTGTGTGTAAAGGCTTCCAAACATTG	1203

RESULT	4	
ID	V99637 standard; DNA; 250 BP.	
AC	V99637;	
DT	29-MAR-1999 (first entry)	
DE	Human t-PALP-related DNA Clone HTAAM28R.	
KW	tissue plasminogen activator-like protease; t-PALP; human;	
KW	circulatory system-related disorder; blood clotting; stroke;	
KW	thrombosis; peripheral arterial occlusion; pulmonary embolism;	
KW	myocardiothrombosis; diagnosis; therapy; ss.	
OS	Homo sapiens.	
PN	WO9854199-A1.	
PD	03-DEC-1998.	
PF	27-MAY-1998; U10728.	
PR	28-MAY-1997; US-048000.	
PA	(HUMA-) HUMAN GENOME SCI INC.	
PI	Ebner R, Moore PA, Ruben SM;	
WPI	99-070207/06.	
PT	New tissue plasminogen activator-like protease - useful in the	
PT	diagnosis and treatment of circulatory system-related disorders	
PS	Claim 20; Page 59; 76pp; English.	
CC	This DNA sequence shows homology to DNA (see V99636) coding for	
CC	novel human tissue plasminogen activator-like protease (t-PALP, see	
CC	W87769). It was obtained from cDNA clone HTAAM28R. A nucleic acid	
CC	molecule comprising a polynucleotide having a sequence at least	
CC	95% identical to one of 7 t-PALP related sequences (see V99637-43)	
CC	is claimed. Full-length t-PALP DNA (also claimed) was discovered	
CC	in a cDNA library derived from activated monocytes. The 2.5 kb	
CC	t-PALP message has also been detected in heart, brain, lung,	
CC	placenta, liver, skeletal muscle, kidney, pancreas, thymus,	
CC	prostate, testis, ovary, small intestine, colon and peripheral	
CC	blood leukocytes. Vectors, host cells and methods for producing	
CC	t-PALP polypeptides are claimed. The homology between t-PALP and	
CC	tissue plasminogen activator indicates that t-PALP may be involved	
CC	in the regulation of normal and abnormal clotting in e.g. stroke,	
CC	deep-vein thrombosis, peripheral arterial occlusion, pulmonary	
CC	embolism and myocardiothrombosis.	
SQ	Sequence 250 BP; 67 A; 52 C; 69 G; 62 T;	
Query Match	10.2%; Score 238; DB 60; Length 250;	
Best Local Similarity	99.2%; Pred. No. 2,82e-137;	

Matches	250;	Conservative	0;	Mismatches	0;	Indels	2;	Gaps	2;
Db	1	attgcactgagcattccacttagaagagagatagaagaagatctgcgcctttggcca	60						
QY	1570	ATTGCACTGAGCATTCACCTTAGGAGAGGATAGAAGGATCTGCTCGCCCTTTGGCCA	1629						
Db	61	caggagcagaggcagacctgggatgccca-tttctcttcaggagatggatagtgaacctgt	119						
QY	1630	CAGGAGCAGAGGAGACCTGGGATGCCCAAGTTCTCTTCAGGAGTGGATAGTACCTGT	1689						
Db	120	cttcattttcacaggttaagagagtagtagtgaactaatggaattactcttgagggcc	179						
QY	1690	CTTCATTTCACAGGTAAAGAGAGTAGTTAGCTTAACCTATGGGAATTACTGTGGGGCC	1749						
Db	180	ttgt-agctgtcttcaagagcgttaacctggaactaaagtccagagcaagggttaataaagc	238						
QY	1750	TTGTGAGCTGCTTCTTAAGAGGCTAAACCTGGAACCTAAGCTCAGAGCAAGGTAATAAAGC	1809						
Db	239	acttcaggaggtt	250						
QY	1810	ACTTCAGGGCTT	1821						
RESULT	5								
ID	V99638	standard; DNA; 247 BP.							
AC	V99638;								
DE	29-MAR-1999	(first entry)							
KW	Human t-PALP-related DNA clone HFKB12R.								
KW	Tissue plasminogen activator-like protease; t-PALP; human;								
KW	circulatory system-related disorder; blood clotting; stroke;								
KW	thrombosis; peripheral arterial occlusion; pulmonary embolism;								
KW	myocardiothrombosis; diagnosis; therapy; ss.								
OS	Homo sapiens.								
PN	WO9854199-A1.								
PD	03-DEC-1998.								
PF	27-MAY-1998.	U10738.							
PR	28-MAY-1997.	US-048000.							
PA	(HUMA-) HUMAN GENOME SCI INC.								
PI	Enser R, Moore PA, Ruben SM;								
WP	91-070307/06.								
PT	New tissue plasminogen activator-like protease - useful in the								
PT	diagnosis and treatment of circulatory system-related disorders								
PS	Claim 20; Page 59; 76pp: English.								
CC	This DNA sequence shows homology to DNA (see V99636) coding for								
CC	novel human tissue plasminogen activator-like protease (t-PALP, see								
CC	W87769). It was obtained from cDNA clone HFKB12R. A nucleic acid								
CC	molecule comprising a polynucleotide having a sequence at least								
CC	95% identical to one of 7 t-PALP related sequences (see V99637-43)								
CC	is claimed. Full-length t-PALP DNA (also claimed) was discovered								
CC	in a cDNA library derived from activated monocytes. The 2.5 kb								
CC	t-PALP message has also been detected in heart, brain, lung,								
CC	placenta, liver, skeletal muscle, kidney, pancreas, spleen, thymus,								
CC	prostate, testis, ovary, small intestine, colon and peripheral								
CC	blood leukocytes. Vectors, host cells and methods for producing								
CC	t-PALP polypeptides are claimed. The homology between t-PALP and								
CC	tissue plasminogen activator indicates that t-PALP may be involved								
CC	in the regulation of normal and abnormal clotting in e.g. stroke,								
CC	deep-vein thrombosis, peripheral arterial occlusion, pulmonary								
CC	embolism and myocardiothrombosis.								
SQ	Sequence	247 BP; 73 A; 63 C; 60 G; 51 T;							
Query Match	10.1%;	Score 235;	DB 60;	Length 247;					
Best Local Similarity	99.2%;	Pred. No. 3.16e-135;							
Matches	247;	Conservative	0;	Mismatches	0;	Indels	2;	Gaps	1;
Db	1	atagagagaatgcctttatagaaaagtagaaccagtaaatattcttcttcagcatcact	60						
Cp	2315	ATAGAGAAATGCCTTTATAGAAAAGTAGAAACCAAGTAATATCTCTTCTCCAGCATCACT	2256						

	Query Match	10.1%	Score 235;	DB 60;	Length 247;
	Best Local Similarity	99.2%	Pred. No. 3.16e-135;		
	Matches	247;	Conservative	0; Mismatches	0; Indels
				2; Gaps	1;
Db	1	atagagaaatgccttttatagaaagtagaaccagtaataattctcttctccagcataact	60		
	1				
	1				
Cp	2315	ATAGAGAAATGCCTTTATAGAAAGTAGAAACCAAGTAATATCTCTTCTCCAGCATCACT	2256		
Db	61	aacaccaagagacacacctgagggtctagggtcccaagcagataggctccatagaaagcccc	120		
Cp	2255	AACACCAAGAGACACACTGAGGTCTAGGTCCCAAAAGCAGATGGCTCCATAGAAAGCCCC	2196		

```
Db 121 actaacccc--gtctccacattggcagtggaagggttctgaaagagagcttatggcta 178
|||||
Cp 2195 ACTAACCCCTGTCTCCACATTGGCAGTGGAGGGTCTGGAAGGAAGCCTCTATGGCTA 2136

Db 179 ggagctgccaagcctctttagttagtgcacacaggttagagccctgctgagctgctag 238
|||||
Cp 2135 GGAGCTGCCAAGGCTCTTGTAGTGTGACATCACAGGTTAGAGGCCCTGCTGAGCTGCTAG 2076

Db 239 cacagtgcga 247
|||||
Cp 2075 CACAGTGCA 2067

RESULT 6
ID V99639 standard; DNA; 461 BP.
AC V99639;
DE 29-MAR-1999 (first entry)
KW Human t-PALP-related DNA clone HAPBL24R.
KW Tissue plasminogen activator-like protease; t-PALP; human;
KW circulatory system-related disorder; blood clotting; stroke;
KW thrombosis; peripheral arterial occlusion; pulmonary embolism;
KW myocardiothrombosis; diagnosis; therapy; ss.
OS Homo sapiens.
PN WO9854199-A1.
PD 03-DEC-1998.
PF 27-MAY-1998; U10728.
PR 28-MAY-1997; US-048000.
PA (HUMA-) HUMAN GENOME SCI INC.
PI Ebner R, Moore PA, Ruben SM;
DR WPI: 99-070207/06.
PT New tissue plasminogen activator-like protease - useful in the
PT diagnosis and treatment of circulatory system-related disorders
PS Claim 20; Page 59-60; 76pp; English.
CC This DNA sequence shows homology to DNA (see V99636) coding for
CC novel human tissue plasminogen activator-like protease (t-PALP, see
CC W87769). It was obtained from cDNA clone HAPBL24R. A nucleic acid
CC molecule comprising a polynucleotide having a sequence at least
CC 95% identical to one of 7 t-PALP related sequences (see V99637-43)
CC is claimed. Full-length t-PALP DNA (also claimed) was discovered
CC in a cDNA library derived from activated monocytes. The 2.5 kb
CC t-PALP message has also been detected in heart, brain, lung,
CC placenta, liver, skeletal muscle, kidney, pancreas, spleen, thymus,
CC prostate, testis, ovary, small intestine, colon and peripheral
CC blood leukocytes. Vectors, host cells and methods for producing
CC t-PALP polypeptides are claimed. The homology between t-PALP and
CC tissue plasminogen activator indicates that t-PALP may be involved
CC in the regulation of normal and abnormal clotting in e.g. stroke,
CC deep-vein thrombosis, peripheral arterial occlusion, pulmonary
CC embolism and myocardiothrombosis.
CC Sequence 461 BP; 95 A; 108 C; 145 G; 113 T;

Query Match 8.2%; Score 191; DB 60; Length 461;
Best Local Similarity 92.3%; Pred. No. 2.63e-105;
Matches 263; Conservative 0; Mismatches 12; Indels 10; Gaps 9;

Db 15 aacagcatacaagggttagtctgactgca-gctgggagctggagggcagagca--cgcca 71
|||||
QY 8 AACAGCATACAGAGGGCAGGTTCTGACTGCAAGCTGGGACTGGGAGGCAGAGCCGCCGCA 67
|||||
Db 72 agggggcctcggttaaacactggttcgttcaatcacctgcaa-acgagaggaagatgc 130
|||||
QY 68 AGGGGGCTCGGTTAAACACTGGTTCGTTCAATCACCTCAAGACGAGGCAAGGATGC 127
|||||
Db 131 tgttgacctgggtaca-gcattcctgttcagacaatcctcctcgttaagcctatgat 189
|||||
QY 128 TGTGGCTGGGTACAAGCAATTCCTCGTCAGCAACATGCTCTAGCAAGGCTATGGAT 187
|||||
Db 190 ctgagagctttctggacaacggccac-tgtaccggagagaccagaccttccc-g-gc 246
|||||
QY 188 CTGAGGCTGTTCTGGGACAAAGCCACCTGTATCCCGGAGGACACAGCACTCCCGCGC 247
|||||
Db 247 cggctccctc-g-tgctcaactggctgacgcgcaggggctgctgg 289
|||||
```

```
QY 248 CGGCGCTCGCTGCCTCAACTGGCTGGACGCCGACAGCGGGGCTGG 292

RESULT 7
ID V99641 standard; DNA; 334 BP.
AC V99641;
DE 29-MAR-1999 (first entry)
KW Human t-PALP-related DNA clone HHPGT42R.
KW Tissue plasminogen activator-like protease; t-PALP; human;
KW circulatory system-related disorder; blood clotting; stroke;
KW thrombosis; peripheral arterial occlusion; pulmonary embolism;
KW myocardiothrombosis; diagnosis; therapy; ss.
OS Homo sapiens.
PN WO9854199-A1.
PD 03-DEC-1998.
PF 27-MAY-1998; U10728.
PR 28-MAY-1997; US-048000.
PA (HUMA-) HUMAN GENOME SCI INC.
PI Ebner R, Moore PA, Ruben SM;
DR WPI: 99-070207/06.
PT New tissue plasminogen activator-like protease - useful in the
PT diagnosis and treatment of circulatory system-related disorders
PS Claim 20; Page 61; 76pp; English.
CC This DNA sequence shows homology to DNA (see V99636) coding for
CC novel human tissue plasminogen activator-like protease (t-PALP, see
CC W87769). It was obtained from cDNA clone HHPGT42R. A nucleic acid
CC molecule comprising a polynucleotide having a sequence at least
CC 95% identical to one of 7 t-PALP related sequences (see V99637-43)
CC is claimed. Full-length t-PALP DNA (also claimed) was discovered
CC in a cDNA library derived from activated monocytes. The 2.5 kb
CC t-PALP message has also been detected in heart, brain, lung,
CC placenta, liver, skeletal muscle, kidney, pancreas, spleen, thymus,
CC prostate, testis, ovary, small intestine, colon and peripheral
CC blood leukocytes. Vectors, host cells and methods for producing
CC t-PALP polypeptides are claimed. The homology between t-PALP and
CC tissue plasminogen activator indicates that t-PALP may be involved
CC in the regulation of normal and abnormal clotting in e.g. stroke,
CC deep-vein thrombosis, peripheral arterial occlusion, pulmonary
CC embolism and myocardiothrombosis.
CC Sequence 334 BP; 74 A; 82 C; 106 G; 72 T;

Query Match 6.4%; Score 150; DB 60; Length 334;
Best Local Similarity 88.0%; Pred. No. 9.67e-78;
Matches 249; Conservative 0; Mismatches 21; Indels 13; Gaps 10;

Db 13 ggaacggctgactgca-gctgggagctggagggcagagcgctc---aagggggcctcgt 68
|||||
QY 21 GGGCAGGCTGACTGCAAGCTGGGACTGGGAGGCAGAGCGCGCCAGGGGCGCTCGGT 80
|||||
Db 69 taacacactggtcttcaatcacctgcaa--cga-gaggaagagatgcttggcctgggt 125
|||||
QY 81 TAAACACTGGTGTGTTCAATCACTGCAAGACGAGGCAAGGATGCTGTGGCTGGGT 140
|||||
Db 126 acaagcattcct-gtcagcaacatgctctctagcagaaacccctatgagctggagagctgt 184
|||||
QY 141 ACAAGCAITTCCTCGTCAGCAACATGCTCTAGCAGAA-GCCTATGGATCTGG-AGGCTGT 198
|||||
Db 185 ttctgggacaacggaacctgtaccgg-aggaccagacctccccggc-cgggaccttccgt 242
|||||
QY 199 TTCTGGGACACAGGCGCACCTGTACCGGAGGAGCACAGACCTCCCGCGCGGCTCCGC 258
|||||
Db 243 ggccttcaattggttgacgtggcaaaaggggctgttcttgcccc 285
|||||
QY 259 TGCCCT-CAACTGGCTGGAGCGCAGAGCGGGGTGGCCTCGGCC 300
|||||

RESULT 8
ID V99643 standard; DNA; 291 BP.
AC V99643;
DE 29-MAR-1999 (first entry)
KW Human t-PALP-related DNA clone HSSES93R.
KW Tissue plasminogen activator-like protease; t-PALP; human;
KW circulatory system-related disorder; blood clotting; stroke;
```

thrombosis; peripheral arterial occlusion; pulmonary embolism;
 KW myocardiothrombosis; diagnosis; therapy; ss.
 OS Homo sapiens.
 PN WO9854199-A1.
 PD 03-DEC-1998.
 PF 27-MAY-1998; U10728.
 PR 28-MAY-1997; US-048000.
 PA (HUMA-) HUMAN GENOME SCI INC.
 PI Ebner R, Moore PA, Ruben SM;
 DR WPI: 99-070207/06.
 PT New tissue plasminogen activator-like protease - useful in the
 PT diagnosis and treatment of circulatory system-related disorders
 PS Claim 20; Page 62; 76pp; English.
 CC This DNA sequence shows homology to DNA (see V99636) coding for
 CC novel human tissue plasminogen activator-like protease (t-PALP, see
 CC W87769). It was obtained from cDNA clone HSSE93R. A nucleic acid
 CC molecule comprising a polynucleotide having a sequence at least
 CC 95% identical to one of 7 t-PALP related sequences (see V99637-43)
 CC is claimed. Full-length t-PALP DNA (also claimed) was discovered
 CC in a cDNA library derived from activated monocytes. The 2.5 kb
 CC t-PALP message has also been detected in heart, brain, lung,
 CC placenta, liver, skeletal muscle, kidney, pancreas, spleen, thymus,
 CC prostate, testis, ovary, small intestine, colon and peripheral
 CC blood leukocytes. Vectors, host cells and methods for producing
 CC t-PALP polypeptides are claimed. The homology between t-PALP and
 CC tissue plasminogen activator indicates that t-PALP may be involved
 CC in the regulation of normal and abnormal clotting in e.g. stroke,
 CC deep-vein thrombosis, peripheral arterial occlusion, pulmonary
 CC embolism and myocardiothrombosis.
 SQ Sequence 291 BP; 66 A; 67 C; 85 G; 73 T;
 Query Match 3.2%; Score 74; DB 60; Length 291;
 Best Local Similarity 98.8%; Pred. No. 2.54e-28;
 Matches 80; Conservative 0; Mismatches 0; Indels 1; Gaps 1;
 Db 151 ggctacgtgctggcattaccatggtgatcatcattgcatcgtgagctgcatc 210
 QY - 631 GGCTACGTGCTGGCATTACCATGATGGTGATCATCATTCATCGAGTGGCATCATC 690
 Db 211 ttgggctactc-tacaagagg 230
 QY 691 TTGGGCTACTCTACAGAGG 711
 RESULT 9
 ID N81164 standard; DNR; 204 BP.
 AC N81164;
 DT 08-NOV-1990 (first entry)
 DE Base substituted E.coli beta-galactosidase alpha-fragment.
 KW E.coli beta galactosidase alpha-fragment; base substitutions; ss.
 OS Escherichia coli.
 FH Key Location/Qualifiers
 FT misc_feature 19..69
 FT /tag= a
 FT /function= multiple cloning site
 FT primer_bind 187..204
 FT /tag= b
 FT EP-285123-A.
 PN 05-MAY-1988.
 PD 30-MAR-1988; 105163.
 PR 03-APR-1987; US-034819.
 PA (SUSO) SUOMEN SOKERI OY.
 PI Lehtovaara P, Knowles J, Koivula A, Bamford J, Reinikainen T;
 DR WPI: 88-279927/40.
 PT Introducing random point mutations into nucleic acids -
 PT by prep of single stranded template, annealing a primer, elongation,
 PT misincorporation, completion of molecules and screening.
 PS Disclosure; p. English.
 CC Random point mutations were introduced into the alpha fragment of
 CC E.coli beta-galactosidase. The wild type sequence was obtained as a
 CC single stranded template and an oligonucleotide was hybridised to
 CC it to generate a popn of DNA molecules which terminate at all
 CC possible nucleotide positions within a specified region. The

CC variable 3' ends generated in this way are used as primers for
 CC reverse transcriptase. Nucleotides are misincorporated by the
 CC transcriptase and the molecules are completed to forms that can be
 CC amplified and then expressed in a suitable host-vector system.
 CC The sequence covers all 176 diff base substitutions, most of which
 CC occurred singularly in any given mutant.
 CC See also P80575.
 SQ Sequence 204 BP; 21 A; 47 C; 17 G; 11 T; 108 Others;
 Query Match 1.9%; Score 44; DB 1; Length 204;
 Best Local Similarity 10.7%; Pred. No. 2.32e-10;
 Matches 11; Conservative 58; Mismatches 33; Indels 1; Gaps 1;
 Db 85 gymrtthhyrmrbvnyrdynrdaaa-wycyrrsvkydcynachdhhyvbbvy 143
 QY 2010 GCAGCTACTGGTGGCAGAGCCAGCTTCTGAGGGAGCCACATTTCCACATGC 2069
 Db 144 nvhnncnccebnhvhbnnhrwnwayvzhrddvhc 186
 QY 2070 ACTGTGCTAGCAGCTCAGCAGGGCCTTAACTGTGTGTGTGCAC 2112
 RESULT 10
 ID Q51746 standard; cDNA; 91 BP.
 AC Q51746;
 DT 31-MAY-1994 (first entry)
 DE Oligonucleotide probe MK14-A
 KW Oligonucleotide; DNA probe; mycobacteria; disease diagnosis;
 KW ss.
 OS Synthetic.
 PN EP-571911-A.
 PD 01-DEC-1993.
 PF 24-MAY-1993; 108325.
 PR 26-MAY-1992; US-889651.
 PA (BECT) BECTON DICKINSON CO.
 PI Shank DD, Spears PA;
 DR WPI: 93-378844/48.
 PT New oligo:nucleotide probes specific for Mycobacteria - used for
 PT detection and amplification of Mycobacteria nucleic acid in
 PT samples
 PS Claim 3; Page 14; 23pp; English.
 CC Oligonucleotide probe MK14-A consists of nucleotides 5-95 of MK14
 CC (Q51735). It hybridized to all spp. of mycobacteria tested, but
 CC cross reacted to a few non-mycobacterial spp. The probe may
 CC be useful as an initial screen for mycobacterial infection.
 CC See also Q51735-45 and Q51747-59.
 SQ Sequence 91 BP; 5 A; 17 C; 15 G; 4 T;
 Query Match 1.8%; Score 42; DB 9; Length 91;
 Best Local Similarity 8.9%; Pred. No. 3.07e-09;
 Matches 5; Conservative 44; Mismatches 7; Indels 0; Gaps 0;
 Db 7 ggcggsvhsvyvvvshhshhshhshhshhshhshhshhshhshhshhshhsvct 62
 QY 894 GGCCGGAGCTCTCTGGGGCTGAGCCCCCAGTGAGGAGGCCACATGCAGACACT 949
 RESULT 11
 ID Q51746 standard; cDNA; 91 BP.
 AC Q51746;
 DT 31-MAY-1994 (first entry)
 DE Oligonucleotide probe MK14-A
 KW Oligonucleotide; DNA probe; mycobacteria; disease diagnosis;
 KW ss.
 OS Synthetic.
 PN EP-571911-A.
 PD 01-DEC-1993.
 PF 24-MAY-1993; 108325.
 PR 26-MAY-1992; US-889651.
 PA (BECT) BECTON DICKINSON CO.
 PI Shank DD, Spears PA;
 DR WPI: 93-378844/48.
 PT New oligo:nucleotide probes specific for Mycobacteria - used for

DT	05-APR-1995	(first entry)
DE	Generic DNA sequence to generate a random TSAR peptide library.	
KW	TSAR; totally synthetic affinity reagent; synthetic; binding domain;	
KW	effector domain; concatenated heterofunctional protein; linker;	
KW	direct; rapid; detection; screening; treatment; generic; ss.	
OS	Synthetic.	
FH		
FT	key	
FT	misc_feature	
FT	55..60	
FT	Location/Qualifiers	
FT	/*tag= a	
FT	/note= "this sequence represents 'Z'; Z can be a	
FT	sequence of 6, 9 or 12 nucleotides (see	
FT	comments)"	
PN	W09418318-A.	
PD	18-AUG-1994.	
PF	01-FEB-1994; U00977.	
PR	01-FEB-1993; US-013416.	
PR	30-DEC-1993; US-176500.	
PR	31-JAN-1994; US-189331.	
PA	(DYNC-) UNIV NORTH CAROLINA.	
PI	Fowlkes DM, Kay BK;	
PI	WPI; 94-279739/34.	
DR	P-PSDB; R65154.	
PT	Identifying proteins or peptide(s) which bind a ligand - by	
PT	screening a recombinant vector library expressing fusion proteins	
PT	comprising a binding domain and an effector domain	
PS	Disclosure; Page 35; 255pp; English.	
CC	Q70468 is a generic DNA sequence used to generate random TSAR (Totally	
CC	Synthetic Affinity Reagents) peptides.This generic formula can also be	
CC	represented as follows: X(NNB)11(TGC)(NNB)6z(NNB)7(TGC)(NNB)10Y. X	
CC	and Y are flanking restriction sites (X is not the same as Y) that are	
CC	not specified further. Other generic sequences are shown in Q70466-68.	
CC	Other specific peptides generated by these generic sequences are shown in	
CC	R65151-54. TSARs are concatenated heterofunctional proteins or peptides,	
CC	comprising at least two functional regions - a binding domain with	
CC	affinity for a ligand and a second effector peptide portion that is	
CC	chemically or biologically active.They may further comprise a linker	
CC	peptide between the 2 domains.The oligonucleotides are also designed so	
CC	that the expressed peptide contains 2 or 4 cysteine residues positioned	
CC	in, or flanking, the unpredicted or variant residues. These residues	
CC	confer some degree of conformational rigidity to the peptides.The TSARs	
CC	or compns. comprising a TSAR binding domain can be used in vivo to	
CC	deliver a chemically or biologically active moiety, eg. metal ion,	
CC	radioisotope, peptide, toxin or enzyme, to the specific target or on the	
CC	cell. They can also replace the function of macromolecules, eg.	
CC	monoclonal or polyclonal antibodies and therefore circumvent the need	
CC	for complex methods of hybridoma formation or in vivo antibody	
CC	production. The TSARs are easily characterised and have designed activity	
CC	allowing direct and rapid detection in a screening process.	
SQ	Sequence 114 BP; 0 A; 2 C; 2 G; 2 T;	
	Query Match 1.6%; Score 38; DB 12; Length 114;	
	Best Local Similarity 4.5%; Pred. No. 4.87e-07;	
	Matches 5; Conservative 34; Mismatches 73; Indels 0; Gaps 0;	
Db	3 bnnbnnbnnbnnbnnbnnbnnbnnbnnbnnbnnbnnbnnbnnbnnbnnnnnnnn 62	
Cp	312 CCCCGACGGGGCCGAGGCCAGCCGCTCTGCGCGTCCAGCCAGTTGAGCGAGCGAG 253	
Db	63 bnnbnnbnnbnnbnnbnnbnnbnnbnnbnnbnnbnnbnnbnnbnnbnnbnnbnn 114	
Cp	252 GCCCGGGCGGGGAGGTCTGCTCCCGGTACAGGTGGCGGTGTGCCAG 201	
RESULT	14	
ID	Q70469 standard; DNA; 114 BP.	
AC	Q70469;	
DE	07-APR-1995 (first entry)	
DE	Generic DNA sequence to generate a random TSAR peptide library.	
KW	TSAR; totally synthetic affinity reagent; synthetic; binding domain;	
KW	effector domain; concatenated heterofunctional protein; linker;	
KW	direct; rapid; detection; screening; treatment; generic; ss.	
OS	Synthetic.	
FH		
FT	key	
FT	Location/Qualifiers	


```

FT misc_feature 55..60
FT /tag= a
FT /note= "this sequence represents '2'; z can be a
FT sequence of 6,9 or 12 nucleotides (see
FT comments)"
PD WO9418318-A.
PD 18-AUG-1994.
PF 01-FEB-1994; U00977.
PR 01-FEB-1993; US-013416.
PR 30-DEC-1993; US-176500.
PR 31-JAN-1994; US-189331.
PA (UYNC-) UNIV NORTH CAROLINA.
PI Fowlkes DM, Kay BK;
DR WPI; 94-279739/34.
PT Identifying proteins or peptide(s) which bind a ligand - by
PT screening a recombinant vector library expressing fusion proteins
PT comprising a binding domain and an effector domain
PS Disclosure; Page 35; 255pp; English.
CC Q70469 is a generic DNA sequence used to generate random TSAR peptide
CC This generic formula can be represented as follows: X(TGC)(NNB)10-
CC (TGC)(NNB)62(NNB)2(TGC)(NNB)14(TGC)Y. X and Y are flanking restriction
CC sites (X is not the same as Y) that are not specified further. This
CC sequence generates peptides that are cloverleaf in structure. Other
CC generic sequences are shown in Q70465-68. Other specific peptides
CC generated by these generic sequences are shown in R65150-54. TSARs are
CC concatenated heterofunctional proteins or peptides, comprising at least
CC two functional regions - a binding domain with affinity for a ligand and
CC a second effector peptide portion that is chemically or biologically
CC active. They may further comprise a linker peptide between the 2 domains.
CC The oligonucleotides are also designed so that the expressed peptide
CC contains 2 or 4 cysteine residues positioned in, or flanking, the
CC unpredicted or variant residues. These residues confer some degree of
CC conformational rigidity to the peptides. The TSARs or compsns. comprising
CC a TSAR binding domain can be used in vivo to deliver a chemically or
CC biologically active moiety, eg. metal ion, radioisotope, peptide, toxin
CC or enzyme, to the specific target or on the cell. They can also replace
CC the function of macromolecules, eg. monoclonal or polyclonal antibodies
CC and therefore circumvent the need for complex methods of hybridoma
CC formation or in vivo antibody production. The TSARs are easily
CC characterised and have designed activity allowing direct and rapid
CC detection in a screening process.
SQ Sequence 114 BP; 0 A; 4 G; 4 T;

Query Match 1.6%; Score 37; DB 12; Length 114;
Best Local Similarity 5.5%; Pred. No. 1.69e-06;
Matches 6; Conservative 32; Mismatches 71; Indels 0; Gaps 0;

Db 3 cnnbnnbnnbnnbnnbnnbnnbnnbnnbnnbnnbnnbnnbnnbnnbnnnnnnnn 62
| : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Cp 312 CCCCAGACAGCGGGCGCGAGCGCCGCTGCGCGTCCAGCCAGTTGAGCGCGGAG 253
| : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 63 bnnbtgcnnbnnbnnbnnbnnbnnbnnbnnbnnbnnbnnbnnbnnbnnbnnbnn 111
| : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Cp 252 GCCCGCGCGGGGAGGTCTGGTCTCCCGGTACAGTGGCGGTGTC 204

RESULT 15
ID Q70465 standard; DNA; 114 BP.
AC Q70465;
DE 05-APR-1995 (first entry)
DE Generic DNA sequence to generate a random TSAR peptide library.
KW TSAR: totally synthetic affinity reagent; synthetic; binding domain;
KW effector domain; concatenated heterofunctional protein; linker;
KW direct; rapid; detection; screening; treatment; generic; ss.
OS Synthetic.
FH Key Location/Qualifiers
FT misc_feature 55..60
FT /tag= a
FT /note= "this sequence represents '2'; z can be a
FT sequence of 6, 9 or 12 nucleotides (see
FT comments)"
PD WO9418318-A.
PD 18-AUG-1994.

```

```

PF 01-FEB-1994; U00977.
PR 01-FEB-1993; US-013416.
PR 30-DEC-1993; US-176500.
PR 31-JAN-1994; US-189331.
PA (UYNC-) UNIV NORTH CAROLINA.
PI Fowlkes DM, Kay BK;
DR WPI; 94-279739/34.
DR P-PSDB; R65150 and R65151.
PT Identifying proteins or peptide(s) which bind a ligand - by
PT screening a recombinant vector library expressing fusion proteins
PT comprising a binding domain and an effector domain
PS Disclosure; Page 35; 255pp; English.
CC Q70465 is a generic DNA sequence used to generate random TSAR (Totally
CC Synthetic Affinity Reagents) peptides. This generic formula can also be
CC represented as follows: X(NNB)6(TGC)(NNB)11Z(NNB)3Y. X
CC and Y are flanking restriction sites (X is not the same as Y) that are
CC not specified further. Other generic sequences are shown in Q70466-68.
CC Other specific peptides generated by these generic sequences are shown in
CC R65151-54. TSARs are concatenated heterofunctional proteins or peptides,
CC comprising at least two functional regions - a binding domain with
CC affinity for a ligand and a second effector peptide portion that is
CC chemically or biologically active. They may further comprise a linker
CC peptide between the 2 domains. The oligonucleotides are also designed so
CC that the expressed peptide contains 2 or 4 cysteine residues positioned
CC in, or flanking, the unpredicted or variant residues. These residues
CC confer some degree of conformational rigidity to the peptides. The TSARs
CC or compsns. comprising a TSAR binding domain can be used in vivo to
CC deliver a chemically or biologically active moiety, eg. metal ion,
CC radioisotope, peptide, toxin or enzyme, to the specific target or on the
CC cell. They can also replace the function of macromolecules, eg.
CC monoclonal or polyclonal antibodies and therefore circumvent the need
CC for complex methods of hybridoma formation or in vivo antibody
CC production. The TSARs are easily characterised and have designed
CC activity allowing direct and rapid detection in a screening process.
SQ Sequence 114 BP; 0 A; 2 C; 2 G; 2 T;

Query Match 1.5%; Score 36; DB 12; Length 114;
Best Local Similarity 4.5%; Pred. No. 5.78e-06;
Matches 5; Conservative 33; Mismatches 74; Indels 0; Gaps 0;

Db 3 bnnbnnbnnbnnbntgcnnbnnbnnbnnbnnbnnbnnbnnbnnbnnbnnbnnbnnnnnn 62
| : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
QY 267 CTGGCTGGACGCGCAGAGCGGGCTGGCCCTCGGCCCGCCGTCGGGGCGCGCAATCACAG 326
| : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 63 bnnbnnbnnbnnbnnbnnbnnbnnbnnbnnbnnbnnbnnbnnbnnbnnbnnbnnbnnb 114
| : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
QY 327 TTAGTCCGGAACCCGCGACGAGGCCCGCGCGGCCCTGGTGTGCTAGTCAGT 378
| : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :

Search completed: Mon Sep 20 20:55:28 1999
Job time : 1033 secs.

```

W P S R L H (TM)

Release 3.1A John F. Collins, Biocomputing Research Unit.
Copyright (c) 1993-1998 University of Edinburgh, U.K.
Distribution rights by Oxford Molecular Ltd

MPsrch_pp protein - protein database search, using Smith-Waterman algorithm

Run on: Fri Sep 17 18:23:46 1999; MasPar time 11.68 Seconds
478.708 Million cell updates/sec
Tabular output not generated.

Title: >US-09-084-491A-2
Description: (1-263) from US09084491A.pep
Perfect Score: 1883
Sequence: 1 MLLWVQAFVLSNMLLAAY.....PVDPQEGSTPLMGAGTPGA 263
Scoring table: PAM 150
Gap 11

Searched: 170751 seqs, 21266608 residues

Post-processing: Minimum Match 0%
Listing first 45 summaries

Database: a-geneseq35
1:part1 2:part2 3:part3 4:part4 5:part5 6:part6 7:part7
8:part8 9:part9 10:part10 11:part11 12:part12 13:part13
14:part14 15:part15 16:part16 17:part17 18:part18
19:part19 20:part20 21:part21 22:part22 23:part23
24:part24 25:part25 26:part26 27:part27 28:part28
29:part29 30:part30 31:part31 32:part32 33:part33
34:part34 35:part35 36:part36 37:part37 38:part38
39:part39

Statistics: Mean 33.039; Variance 139.441; scale 0.237

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match %	Length	ID	Description	Pred. No.
1	1883	100.0	263	39	W87769 Human tissue plasmino	1.04e-174
2	256	13.6	39	36	W72641 Nervous glia cell gro	3.64e-13
3	255	13.5	39	36	W72640 Nervous glia cell gro	4.50e-13
4	184	9.8	812	15	R83959 Complete mouse plasm	1.03e-06
5	184	9.8	812	21	W07585 Murine plasminogen se	1.03e-06
6	181	9.6	655	17	R89197 Human hepatocellular	1.88e-06
7	181	9.6	655	10	R53962 Hepatocyte growth fac	1.88e-06
8	177	9.4	701	22	W14271 Mouse L5/3 tumour sup	4.17e-06
9	177	9.4	701	22	W14271 Mouse L5/3 tumour sup	4.17e-06
10	177	9.4	716	22	W14272 Mouse growth factor L	4.17e-06
11	177	9.4	716	22	W14272 Mouse growth factor L	4.17e-06
12	176	9.3	217	28	W46423 Bovine macrophage sti	5.09e-06
13	175	9.3	380	1	R05433 cPA-P2 Hybrid plasmin	6.21e-06
14	171	9.1	504	6	R32710 Haematopoietic stem c	1.38e-05
15	170	9.0	728	4	R21976 Human Hepatocyte grow	1.68e-05
16	167	8.9	723	3	R15624 Human leukocyte-deriv	3.03e-05

17	167	8.9	723	6	R29819 TCF-II.	3.03e-05
18	167	8.9	723	15	R82885 Tumour cytotoxic fact	3.03e-05
19	167	8.9	723	2	R07144 Tumour cytotoxic fact	3.03e-05
20	167	8.9	723	36	W59923 Human leukocyte-deriv	3.03e-05
21	167	8.9	723	37	W76690 Human plasminogen-lik	3.03e-05
22	167	8.9	723	11	R57026 Human wild-type tumor	3.03e-05
23	167	8.9	727	2	R10856 Hepatic parenchymal c	3.03e-05
24	167	8.9	728	39	W88529 Human hepatocyte grow	3.03e-05
25	167	8.9	728	39	W88532 Human hepatocyte grow	3.03e-05
26	167	8.9	728	39	W88530 Human hepatocyte grow	3.03e-05
27	167	8.9	728	39	W88531 Human hepatocyte grow	3.03e-05
28	167	8.9	728	5	R25160 Human HGF.	3.03e-05
29	167	8.9	728	32	W58696 Human hepatocyte grow	3.03e-05
30	167	8.9	728	31	W42998 Recombinant human hep	3.03e-05
31	167	8.9	728	21	W00338 Human hepatic parench	3.03e-05
32	167	8.9	728	8	R52943 Human hepatocyte grow	3.03e-05
33	167	8.9	728	16	R87525 Mutant hepatocyte gro	3.03e-05
34	167	8.9	728	8	R52940 Human hepatocyte grow	3.03e-05
35	167	8.9	728	8	R52948 Human hepatocyte grow	3.03e-05
36	167	8.9	728	28	W39207 Human hepatocyte grow	3.03e-05
37	167	8.9	728	8	R52945 Human hepatocyte grow	3.03e-05
38	167	8.9	728	8	R52949 Human hepatocyte grow	3.03e-05
39	167	8.9	728	36	W59922 Human leukocyte-deriv	3.03e-05
40	167	8.9	728	5	R25876 Recombinant human hep	3.03e-05
41	167	8.9	728	8	R52942 Human hepatocyte grow	3.03e-05
42	167	8.9	728	8	R52944 Human hepatocyte grow	3.03e-05
43	167	8.9	728	8	R40862 Competitive inhibitor	3.03e-05
44	167	8.9	728	19	W00340 Wild type hepatocyte	3.03e-05
45	167	8.9	728	3	R15623 Human leukocyte-deriv	3.03e-05

ALIGNMENTS

RESULT 1
ID W87769 standard; Protein; 263 AA.
AC W87769;
DE Human tissue plasminogen activator-like protease t-PALP.
KW Tissue plasminogen activator-like protease; t-PALP; human;
KW circulatory system-related disorder; blood clotting; stroke;
KW thrombosis; peripheral arterial occlusion; pulmonary embolism;
OS Myocardiothrombosis; diagnosis; therapy.
FH Homo sapiens.
FH Key Location/Qualifiers
FT 1..21
FT Peptide
FT 1..21
FT label= Sig_peptide
FT 22..263
FT Protein
FT 22..263
FT label= Mat_protein
FT 25..84
FT Domain
FT 25..84
FT note= "kringle domain"
FT Domain
FT 85..263
FT note= "protease domain"
FT 22..31
FT Peptide
FT 22..31
FT note= "epitope-bearing region"
FT 35..44
FT Peptide
FT 35..44
FT note= "epitope-bearing region"
FT 71..81
FT Peptide
FT 71..81
FT note= "epitope-bearing region"
FT 91..107
FT Peptide
FT 91..107
FT note= "epitope-bearing region"
FT 119..128
FT Peptide
FT 119..128
FT note= "epitope-bearing region"
FT 138..147
FT Peptide
FT 138..147
FT note= "epitope-bearing region"
FT 155..167
FT Peptide
FT 155..167
FT note= "epitope-bearing region"
FT 193..203
FT Peptide
FT 193..203
FT note= "epitope-bearing region"
FT 206..215
FT Peptide
FT 206..215
FT note= "epitope-bearing region"
FT 227..237
FT Peptide
FT 227..237
FT note= "epitope-bearing region"
FT 243..252
FT Peptide
FT 243..252

```
FT W09854199-A1. /note= "epitope-bearing region"
PN 03-DEC-1998.
PD 27-MAY-1998; U10728.
PF 28-MAY-1997; US-048000.
PR (HUMA-) HUMAN GENOME SCI INC.
PA Ebner R, Moore PA, Ruben SM,
PI WPI: 99-070207/06.
DR N-PSDB; V99636.
DR New tissue plasminogen activator-like protease - useful in the
PT diagnosis and treatment of circulatory system-related disorders
PT Claim 1: Page 56-57; 76pp; English.
PS This is the amino acid sequence of tissue plasminogen activator-like
CC protease (t-PALP), a novel member of the serine protease family
CC that shares sequence homology to human tissue plasminogen activator
CC (see W87770). The t-PALP sequence was deduced from a cDNA clone
CC (see V99636) derived from activated monocytes. The 2.5 kb t-PALP
CC message has also been detected in heart, brain, lung, placenta,
CC liver, skeletal muscle, kidney, pancreas, spleen, thymus, prostate,
CC testis, ovary, small intestine, colon and peripheral blood
CC leukocytes. Isolated nucleic acids encoding amino acids -21 to
CC 242, -20 to 242, 1-242, 4-63 (kringle domain) and 64-242 (protease
CC domain) of t-PALP, or encoding epitope-bearing portions of t-PALP,
CC are also claimed, as are recombinant vectors, host cells, and
CC methods for producing t-PALP polypeptides. t-PALP may be used to
CC detect and treat disorders related to the circulatory system, and
CC to identify agonists and antagonists of t-PALP activity. The
CC homology between t-PALP and tPA indicates that t-PALP may be
CC involved in the regulation of normal and abnormal clotting
CC in e.g. stroke, deep-vein thrombosis, peripheral arterial
CC occlusion, pulmonary embolism and myocardiothrombosis.
SQ Sequence 263 AA;

Query Match 100.0%; Score 1883; DB 39; Length 263;
Best Local Similarity 100.0%; Pred. No. 1.04e-174;
Matches 263; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Db 1 mllawqafivsnmlaeyvgggcfwdnglhlyredqtsppagrlcrlnwldagsglasap 60
QY 1 MLLAWQAFIVSNMLLAEAYSGGCFWDNGHLHYREDQTSPPAGRLCLNWLDAQSGLASAP 60

Db 61 vsgagnhscyrnpdprgpcwcyvgeagvpekrpcedlrcpettsqalpafteiqeas 120
QY 61 VSGAGNHSYCRNPDEDPGRPCWCYVGEAGVPEKRPCEDLRCPETTSQALPAFTEIQEAS 120

Db 121 epgadeqvafapanalparseaavqpvigisqrvmaskekddltgtyvlgtmmvi 180
QY 121 EPGADEVQVFAPANALPARSEAAAVQPVIGISQRYRMNSKEKKDGLTGLYVLGTMVMI 180

Db 181 iiaigagilgysykrkalkqehdgkvceremqritlplsafntpcelivdektvvvht 240
QY 181 IIAIGAGIILGYSYRKGLKDKQHDQKVCEREMQRIITLPLSAFTNPTCEIVDEKTVVHT 240

Db 241 sctpvdpcgsgtplmgagtpga 263
QY 241 SOTPDVDPQSGSTPLMGQACTPGA 263

RESULT 2
ID W72641 standard; peptide: 39 AA.
AC W72641;
DE 05-JAN-1999 (first entry)
DE Nervous glia cell growth factor N-terminal peptide #2.
KW Nervous glia cell growth factor; human; urine; secretion promoter;
KW choline acetyltransferase activity enhancer; nervous disease.
OS Homo sapiens.
FH Key Location/Qualifiers
FT Misc_difference 25 /note= "unspecified"
FT Misc_difference 29 /note= "unspecified"
FT J10265498-A.
PD 06-OCT-1998.
PN 24-MAR-1997; 090305.
PR (NICH-) JAPAN CHEM RES CO LTD.
PA WPI: 98-589719/50.
PT Nervous glia cell growth factor derived from human urine - used for
PT treatment of nervous diseases
PS Claim 2: Fig 6; 14pp; Japanese.
CC The present invention describes nervous glia cell growth factor, which
CC is purified from human urine by ultrafiltration, salting-out by ammonium
CC sulphate, gel filtration, ion exchange chromatography and reversed phase
CC chromatography, and has a M.W. of 29 kDa by sodium dodecyl sulphate-
CC chromatography gel electrophoresis. Also described are: (1) a secretion
CC promoter for the nerve growth factor of glia cell consisting of the
CC above growth factor, an enhancer for choline acetyltransferase activity
CC of neuron consisting of the above growth factor; and (2) DNA encoding
CC nervous glia growth factor containing a DNA sequence coding the amino
CC acid sequence shown by the two 39 amino acid sequences as given in
CC W72640 and W72641, which are identical, except one starts with Tyr and
CC the other with Ser (i.e. they are from different DNA transcripts). The
CC glia cell growth factor can be prepared in a large amount and the factor
CC can be used for the treatment of nervous diseases.
SQ Sequence 39 AA;

Query Match 13.68; Score 256; DB 36; Length 39;
Best Local Similarity 92.3%; Pred. No. 3.64e-13;
Matches 36; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Db 1 sgqgfdnglhlyredqtsppagrlcrlnwldagsglasap 39
QY 22 SGGCFWDNGHLHYREDQTSPPAGRLCLNWLDAQSGLASAP 60

RESULT 3
ID W72640 standard; peptide: 39 AA.
AC W72640;
DE 05-JAN-1999 (first entry)
DE Nervous glia cell growth factor N-terminal peptide #1.
KW Nervous glia cell growth factor; human; urine; secretion promoter;
KW choline acetyltransferase activity enhancer; nervous disease.
OS Homo sapiens.
FH Key Location/Qualifiers
FT Misc_difference 25 /note= "unspecified"
FT Misc_difference 29 /note= "unspecified"
FT J10265498-A.
PD 06-OCT-1998.
PN 24-MAR-1997; 090305.
PR (NICH-) JAPAN CHEM RES CO LTD.
PA WPI: 98-589719/50.
PT Nervous glia cell growth factor derived from human urine - used for
PT treatment of nervous diseases
PS Claim 2: Fig 6; 14pp; Japanese.
CC The present invention describes nervous glia cell growth factor, which
CC is purified from human urine by ultrafiltration, salting-out by ammonium
CC sulphate, gel filtration, ion exchange chromatography and reversed phase
CC chromatography, and has a M.W. of 29 kDa by sodium dodecyl sulphate-
CC chromatography gel electrophoresis. Also described are: (1) a secretion
CC promoter for the nerve growth factor of glia cell consisting of the
CC above growth factor, an enhancer for choline acetyltransferase activity
CC of neuron consisting of the above growth factor; and (2) DNA encoding
CC nervous glia growth factor containing a DNA sequence coding the amino
CC acid sequence shown by the two 39 amino acid sequences as given in
CC W72640 and W72641, which are identical, except one starts with Tyr
CC the other with Ser (i.e. they are from different DNA transcripts). The
CC glia cell growth factor can be prepared in a large amount and the factor
CC can be used for the treatment of nervous diseases.
SQ Sequence 39 AA;

Query Match 13.5%; Score 255; DB 36; Length 39;
Best Local Similarity 90.2%; Pred. No. 4.50e-13;
Matches 37; Conservative 0; Mismatches 2; Indels 2; Gaps 2;
```

```
PF 24-MAR-1997; 090305.
PR 24-MAR-1997; JP-090305.
PA (NICH-) JAPAN CHEM RES CO LTD.
DR WPI: 98-589719/50.
PT Nervous glia cell growth factor derived from human urine - used for
PT treatment of nervous diseases
PS Claim 3: Fig 7; 14pp; Japanese.
CC The present invention describes nervous glia cell growth factor, which
CC is purified from human urine by ultrafiltration, salting-out by ammonium
CC sulphate, gel filtration, ion exchange chromatography and reversed phase
CC chromatography, and has a M.W. of 29 kDa by sodium dodecyl sulphate-
CC polyacrylamide gel electrophoresis. Also described are: (1) a secretion
CC promoter for the nerve growth factor of glia cell consisting of the
CC above growth factor, an enhancer for choline acetyltransferase activity
CC of neuron consisting of the above growth factor; and (2) DNA encoding
CC nervous glia growth factor containing a DNA sequence coding the amino
CC acid sequence shown by the two 39 amino acid sequences as given in
CC W72640 and W72641, which are identical, except one starts with Tyr and
CC the other with Ser (i.e. they are from different DNA transcripts). The
CC glia cell growth factor can be prepared in a large amount and the factor
CC can be used for the treatment of nervous diseases.
SQ Sequence 39 AA;
```

```
Query Match 13.68; Score 256; DB 36; Length 39;
Best Local Similarity 92.3%; Pred. No. 3.64e-13;
Matches 36; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Db 1 sgqgfdnglhlyredqtsppagrlcrlnwldagsglasap 39
QY 22 SGGCFWDNGHLHYREDQTSPPAGRLCLNWLDAQSGLASAP 60
```

```
RESULT 3
ID W72640 standard; peptide: 39 AA.
AC W72640;
DE 05-JAN-1999 (first entry)
DE Nervous glia cell growth factor N-terminal peptide #1.
KW Nervous glia cell growth factor; human; urine; secretion promoter;
KW choline acetyltransferase activity enhancer; nervous disease.
OS Homo sapiens.
FH Key Location/Qualifiers
FT Misc_difference 25 /note= "unspecified"
FT Misc_difference 29 /note= "unspecified"
FT J10265498-A.
PD 06-OCT-1998.
PN 24-MAR-1997; 090305.
PR (NICH-) JAPAN CHEM RES CO LTD.
PA WPI: 98-589719/50.
PT Nervous glia cell growth factor derived from human urine - used for
PT treatment of nervous diseases
PS Claim 2: Fig 6; 14pp; Japanese.
CC The present invention describes nervous glia cell growth factor, which
CC is purified from human urine by ultrafiltration, salting-out by ammonium
CC sulphate, gel filtration, ion exchange chromatography and reversed phase
CC chromatography, and has a M.W. of 29 kDa by sodium dodecyl sulphate-
CC chromatography gel electrophoresis. Also described are: (1) a secretion
CC promoter for the nerve growth factor of glia cell consisting of the
CC above growth factor, an enhancer for choline acetyltransferase activity
CC of neuron consisting of the above growth factor; and (2) DNA encoding
CC nervous glia growth factor containing a DNA sequence coding the amino
CC acid sequence shown by the two 39 amino acid sequences as given in
CC W72640 and W72641, which are identical, except one starts with Tyr
CC the other with Ser (i.e. they are from different DNA transcripts). The
CC glia cell growth factor can be prepared in a large amount and the factor
CC can be used for the treatment of nervous diseases.
SQ Sequence 39 AA;
```

```
Query Match 13.5%; Score 255; DB 36; Length 39;
Best Local Similarity 90.2%; Pred. No. 4.50e-13;
Matches 37; Conservative 0; Mismatches 2; Indels 2; Gaps 2;
```



```

Best Local Similarity 40.5%; Pred. No. 1.88e-06;
Matches 30; Conservative 19; Mismatches 17; Indels 8; Gaps 4;

Db 286 cflngtgyrgvastasaglsclawnsdllyqelhdsvgaallglghaycrnpdnde 345
   || || :||:| | | | : : :||:| | | | | | | | | | | | | | | | |
Qy 25 CFWDNGHLYREDQTSAPGLRCLNW---L--DAQ-SGLASAPVSGAGNHSYCRNPDEDP 77

Db 346 r-pwcyvkvdsals 358
   | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Qy 78 RGPWCYVSGEAGVP 91

RESULT 7
ID R53962 standard; Protein: 655 AA.
AC R53962;
DE 06-JAN-1995 (first entry)
DE Hepatocyte growth factor converting protease.
KW Hepatocyte growth factor; protease; cleavage; active; inactive;
KW precursor.
OS Homo sapiens.
PN EP-596524-A.
PD 11-MAY-1994.
PF 05-NOV-1993; 117988.
PR 05-NOV-1992; JP-296133.
PR 20-NOV-1992; JP-312234.
PR 20-NOV-1992; JP-312242.
PA (SHIM/) SHIMOMURA T.
PA (MITU ) MITSUBISHI KASEI CORP.
PI Kitamura N, Miyazawa K, Morimoto Y, Shimomura T;
PI Yamada K;
DR WPI; 94-152921/19.
DR N-PSDB; 063951.
PT Hepatocyte growth factor converting protease and precursor and
PT gene encoding them - for producing active two chain HGF from
PT inactive single chain HGF.
PS Claim 12; Page 21-24; 30pp; English.
CC Hepatocyte growth factor converting protease is capable of converting
CC -inactive single chain hepatocyte growth factor (HGF) into active two
CC chain HGF by cleavage at a specific site.
SQ Sequence 655 AA;

Query Match 9.6%; Score 181; DB 10; Length 655;
Best Local Similarity 40.5%; Pred. No. 1.88e-06;
Matches 30; Conservative 19; Mismatches 17; Indels 8; Gaps 4;

Db 286 cflngtgyrgvastasaglsclawnsdllyqelhdsvgaallglghaycrnpdnde 345
   || || :||:| | | | : : :||:| | | | | | | | | | | | | | | | |
Qy 25 CFWDNGHLYREDQTSAPGLRCLNW---L--DAQ-SGLASAPVSGAGNHSYCRNPDEDP 77

Db 346 r-pwcyvkvdsals 358
   | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Qy 78 RGPWCYVSGEAGVP 91

RESULT 8
ID R66600 standard; Protein: 701 AA.
AC R66600;
DE 13-FEB-1995 (first entry)
DE Mouse L5/3 tumour suppressor protein.
KW Mouse L5/3 gene; small lung cell carcinoma; tumour suppression;
KW chromosome 3; 3p21; D3F15S2 locus; hepatocyte growth factor;
KW renal cell carcinoma; Von Hippel-Lindau syndrome; predisposition;
KW kringie domain.
OS Mus musculus.
FH Key Location/Qualifiers
FT peptide 1..16
FT /label= signal_peptide_(16-31)
FT /note= "putative"
FT misc_difference 4
FT /label= polymorphic_site
FT /note= "Pro corresponds to CCG codon in cDNA;
FT in the genomic DNA, codon 19 is CAG (Gln)"
FT protein 17..701

```

```

FT /note= "putative protein contains 4 kringie domains
FT followed by a serine protease-like domain"
FT modified_site 57..59
FT /label= N-glycosylation_site
FT /note= "potential"
FT modified_site 158..160
FT /label= N-glycosylation_site
FT /note= "potential"
FT modified_site 290..292
FT /label= N-glycosylation_site
FT /note= "potential"
FT modified_site 605..607
FT /label= N-glycosylation_site
FT /note= "potential"

US5315000-A.
PN 24-MAY-1994.
PD 14-MAY-1992; 882925.
PR 14-MAY-1992; US-882925.
PA (CHIL-) CHILDRENS HOSPITAL MEDICAL CENT.
PI Degen SJ;
PI WPI; 94-166645/20.
DR N-PSDB; 079726.
PT DNA from D3F15S2 locus of human chromosome 3 - encoding novel
PT growth factor, L5/3, useful as probe for detecting
PT pre-deposition towards cancer
PS Disclosure; Columns 27-32; 31pp; English.
CC A mouse liver cDNA library was screened with cDNA coding for human
CC L5/3; the L5/3 gene, located at the D3F15S2 locus of human
CC chromosome 3, codes for a protein composed of 4 kringie domains,
CC followed by a serine protease-like domain. The longest murine clone
CC to be isolated (pML5-2, Q79726) was not full-length. The open
CC reading frame was present at the 5' end of the sequence with no
CC codon for the initiator methionine in-frame with the coding
CC sequence. After determination of the sequence of the mouse gene it
CC was determined that the cDNA lacked 44bp of coding and 94bp of
CC non-coding sequence at its 5' end.
SQ Sequence 701 AA;

Query Match 9.4%; Score 177; DB 10; Length 701;
Best Local Similarity 41.3%; Pred. No. 4.17e-06;
Matches 26; Conservative 9; Mismatches 26; Indels 2; Gaps 2;

Db 95 clmdngsvyrgvttaglpcqawrrfpndhkytpkngleenfcrrpddgprgpcw 154
   | : | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Qy 25 CFWDNGHLYREDQTSAPGLRCLNWLDL-QSGLASAPVSGAG-NHSYCRNPDEDPRGPCW 82

Db 155 ytt 157
   | :
Qy 83 YVS 85

RESULT 9
ID W14271 standard; Protein: 701 AA.
AC W14271;
DE 21-JUL-1997 (first entry)
DE Mouse growth factor L5/3 partial cDNA clone ML5-2 encoded protein.
KW Mouse; growth factor; foetal; liver; probe; bovine; prothrombin; locus;
KW polymorphism; transition; exon; intron; chromosome; kringie domain;
KW cell growth; tumour suppressor; hepatocyte growth factor; regeneration.
OS Mus musculus.
FH Key Location/Qualifiers
FT peptide 1..16
FT /note= "partial signal peptide sequence"
FT misc_difference 19
FT /note= "amino acid residue is Gln in this position
FT in the protein encoded by the genomic sequence
FT (T62442); this may be due to a polymorphism"
FT protein 17..701
FT /note= "mature protein"

US5606029-A.
PN 25-FEB-1997.
PD 14-MAY-1992; 882925.
PR 14-MAY-1992; US-882925.

```

```

PR 14-MAY-1992; US-882925..
PA (CHIL-) CHILDRENS HOSPITAL MEDICAL CENT.
PI Degen SJ;
DR WPI; 94-166645/20.
DR N-PSDB; Q79727.
PT DNA from D3F15S2 locus of human chromosome 3 - encoding novel
PT growth factor, L5/3, useful as probe for detecting
PT pre-deposition towards cancer
PS Disclosure; Columns 33-42; 31pp; English.
CC The sequence of mouse genomic DNA coding for the L5/3 tumour
CC suppressor protein is composed of 18 exons separated by 17
CC intervening sequences. There is only one difference found between
CC the cDNA (Q79726) and genomic DNA (Q79727) coding sequences which
CC results in the substitution of a Gln in the gene to a Pro in the
CC cDNA at amino acid position 19. The putative mouse protein has the
CC same domain structure as its human homologue with four Kringle
CC domains followed by a serine protease-like domain.
SQ Sequence 716 AA;

Query Match 9.4%; Score 177; DB 10; Length 716;
Best Local Similarity 41.3%; Pred. No. 4.17e-06;
Matches 26; Conservative 9; Mismatches 26; Indels 2; Gaps 2;

Db 110 cimdngsvyrgtvtartaggglpcqawsrrfndhkytptkngleenferndgdpgrpwc 169
QY 25 CFWDNGHLYREDQSPAPGLRCLNWLDA-QSGLASAPVSGAG-NHSYCRNPDDEPRGFWC 82
|: ||| || : || | | | | | | | | | | | | | | | | | | | | | | | | | | | |
|: ||| || : || | | | | | | | | | | | | | | | | | | | | | | | | | | | |

Db 170 ytt 172
QY 83 YVS 85
|:
|:

RESULT 11
ID W14272 standard; Protein; 716 AA.
AC W14272; 1997 (first entry)
DE Mouse growth factor L5/3 complete protein.
DT Mouse; growth factor; foetal; liver; probe; bovine; prothrombin; locus;
KW Polymorphism; transition; exon; intron; chromosome; kringle domain;
KW cell growth; tumour suppressor; hepatocyte growth factor; regeneration.
KW Mus musculus.
FS Key Location/Qualifiers
FT peptide 1..31
FT FT /note= "signal peptide"
FT FT /note= "amino acid residue is Pro at this position
FT FT in the protein encoded by the cDNA clone ML5-2
FT FT (T62441); this may be due to a polymorphism"
FT FT 32..716
FT FT /note= "mature protein"
FT FT 72
FT FT /note= "N-linked glycosylation site"
FT FT 173
FT FT /note= "N-linked glycosylation site"
FT FT 305
FT FT /note= "N-linked glycosylation site"
FT FT 624
FT FT /note= "N-linked glycosylation site"
FT FT /note= "N-linked glycosylation site"
PN US5606029-A.
PD 25-FEB-1997.
PF 14-MAY-1992; 882925.
PR 14-MAY-1992; US-882925.
PR 18-JAN-1994; US-184012.
PA (CHIL-) CHILDREN'S HOSPITAL MEDICAL CENT.
PI Degen SJ;
DR WPI; 97-153621/14.
DR N-PSDB; T62442.
PT Human growth factor protein L5/3 - useful for altering cell growth,
PT e.g. as tumour suppressor
PT Disclosure; Column 33-42; 34pp; English.
CC This is the amino acid sequence of the wild type mouse growth factor
CC designated L5/3. The protein sequence differs from that encoded by the
CC cDNA clone (T62441) at position 19; in this sequence a Gln, in the cDNA

```

CC clone a Pro. This difference may be due to a polymorphism at this codon.
 CC The full length mouse gene contains 18 exons and encodes a protein having
 CC a molecular weight 80 kD. The protein can be used to alter cell growth
 CC (as a growth factor or tumour suppressor) and has similar properties to
 CC the hepatocyte growth factor that is actively involved in liver
 CC regeneration.
 SQ Sequence 716 AA;

Query Match 9.4%; Score 177; DB 22; Length 716;
 Best Local Similarity 41.3%; Pred. No. 4.17e-06;
 Matches 26; Conservative 9; Mismatches 26; Indels 2; Gaps 2;

Db 110 cimdgvsyrgtvarataglpqcasrrfndhkyrtptkngleefcnrpdgdpgrpwc 169

Qy 25 CFWDNGHLYREDQTSAPGLRCLNMLDA-QSGLASAPVSGAG-NHSCYCRNPDEDPGRPMC 82

Db 170 ytt 172

Qy 83 YVS 85

RESULT 12
 ID W46423 standard; protein; 217 AA.

AC W46423;
 DT 13-MAY-1998 (first entry)

DE Bovine macrophage stimulating protein (MSP).

KW p55; p22; p75; human; macrophage stimulating protein; MSP;

KW bovine analogue; colony formation; crypt cell; proliferation;

KW crypt stem cell; intestinal epithelial cell; treatment; disorder;

KW gastrointestinal tract lining.

OS Bos sp.

PN W09735606-A1.

PD 02-OCT-1997.

PF 25-MAR-1997; U05216.

PR 26-MAR-1996; US-622720.

PA (AMGE-) AMGEN INC.

PI Zhang K;

DR WPI; 97-489386/45.

PT Treatment of disorders of gastrointestinal tract lining in mammals -

PT which result from chemotherapy, radiation therapy, inflammatory

PT bowel disease, ulcers or infection

PS Disclosure; Fig 8; 57pp; English.

CC The present sequence represents the bovine analogue of macrophage

CC stimulating protein (MSP). MSP stimulates colony formation by crypt

CC cells and may also stimulate proliferation of crypt stem cells. In this

CC respect, MSP is useful for elevating production of all intestinal

CC epithelial cell types. Disorders of the gastrointestinal tract lining in

CC mammals can be treated by administering MSP. The method can be used to

CC treat disorders of the gastrointestinal tract tract lining in a mammal

CC which result from chemotherapy, radiation therapy, inflammatory bowel

CC disease, ulcers, infection, ulcerative colitis or Crohn's disease.

CC Sequence 217 AA;

Query Match 9.3%; Score 176; DB 28; Length 217;
 Best Local Similarity 32.4%; Pred. No. 5.09e-06;
 Matches 23; Conservative 20; Mismatches 23; Indels 5; Gaps 5;

Db 87 cyhgagelyrgsvsktrgircqwsaetphkpfqkhtsaphtpleenfcnpdgdshrp 146

Qy 25 CFWDNGHLYREDQTSAPGLRCLNWLDA-Q-SGLASAPVSGAG-NHSCYCRNPDEDPGRGP 80

Db 147 wcytt-dpqt 156

Qy 81 WCYVSGEAGVP 91

RESULT 13
 ID R05433 standard; protein; 380 AA.

AC R05433;

DT 30-JUL-1990 (first entry)

DE cPA-P2 Hybrid plasminogen activator.

KW Plasminogen activator; fibrin; urokinase; thromboembolic

KW disease; ds.

OS Synthetic.

FH Key

FT domain

FT 1..23

FT /label=Secretory leader.

FT 24..102

FT /label=plasminogen Kringle 1

FT 103..116

FT /label=Urokinase linker

FT 117..380

FT /label=ScuPA protease domain.

PN W09001332-A.

PD 22-FEB-1990.

PF 10-AUG-1988; 02771.

PR 10-AUG-1988; WO-002771.

PA (CETU) Cetus Corp.

PI Halluin AP;

DR WPI; 90-083374/11.

DR N-PSDB; Q02301.

PT Compsn. contg. plasminogen activator conjugated to heparin component -

PT used for treatment of thromboembolic disease, with longer half

PT life and improved targeting.

PS Disclosure; P; English.

CC Gene encodes hybrid plasminogen activator (PA) comprising Kringle 1, an

CC urokinase linker, and an urokinase protease domain wherein glycine residue

CC at position 158 is replaced with a lysine.

CC The compound is used to treat thromboembolic disease esp. with myocardial

CC infarction, has a longer half-life than free PA and targets the heparin

CC site of thrombus or embolism reducing the risk of reocclusion.

CC Sequence 380 AA;

SQ

Query Match 9.3%; Score 175; DB 1; Length 380;

Best Local Similarity 34.8%; Pred. No. 6.21e-06;

Matches 39; Conservative 23; Mismatches 39; Indels 11; Gaps 8;

Db 1 malaitalalllllllpgwase-ctgdgknyrgtmstkgitcqkwsstsphrprfs 59

Qy 1 MLLAVQAFILVSNMLLAAYGSGGCFWDNGHLYREDQTSAPGLRCLNWL-LDAQSG-LA 57

Db 60 pathpsegleenycrnpdndpgpwytt-d---pekrydydcileceeps 107

Qy 58 SAPVSGAG-NHSCYCRNPDEDPGRVWYVSGEAGVPEKR-P-CEDLRCPETTS 106

RESULT 14

ID R32710 standard; Protein; 504 AA.

AC R32710;

DT 16-JUN-1993 (first entry)

DE Haematopoietic stem cell multiplier.

KW Bone marrow deficiencies; cancer therapy; tumour; carcinoma;

KW bone marrow transplants.

PN W09303061-A.

PD 18-FEB-1993.

PF 24-JUL-1992; J00949.

PR 26-JUL-1991; JP-187470.

PR 26-JUL-1991; JP-187481.

PA (TORA) TORAY IND INC.

PI Kawano G, Kojima K, Komiyama A, Kubo T, Nakahata T;

PI Sano E, Sudot, Tanaka R;

DR WPI; 93-076441/09.

DR N-PSDB; Q37308.

PT Haematopoietic stem cell multiplier comprising IL-3 and IL-7 -

PT used for treatment and prevention of bone marrow disorders e.g.

PT after cancer therapy or bone marrow transplants

PS Disclosure; Page 60; 90pp; Japanese.

CC This sequence is haematopoietic stem cell multiplier of mol.

CC wt. 60,000, and having N-terminal sequence R32709. It can be used

CC in the treatment (claimed) of bone marrow deficiencies eg. after cancer

CC therapy or bone marrow transplants.

SQ Sequence 504 AA;

Query Match 9.1%; Score 171; DB 6; Length 504;

Best Local Similarity 31.5%; Pred. No. 1.38e-05;

Matches 29; Conservative 22; Mismatches 35; Indels 6; Gaps 4;

Db 386 cyrgngknyngnlsqtsrgltscsmwknmedllrhfwepdaasklnenycrnpddahgp 445
 QY 25 CFWDNGHLYREDTSPAGPLRLNW---LDA-OSGLASAPVSGAGNHSYCRNPDEDPGP 80
 Db 446 wcy-tgnplip-wdycpsicrcegdttptnsqf 475
 QY 81 WCYVSGAGVPEKRPCCEDLRCPTTTSQALPAF 112

RESULT	15
ID	R21976 standard; Protein; 728 AA.
AC	R21976;
DT	03-JUL-1992 (first entry)
DE	Human Hepatocyte growth factor.
KW	rhHGF; beta chain; rat HGF; HBC25; HAC19; ss.
OS	Homo sapiens.
PN	J04030000-A.
PD	31-JAN-1992.
PF	24-MAY-1990; 212818.
PR	05-JUN-1989; JP-142697.
PR	01-JAN-1990; JP-212818.
PR	24-MAY-1990; JP-134487.
PA	(TOYM) TOYOCO KK.
DR	WPI: 92-085905/11.
DR	N-PSDB: Q22146.
PT	Recombinant human hepatocyte growth factor - for treatment and
PT	diagnosis of liver diseases
PS	Claim 2; Fig 4; 21pp; Japanese.
CC	A first cDNA library (I) was prepared from human liver RNA. The
CC	library was screened with the rat HGF beta chain coding sequence
CC	RBC1 (see Q22142). Clone HBC25 was isolated and sequenced (see
CC	Q22143). The partial human HGF coding sequence was itself used
CC	as a probe to screen a second cDNA library (II). A clone which
CC	partially overlapped with HBC25 was identified and designated
CC	HAC19 (see Q22144). The complete human HGF coding sequence could
CC	then be derived from the two overlapping sequences and the amino
CC	acid sequence of HGF deduced from it.
CC	See also Q22141 and Q22145.
CC	Sequence 728 AA;
SQ	Sequence 728 AA;

Query Match 9.0%; Score 170; DB 4; Length 728;
Best Local Similarity 31.5%; Pred. No. 1.68e-05;
Matches 28; Conservative 22; Mismatches 33; Indels 6; Gaps 4;

Db	391	cyrgngknyngnlsqtsrgilscsmwnknmedllhrhifwepdaaslnenycrnpddahpg	450
QY	25	CFWDNGHLYREDQTSAPGIRCLNW---LDA-OSGLASAPVSGAGNHSYCRNPDEDP	80
Db	451	wcy-tgnplip-wdcyplsrcegttpti	477
QY	81	WCYVSGEAGVPEKRCPCEDLRCPTTSOAL	109

Search completed: Fri Sep 17 18:25:31 1999
Job time : 105 secs.

W P E R L H (TM)

Release 3.1A John F. Collins, Biocomputing Research Unit.
Copyright (c) 1993-1998 University of Edinburgh, U.K.
Distribution rights by Oxford Molecular Ltd

MPSrch_pp protein - protein database search, using Smith-Waterman algorithm

Run on: Fri Sep 17 18:29:09 1999; MasPar time 4.08 Seconds
Tabular output not generated. 654.758 Million cell updates/sec

Title: >US-09-084-491A-2
Description: (1-263) from US09084491A.pep
Perfect Score: 1883
Sequence: 1 MLLAWQAFVLSNMLAEAY.....PVDPEGSTPLMGOAGTPGA 263

Scoring table: PAM 150
Gap 11

Searched: 106580 seqs, 10152877 residues

Post-processing: Minimum Match 0%
Listing first 45 summaries

Database: a-issued
1:5A_COMB 2:5B_COMB 3:PCT9_COMB 4:backfiles1

Statistics: Mean 31.020; Variance 137.816; scale 0.225

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description	Pred. No.
1	184	9.8	812	3	PCT-US95-0 Sequence 1, Applicatio	8.64e-07
2	184	9.8	812	2	US-08-612- Sequence 1, Applicatio	8.64e-07
3	184	9.8	812	2	US-08-605- Sequence 1, Applicatio	8.64e-07
4	184	9.8	812	2	US-08-452- Sequence 1, Applicatio	8.64e-07
5	184	9.8	812	2	US-08-429- Sequence 1, Applicatio	8.64e-07
6	184	9.8	812	1	US-08-451- Sequence 1, Applicatio	8.64e-07
7	184	9.8	812	2	US-08-326- Sequence 1, Applicatio	8.64e-07
8	184	9.8	812	1	US-08-248- Sequence 1, Applicatio	8.64e-07
9	181	9.6	655	1	US-08-148- Sequence 12, Applicati	1.54e-06
10	181	9.6	655	1	US-08-448- Sequence 12, Applicati	1.54e-06
11	176	9.3	217	2	US-08-622- Sequence 24, Applicati	4.04e-06
12	167	8.9	723	1	US-08-290- Sequence 3, Applicatio	2.26e-05
13	167	8.9	723	1	US-08-290- Sequence 2, Applicatio	2.26e-05
14	167	8.9	723	1	US-08-290- Sequence 1, Applicatio	2.26e-05
15	167	8.9	723	1	US-08-404- Sequence 1, Applicatio	2.26e-05
16	167	8.9	723	1	US-07-838- Sequence 1, Applicatio	2.26e-05
17	167	8.9	728	1	US-07-815- Sequence 2, Applicatio	2.26e-05
18	167	8.9	728	1	US-08-087- Sequence 22, Applicati	2.26e-05
19	165	8.8	579	1	US-08-295- Sequence 4, Applicatio	3.30e-05
20	165	8.8	579	3	PCT-US92-1 Sequence 3, Applicatio	3.30e-05
21	165	8.8	615	1	US-07-998- Sequence 4, Applicatio	3.30e-05
22	165	8.8	615	3	PCT-US92-1 Sequence 3, Applicatio	3.30e-05
23	165	8.8	615	1	US-08-462- Sequence 3, Applicatio	3.30e-05

24	165	8.8	615	1	US-08-463- Sequence 3, Applicatio	3.30e-05
25	166	8.8	711	1	US-08-184- Sequence 8, Applicatio	2.73e-05
26	166	8.8	711	3	PCT-US95-1 Sequence 2, Applicatio	2.73e-05
27	166	8.8	711	1	US-08-334- Sequence 2, Applicatio	2.73e-05
28	161	8.6	790	1	US-08-469- Sequence 54, Applicati	7.04e-05
29	161	8.6	791	2	US-08-643- Sequence 1, Applicatio	7.04e-05
30	161	8.6	810	4	5200340-8 Patent No. 5200340	7.04e-05
31	161	8.6	810	1	US-07-854- Sequence 2, Applicatio	7.04e-05
32	161	8.6	810	1	US-08-147- Sequence 29, Applicati	7.04e-05
33	161	8.6	814	1	US-08-750- Sequence 1, Applicatio	7.04e-05
34	158	8.4	101	2	US-08-643- Sequence 11, Applicati	1.24e-04
35	159	8.4	378	2	US-08-612- Sequence 41, Applicati	1.03e-04
36	157	8.3	160	2	US-08-612- Sequence 35, Applicati	1.50e-04
37	157	8.3	339	3	PCT-US95-0 Sequence 3, Applicatio	1.50e-04
38	157	8.3	339	2	US-08-429- Sequence 3, Applicatio	1.50e-04
39	157	8.3	339	2	US-08-326- Sequence 3, Applicatio	1.50e-04
40	157	8.3	339	1	US-08-248- Sequence 3, Applicatio	1.50e-04
41	157	8.3	339	2	US-08-612- Sequence 3, Applicatio	1.50e-04
42	157	8.3	339	1	US-08-451- Sequence 3, Applicatio	1.50e-04
43	157	8.3	339	2	US-08-452- Sequence 3, Applicatio	1.50e-04
44	157	8.3	352	2	US-08-612- Sequence 40, Applicati	1.50e-04
45	157	8.3	378	2	US-08-612- Sequence 42, Applicati	1.50e-04

ALIGNMENTS

RESULT 1
ID PCT-US95-05107-1 STANDARD; PRT: 812 AA.
XX
AC xxxxxx
XX
DT
XX
DE Sequence 1, Application PC/TUS9505107
XX
CC Sequence 1, Application PC/TUS9505107
CC GENERAL INFORMATION:
CC APPLICANT: THE CHILDREN'S MEDICAL CENTER, CORPORATION
CC TITLE OF INVENTION: Angiostatin and Method of Use
CC NUMBER OF SEQUENCES: 6
CC CORRESPONDENCE ADDRESS:
CC ADDRESSEE: Jones & Askew
CC STREET: 191 Peachtree Street, 37th Floor
CC CITY: Atlanta
CC STATE: Georgia
CC COUNTRY: U.S.
CC ZIP: 30303-1769
CC COMPUTER READABLE FORM:
CC MEDIUM TYPE: Floppy disk
CC OPERATING SYSTEM: PC-DOS/MS-DOS
CC SOFTWARE: Patentin Release #1.0, Version #1.30
CC CURRENT APPLICATION DATA:
CC APPLICATION NUMBER: PCT/US95/05107
CC FILING DATE:
CC CLASSIFICATION:
CC PRIOR APPLICATION DATA:
CC APPLICATION NUMBER: US 08/248,629
CC FILING DATE: 26-APR-1994
CC PRIOR APPLICATION DATA:
CC APPLICATION NUMBER: US 08/326,785
CC FILING DATE: 20-OCT-1994
CC ATTORNEY/AGENT INFORMATION:
CC NAME: Johnson, James D.
CC REGISTRATION NUMBER: 31,771
CC REFERENCE/DOCKET NUMBER: 05213-0122
CC TELECOMMUNICATION INFORMATION:
CC TELEPHONE: 404-818-3700
CC TELEFAX: 404-818-3799
CC INFORMATION FOR SEQ ID NO: 1:
CC SEQUENCE CHARACTERISTICS:
CC LENGTH: 812 amino acids
CC TYPE: amino acid

```
CC STRANDEDNESS:
CC TOPOLOGY: linear
CC MOLECULE TYPE: protein
CC HYPOTHETICAL: NO
CC ORIGINAL SOURCE:
CC ORGANISM: Murine
CC IMMEDIATE SOURCE:
CC CLONE: Plasmidogen
SQ SEQUENCE 812 AA; 90846 MW; 3411937 CN;

Query Match 9.8%; Score 184; DB 3; Length 812;
Best Local Similarity 27.8%; Pred. No. 8.64e-07;
Matches 35; Conservative 38; Mismatches 43; Indels 10; Gaps 9;

Db 377 CYQDQSGYRGTSITGKKQCSWAAMPFPHRHSKTPENFPDAGLEMYCRNPDGD-KGP 435
QY 25 CFWDNGHLYREDQTSAPGLRCLNWLDD--AQSGLASAPVSGAG-NHSYCRNPDEDPGRP 80
Db 436 WCYTT-DPSVR-WEYNLKRCSGSG-SVVELPTVSQEPS-GPSDSETCMYGNGKDYRG 491
QY 81 WCYVSGEAGVPEKPCEDLRCPTTSQALPAFTTEIQEASGEGGADEVQ-VFAPANALPA 139
Db 492 KTAVTA 497
QY 140 RSEAAA 145

RESULT 2
ID US-08-612-788-1 STANDARD; PRT; 812 AA.
XX
AC xxxxxx
XX
DT
XX
DE
XX
XX
CC Sequence 1, Application US/08612788
CC Sequence 1, Application US/08612788
CC Patent No. 5837682
CC GENERAL INFORMATION:
CC APPLICANT: Folkman, M. Judah
CC APPLICANT: O'Reilly, Micheal
CC APPLICANT: Cao, Yihai
CC APPLICANT: Sim, B. Kim Lee
CC TITLE OF INVENTION: Angiostatin Fragments and Method of Use
CC NUMBER OF SEQUENCES: 45
CC CORRESPONDENCE ADDRESS:
CC ADDRESSEE: Jones & Askew
CC STREET: 191 Peachtree Street, 37th Floor
CC CITY: Atlanta
CC STATE: Georgia
CC COUNTRY: U.S.
CC ZIP: 30303-1769
CC COMPUTER READABLE FORM:
CC MEDIUM TYPE: Floppy disk
CC COMPUTER: IBM PC compatible
CC OPERATING SYSTEM: PC-DOS/MS-DOS
CC SOFTWARE: PatentIn Release #1.0, Version #1.30
CC CURRENT APPLICATION DATA:
CC APPLICATION NUMBER: US/08/612,788
CC FILING DATE:
CC CLASSIFICATION: 514
CC ATTORNEY/AGENT INFORMATION:
CC NAME: Warren, William L.
CC REGISTRATION NUMBER: 36,714
CC REFERENCE/DOCKET NUMBER: 05213-0126
CC TELECOMMUNICATION INFORMATION:
CC TELEPHONE: 404-818-3700
CC TELEFAX: 404-818-3799
CC INFORMATION FOR SEQ ID NO: 1:
CC SEQUENCE CHARACTERISTICS:
CC LENGTH: 812 amino acids
CC TYPE: amino acid
CC STRANDEDNESS:
CC TOPOLOGY: linear
CC MOLECULE TYPE: protein

CC STRANDEDNESS: NO
CC ANTI-SENSE: NO
CC FRAGMENT TYPE: N-terminal
CC ORIGINAL SOURCE:
CC ORGANISM: Murine
CC IMMEDIATE SOURCE:
CC CLONE: Plasmidogen
SQ SEQUENCE 812 AA; 90846 MW; 3411937 CN;

Query Match 9.8%; Score 184; DB 2; Length 812;
Best Local Similarity 27.8%; Pred. No. 8.64e-07;
Matches 35; Conservative 38; Mismatches 43; Indels 10; Gaps 9;

Db 377 CYQDQSGYRGTSITGKKQCSWAAMPFPHRHSKTPENFPDAGLEMYCRNPDGD-KGP 435
QY 25 CFWDNGHLYREDQTSAPGLRCLNWLDD--AQSGLASAPVSGAG-NHSYCRNPDEDPGRP 80
Db 436 WCYTT-DPSVR-WEYNLKRCSGSG-SVVELPTVSQEPS-GPSDSETCMYGNGKDYRG 491
QY 81 WCYVSGEAGVPEKPCEDLRCPTTSQALPAFTTEIQEASGEGGADEVQ-VFAPANALPA 139
Db 492 KTAVTA 497
QY 140 RSEAAA 145

RESULT 3
ID US-08-605-598B-1 STANDARD; PRT; 812 AA.
XX
AC xxxxxx
XX
DT
XX
DE
XX
XX
CC Sequence 1, Application US/08605598B
CC Sequence 1, Application US/08605598B
CC Patent No. 5861372
CC GENERAL INFORMATION:
CC APPLICANT: Folkman, M. Judah
CC APPLICANT: Lin, Jie
CC APPLICANT: O'Reilly, Michael S.
CC TITLE OF INVENTION: Aggregate Angiostatin and Method of Use
CC NUMBER OF SEQUENCES: 6
CC CORRESPONDENCE ADDRESS:
CC ADDRESSEE: Jones & Askew
CC STREET: 191 Peachtree Street, 37th Floor
CC CITY: Atlanta
CC STATE: Georgia
CC COUNTRY: U.S.
CC ZIP: 30303-1769
CC COMPUTER READABLE FORM:
CC MEDIUM TYPE: Floppy disk
CC COMPUTER: IBM PC compatible
CC OPERATING SYSTEM: PC-DOS/MS-DOS
CC SOFTWARE: PatentIn Release #1.0, Version #1.30
CC CURRENT APPLICATION DATA:
CC APPLICATION NUMBER: US/08/605,598B
CC FILING DATE: 22-FEB-1996
CC CLASSIFICATION: 514
CC ATTORNEY/AGENT INFORMATION:
CC NAME: Warren, William L.
CC REGISTRATION NUMBER: 36,714
CC REFERENCE/DOCKET NUMBER: 05213-0127
CC TELECOMMUNICATION INFORMATION:
CC TELEPHONE: 404-818-3700
CC TELEFAX: 404-818-3799
CC INFORMATION FOR SEQ ID NO: 1:
CC SEQUENCE CHARACTERISTICS:
CC LENGTH: 812 amino acids
CC TYPE: amino acid
CC STRANDEDNESS:
CC TOPOLOGY: linear
CC MOLECULE TYPE: peptide
```

Query Match 9.8%; Score 184; DB 2; Length 812;
Best Local Similarity 27.8%; Pred. No. 8.64e-07;

XX Sequence 12, Application US/08448937A
CC Patent No. 5677164
CC GENERAL INFORMATION:
CC APPLICANT: Takeshi SHIMOMURA et al.
CC TITLE OF INVENTION: No. 5677164el Protein and Gene Encoding Said Protein
CC NUMBER OF SEQUENCES: 14
CC CORRESPONDENCE ADDRESS:
CC ADDRESSEE: Wenderoth, Lind & Ponack
CC STREET: 805 Fifteenth Street, N.W., #700
CC CITY: Washington
CC STATE: D.C.
CC COUNTRY: U.S.A.
CC ZIP: 20005
CC COMPUTER READABLE FORM:
CC MEDIUM TYPE: Diskette, 5.25 inch,
CC MEDIUM TYPE: 500 Kb Storage
CC COMPUTER: IBM Compatible
CC OPERATING SYSTEM: MS-DOS
CC SOFTWARE: Wordperfect
CC CURRENT APPLICATION DATA:
CC APPLICATION NUMBER: US/08/448,937A
CC FILING DATE: May 24, 1995
CC CLASSIFICATION: 435
CC PRIOR APPLICATION DATA:
CC APPLICATION NUMBER: 08/148,910
CC FILING DATE: No. 5677164ember 5, 1993
CC ATTORNEY/AGENT INFORMATION:
CC NAME: Warren M. Cheek, Jr.
CC REGISTRATION NUMBER: 33,367
CC REFERENCE/DOCKET NUMBER:
CC TELECOMMUNICATION INFORMATION:
CC TELEPHONE: 202-371-8850
CC TELEFAX: 202-371-8856
CC TELEX:
CC INFORMATION FOR SEQ ID NO: 12:
CC SEQUENCE CHARACTERISTICS:
CC LENGTH: 655 amino acids
CC TYPE: amino acid
CC STRANDEDNESS: single
CC TOPOLOGY: linear
CC MOLECULE TYPE: protein
CC ORIGINAL SOURCE:
CC ORGANISM: human
SQ SEQUENCE 655 AA; 70681 MW; 2184486 CN;

Query Match 9.6%; Score 181; DB 1; Length 655;
Best Local Similarity 40.5%; Pred. No. 1.54e-06;
Matches 30; Conservative 19; Mismatches 17; Indels 8; Gaps 4;

Db 286 CFLGNGTGYRGVASTSASGLSCLANSDLLYOELHVDVSGAALLGLGPHAYCRNPNDDE 345
QY 25 CFWDNGHYREDQTSAPGLRCLNW----L--DAQ-SGLASAPVSGAGNHSYCRNPDEDP 77
| | | | | : : : : : | | | | : : : : : | | | | : : : : : |
| | | | | : : : : : | | | | : : : : : | | | | : : : : : |
Db 346 R-PWCYVVKDSALS 358
QY 78 RGPWCYVSGEAGVP 91
| | | | | : : : : : | | | | : : : : : | | | | : : : : : |


RESULT 11
ID US-08-622-720A-24 STANDARD; PRT; 217 AA.
XX
AC xxxxxx
XX
DT
XX
XX
DE
XX
XX
Sequence 24, Application US/08622720A
CC
CC Sequence 24, Application US/08622720A
CC Patent No. 5814308
CC GENERAL INFORMATION:
CC APPLICANT: Zhang, Ke
CC TITLE OF INVENTION: METHODS FOR THE TREATMENT OF

CC TITLE OF INVENTION: GASTROINTESTINAL TRACT DISORDERS
CC NUMBER OF SEQUENCES: 25
CC CORRESPONDENCE ADDRESS:
CC ADDRESSEE: Amgen Inc.
CC STREET: 1840 Dehavilland Drive
CC CITY: Thousand Oaks
CC STATE: California
CC COUNTRY: U.S.A.
CC ZIP: 91320
CC COMPUTER READABLE FORM:
CC MEDIUM TYPE: Floppy disk
CC COMPUTER: IBM PC compatible
CC OPERATING SYSTEM: PC-DOS/MS-DOS
CC SOFTWARE: PatentIn Release #1.0, Version #1.30
CC CURRENT APPLICATION DATA:
CC APPLICATION NUMBER: US/08/622,720A
CC FILING DATE:
CC CLASSIFICATION: 424
CC ATTORNEY/AGENT INFORMATION:
CC NAME: Winter, Robert B.
CC REFERENCE/DOCKET NUMBER: A-396
CC INFORMATION FOR SEQ ID NO: 24:
CC SEQUENCE CHARACTERISTICS:
CC LENGTH: 217 amino acids
CC TYPE: amino acid
CC STRANDEDNESS: single
CC TOPOLOGY: linear
CC MOLECULE TYPE: protein
CC SEQUENCE 217 AA; 24688 MW; 238595 CN;

Query Match 9.3%; Score 176; DB 2; Length 217;
Best Local Similarity 32.4%; Pred. No. 4.04e-06;
Matches 23; Conservative 20; Mismatches 23; Indels 5; Gaps 5;

Db 87 CYHGAGELYRGVSKTRKIRCONWSAETPHKQFKHTSAPHTPLENFCRNPDDGSHGP 146
QY 25 CFWDNGHYREDQTSAPGLRCLNW-LDA-Q-SGLASAPVSGAG-NHSYCRNPDEDP 80
| | | | | : : : : : | | | | : : : : : | | | | : : : : : |
| | | | | : : : : : | | | | : : : : : | | | | : : : : : |
Db 147 WCYTT-DPGTP 156
QY 81 WCYVSGEAGVP 91
| | | | | : : : : : | | | | : : : : : | | | | : : : : : |

RESULT 12
ID US-08-290-937B-3 STANDARD; PRT; 723 AA.
XX
AC xxxxxx
XX
DT
XX
XX
DE
XX
XX
Sequence 3, Application US/08290937B
CC
CC Sequence 3, Application US/08290937B
CC Patent No. 5648233
CC GENERAL INFORMATION:
CC APPLICANT: YAMAGUCHI, KYOJI
CC APPLICANT: SHIMA, NOBUYUKI
CC APPLICANT: MURAKAMI, AKIHIRO
CC APPLICANT: GOTO, MASAOKI
CC APPLICANT: TSUDA, EISUKE
CC APPLICANT: MASUNAGA, HIROAKI
CC APPLICANT: TAKAHIRA, REIKO
CC APPLICANT: OOGAKI, FUMIKO
CC APPLICANT: UEDA, MASATSUGU
CC APPLICANT: HIGASHIO, KANJI
CC TITLE OF INVENTION: MODIFIED TCF
CC NUMBER OF SEQUENCES: 13
CC CORRESPONDENCE ADDRESS:
CC ADDRESSEE: Testa, Hurwitz & Thibault
CC STREET: 125 High St.
CC CITY: Boston
CC STATE: MA
CC COUNTRY: USA



Release 3.1A John F. Collins, Biocomputing Research Unit.
Copyright (c) 1993-1998 University of Edinburgh, U.K.
Distribution rights by Oxford Molecular Ltd

MPsrch_pp protein - protein database search, using Smith-Waterman algorithm

Run on: Fri Sep 17 18:25:49 1999; MasPar time 12.81 Seconds
Tabular output not generated. 822.688 Million cell updates/sec

Title: >US-09-084-491A-2
Description: (1-263) from US09084491A.pap
Perfect Score: 1883
Sequence: 1 MLLAWQAFVLSNMLAEAY.....PVDQEGSTPLMQAGTPGA 263

Scoring table: PAM 150
Gap 11

Searched: 122810 seqs, 40068593 residues

Post-processing: Minimum Match 0%
Listing first 45 summaries

Database: pir60
1:pir1 2:pir2 3:pir3 4:pir4

Statistics: Mean 45.508; Variance 88.911; scale 0.512

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description	Pred. No.
1	204	10.8	169	2	A40522 plasmin (EC 3.4.21.7)	2.52e-17
2	184	9.8	812	1	PLMS plasmin (EC 3.4.21.7)	7.26e-14
3	183	9.7	4548	1	S00657 apoprotein(a) (EC 3.4	1.07e-13
4	181	9.6	655	1	A46688 hepatocyte growth fac	2.35e-13
5	178	9.5	716	1	JC5061 macrophage-stimulatin	7.55e-13
6	177	9.4	685	2	A48289 neurotrophic receptor	1.11e-12
7	177	9.4	716	1	A40332 macrophage-stimulatin	1.11e-12
8	176	9.3	810	2	I46260 plasmin (EC 3.4.21.7)	1.64e-12
9	173	9.2	810	2	B30848 plasmin (EC 3.4.21.7)	5.22e-12
10	171	9.1	790	1	PLPG plasmin (EC 3.4.21.7)	1.13e-11
11	172	9.1	812	1	PLBO plasmin (EC 3.4.21.7)	7.67e-12
12	168	8.9	728	1	A60185 hepatocyte growth fac	3.54e-11
13	167	8.9	728	1	JH0579 hepatocyte growth fac	5.19e-11
14	165	8.8	622	1	TBHU thrombin (EC 3.4.21.5	1.11e-10
15	166	8.8	711	1	A47136 macrophage-stimulatin	7.58e-11
16	165	8.8	728	1	A35644 hepatocyte growth fac	1.11e-10
17	164	8.7	625	1	TBBO thrombin (EC 3.4.21.5	1.62e-10
18	163	8.7	1420	2	A32869 apolipoprotein(a) (EC	2.36e-10
19	161	8.6	810	1	PLHU plasmin (EC 3.4.21.7)	5.01e-10
20	158	8.4	603	2	S28941 coagulation factor XI	1.54e-09
21	156	8.3	89	2	A60140 plasmin (EC 3.4.21.7)	3.24e-09
22	156	8.3	431	2	J50599 t-plasminogen activat	3.24e-09
23	156	8.3	477	2	J50598 t-plasminogen activat	3.24e-09

24	156	8.3	477	2	A34369 t-plasminogen activat	3.24e-09
25	152	8.1	120	2	E61545 plasmin (EC 3.4.21.7)	1.42e-08
26	152	8.1	433	1	UKBAY u-plasminogen activat	1.42e-08
27	152	8.1	434	1	A35005 u-plasminogen activat	1.42e-08
28	151	8.0	432	1	S18932 u-plasminogen activat	2.05e-08
29	150	8.0	442	1	UKPG u-plasminogen activat	2.96e-08
30	150	8.0	562	1	UKHUT u-plasminogen activat	2.96e-08
31	151	8.0	943	2	B45082 neurotrophic receptor	2.05e-08
32	149	7.9	593	2	S45281 coagulation factor XI	4.26e-08
33	147	7.8	123	2	E61545 plasmin (EC 3.4.21.7)	8.83e-08
34	147	7.8	394	2	J50600 t-plasminogen activat	8.83e-08
35	146	7.8	411	2	S65783 plasminogen activator	1.27e-07
36	146	7.8	431	1	UKHU u-plasminogen activat	1.27e-07
37	147	7.8	433	1	UKMS u-plasminogen activat	8.83e-08
38	147	7.8	455	2	A61545 plasmin (EC 3.4.21.7)	8.83e-08
39	147	7.8	460	2	B61545 plasmin (EC 3.4.21.7)	8.83e-08
40	146	7.8	617	2	S10511 thrombin (EC 3.4.21.5	1.27e-07
41	144	7.6	618	2	A35827 thrombin (EC 3.4.21.5	2.61e-07
42	141	7.5	433	1	JN0560 u-plasminogen activat	7.65e-07
43	141	7.5	559	2	A29941 t-plasminogen activat	7.65e-07
44	142	7.5	710	1	I51283 hepatocyte growth fac	5.35e-07
45	138	7.3	291	2	I38098 t-plasminogen activat	2.22e-06

ALIGNMENTS

RESULT 1
ENTRY A40522 #type fragment
TITLE plasmin (EC 3.4.21.7) precursor - rat (fragment)
ORGANISM #formal_name Rattus norvegicus #common_name Norway rat
DATE 28-Feb-1992 #sequence_revision 17-Apr-1993 #text_change 08-Sep-1997
ACCESSIONS A40522
REFERENCE A40522
#authors Kanalas, J.J.; Makker, S.P.
#journal J. Biol. Chem. (1991) 266:10825-10829
#title Identification of the rat Heymann nephritis autoantigen (GP330) as a receptor site for plasminogen.
#cross-references MUID:91250378
#accession A40522
#status preliminary
#molecule_type mRNA
#residues 1-169 #label KAN
#cross-references GB:M62832; NID:g206215; PID:g554488
#note the authors translated the codon TCT for residue 76 as Ala

CLASSIFICATION #superfamily plasmin; kringle homology; plasminogen-related
protein precursor homology; trypsin homology
KEYWORDS fibrinolysis; glycoprotein; hydrolase; kringle; serine proteinase

FEATURE
34-112 #domain kringle homology #label KRL\
34-112,55-95, #disulfide_bonds #status predicted
83-107 #length 169 #checksum 4101

SUMMARY
Query Match 10.8%; Score 204; DB 2; Length 169;
Best Local Similarity 26.2%; Pred. No. 2.52e-17;
Matches 33; Conservative 44; Mismatches 40; Indels 9; Gaps 8;

Db 34 CYQNGKSGYRGTSSTNTGKKQSWVMTPHSHKSTPANFPDSGLEMYCRNPNDQRP 93

Qy 25 CFWDNGHLYREDQTSFAPGLRCLNW--LDAQS-GLASAPVSGAG-NH5VCRNPDEDPRGP 80

Db 94 WCFTT-DPSVR-WEYCNLKRCSGEGG-GVAE-SATVPQVPSAPGTSETDCMVGNGKRYRG 149

Qy 81 WCYVSGEAGVPEKRCEDLRCPETTSQALPAFTTEIQEASEGPGADVQ-VFAPANALPA 139

Db 150 KTAATA 155

Qy 140 RSEAAA 145

1054-1131	#domain	kringle	homology	label	KR10\				
1168-1245	#domain	kringle	homology	label	KR11\				
1282-1359	#domain	kringle	homology	label	KR12\				
1396-1473	#domain	kringle	homology	label	KR13\				
1510-1587	#domain	kringle	homology	label	KR14\				
1624-1701	#domain	kringle	homology	label	KR15\				
1738-1815	#domain	kringle	homology	label	KR16\				
1852-1929	#domain	kringle	homology	label	KR17\				
1966-2043	#domain	kringle	homology	label	KR18\				
2080-2157	#domain	kringle	homology	label	KR19\				
2194-2271	#domain	kringle	homology	label	KR20\				
2308-2385	#domain	kringle	homology	label	KR21\				
2422-2499	#domain	kringle	homology	label	KR22\				
2536-2613	#domain	kringle	homology	label	KR23\				
2650-2727	#domain	kringle	homology	label	KR24\				
2764-2841	#domain	kringle	homology	label	KR25\				
2878-2955	#domain	kringle	homology	label	KR26\				
2992-3069	#domain	kringle	homology	label	KR27\				
3106-3183	#domain	kringle	homology	label	KR28\				
3220-3297	#domain	kringle	homology	label	KR29\				
3334-3411	#domain	kringle	homology	label	KR30\				
3448-3525	#domain	kringle	homology	label	KR31\				
3562-3639	#domain	kringle	homology	label	KR32\				
3676-3753	#domain	kringle	homology	label	KR33\				
3782-3859	#domain	kringle	homology	label	KR34\				
3896-3973	#domain	kringle	homology	label	KR35\				
4010-4087	#domain	kringle	homology	label	KR36\				
4124-4201	#domain	kringle	homology	label	KR37\				
4228-4307	#domain	kringle	homology	label	KR38\				
4328-4341	#domain	trypsin	homology	label	TRY				
SUMMARY	#length	4548	#molecular-weight	501316	#checksum	1998			
Query Match	9.7%	Score	183;	DB 1;	Length	4548;			
Best Local Similarity	27.5%;	Pred. No.	1.07e-13;						
Matches	36;	Conservative	34;	Mismatches	52;	Indels	9;	Gaps	
Db	3539	ILAPLEAFT-EQALTEEPGVQDCYHYHYGQSYRGTYSTTVTGRTQCAWSMTPHQHSRT	3597						
QY	1	MLLAWQAFVLSNMLLAAYSGGCFWDNGHLHYREDQTSAPGLRCLNW--LDA-QSGLA	57						
Db	3598	PENYPNAGLTRNCRPDAEIR-PWCYTM-DPSVR-WEVCNLTQCLVTTESSVLATLV-V	3553						
QY	58	SAPVSGAG-NHSCYRNPDPRDPGRPCWYSGVGEAGVPEKRPCEDLRCPETTSQALPAFTTEI	116						
Db	3654	PDPSTEASSE	3664						
QY	117	QEASEGPGADE	127						
RESULT	4	A45688	#type	complete					
ENTRY		hepatocyte	growth	factor	activator	(EC 3.4.21.-)	precursor		
TITLE		human							
ORGANISM		#formal_name	Homo sapiens	#common_name	man				
DATE		21-Sep-1993	#sequence_revision	25-Aug-1995	#text_change				
		07-Aug-1998							
ACCESSIONS		A45688							
REFERENCE		A45688							
#authors		Miyazawa, K.; Shimomura, T.; Kitamura, A.; Kondo, J.;							
		Morimoto, Y.; Kitamura, N.							
#journal		J. Biol. Chem. (1993) 268:10024-10028							
#title		Molecular cloning and sequence analysis of the cDNA for a human serine protease responsible for activation of the hepatocyte growth factor. Structural similarity of the protease precursor to blood coagulation factor XII.							
#cross-references		MUID:93252878							
#accession		A45688							
		#molecule_type	mrna						
		#residues	1-655	#label	MIY				
		#cross-references	DBU:DI4012; NID:g219680; PID:g219681						
		#experimental_source	liver (MRNA); serum (protein)						
		#note	sequence extracted from NCBI backbone (NCBIN:131227, NCBIIP:131228)						

```

#note      parts of the sequence, including the amino ends of the
#           heavy and light chains, confirmed by protein
#           sequencing
FUNCTION
#description activates hepatocyte growth factor by specific proteolytic
#           cleavage
#pathway      tissue repair and regeneration
CLASSIFICATION
#superfamily coagulation factor XII; EGF homology;
#fibronectin type I repeat homology; fibronectin type II
#repeat homology; kringle homology; trypsin homology
KEYWORDS      glycoprotein; hydrolase; kringle; liver; plasma; serine
#proteinase
FEATURE
1-34          #domain signal sequence #status predicted #label SIG\
108-148       #domain fibronectin type II repeat homology #label FN2\
164-197       #domain EGF homology #label EGF1\
202-237       #domain fibronectin type I repeat homology #label FN1\
245-278       #domain EGF homology #label EGF2\
286-367       #domain kringle homology #label KGL\
373-407       #product hepatocyte growth factor activator light chain
#status experimental #label LCH\
408-655       #product hepatocyte growth factor activator heavy chain
#status experimental #label HCH\
#domain trypsin homology #label TRY\
408-641       #binding_site carbohydrate (Asn) (covalent) #status
40,48,290,468,492,
546           predicted\
164-175,169-186,
188-197,202-230,
228-237,245-256,
250-267,269-278,
286-367,307-349,
338-362,394-521,
432-448,440-510,
535-604,567-583,
594-622       #disulfide_bonds #status predicted\
447,497,598   #active_site His, Asp, Ser #status predicted
SUMMARY      #length 655 #molecular-weight 70681 #checksum 645
Query Match   9.6%; Score 181; DB 1; Length 655;
Best Local Similarity 40.5%; Pred. No. 2,35e-13;
Matches 30; Conservative 19; Mismatches 17; Indels 8; Gaps 4;
Db 286 CFLGSGTGYRGVASTSASGLSLAWNSDLLYOLHVDVSGAALLGLGPHAYCRNPNDNE 345
QY 25 CFWDNGHLYREDQTSAPGLRCLNW---L-DAQ-SGLASAPVSGAGNHSYCRNPDED 77
Db 346 R-PWCYVVKDSALS 358
QY 78 RGPWCYVSGAGVP 91
RESULT 5
ENTRY      JC5061          #type complete
TITLE      macrophage-stimulating protein 1 precursor - rat
ORGANISM   #formal_name Rattus norvegicus #common_name Norway rat
DATE       31-Jan-1997 #sequence_revision 31-Jan-1997 #text_change
13-Sep-1997
ACCESSIONS JC5061
REFERENCE   Ohshiro, K.; Iwama, A.; Matsuno, K.; Ezaki, T.; Sakamoto, O.;
#authors   Hamaguchi, I.; Takasu, N.; Suda, T.
#journal   Biochem. Biophys. Res. Commun. (1996) 227:273-280
#title     Molecular cloning of rat macrophage-stimulating protein and
#           its involvement in the male reproductive system.
#cross-references MUID:97011126
#accession   JC5061
#molecule_type mRNA
#residues   1-716 ##label OHS
##cross-references EMBL:X95096; NID:g1669718; PID:e223604; PID:g1669719
#precursor  disulfide-bonded heterodimer of chains derived from the same
#CLASSIFICATION #superfamily hepatocyte growth factor; kringle homology;

```

```

trypsin homology
duplication; glycoprotein; growth factor; kringle
FEATURE
1-31          #domain signal sequence #status predicted #label SIG\
32-488,489-716 #product macrophage-stimulating protein 1 #status
#predicted #label MAP\
32-488       #domain macrophage-stimulating protein 1 alpha chain
#status predicted #label ACH\
110-186      #domain kringle homology #label KRI1\
191-268      #domain kringle homology #label KRI2\
292-370      #domain kringle homology #label KRI3\
379-457      #domain kringle homology #label KRI4\
489-716      #domain macrophage-stimulating protein 1 beta chain
#status predicted #label BCH\
489-709      #domain trypsin homology #label TRY\
72,305,620   #binding_site carbohydrate (Asn) (covalent) #status
#predicted
SUMMARY      #length 716 #molecular-weight 80733 #checksum 9217
Query Match   9.5%; Score 178; DB 1; Length 716;
Best Local Similarity 41.3%; Pred. No. 7.55e-13;
Matches 26; Conservative 9; Mismatches 26; Indels 2; Gaps 2;
Db 110 CIMDNGASYRGTVARTADGLPCQAWRRFPNDHKYTPFPKNGLEENFCRNPDPGRGFWC 169
QY 25 CFWDNGHLYREDQTSAPGLRCLNWLDLA-QSGLASAPVSGAG-NHSYCRNPDEDPRGFWC 82
Db 170 YTT 172
QY 83 YVS 85
RESULT 6
ENTRY      A48289          #type complete
TITLE      neurotrophic receptor for precursor - fruit fly (Drosophila
#melanogaster)
ALTERNATE_NAMES trk-related receptor
CONTAINS         protein-tyrosine kinase (EC 2.7.1.112)
ORGANISM        #formal_name Drosophila melanogaster
DATE            27-Jun-1994 #sequence_revision 27-Jun-1994 #text_change
17-Mar-1999
ACCESSIONS     A48289
REFERENCE       Wilson, C.; Goberdhan, D.C.I.; Steller, H.
#authors        Proc. Natl. Acad. Sci. U.S.A. (1993) 90:7109-7113
#journal         Dror, a potential neurotrophic receptor gene, encodes a
#title           Drosophila homolog of the vertebrate Ror family of
#               Trk-related receptor tyrosine kinases.
#cross-references MUID:93348222
#accession      A48289
#status         preliminary
##molecule_type mRNA
##residues      1-685 ##label WIL
##cross-references GB:L20297; NID:g348103; PID:g348104
GENETICS
#gene          FlyBase:bsk
##cross-references FlyBase:FBgn0000229
CLASSIFICATION #superfamily Drosophila neurotrophic receptor ror; kringle
#homology; protein kinase homology
KEYWORDS       ATP; glycoprotein; kringle; phosphotransferase; transmembrane
#protein; tyrosine-specific protein kinase
FEATURE
237-310       #domain kringle homology #label KRI\
314-338       #domain transmembrane #status predicted #label TM1\
408-677       #domain protein kinase homology #label KIN\
416-424       #region protein kinase ATP-binding motif\
45,63,129,144,250 #binding_site carbohydrate (Asn) (covalent) #status
#predicted
SUMMARY      #length 685 #molecular-weight 78142 #checksum 8512
Query Match   9.4%; Score 177; DB 2; Length 685;
Best Local Similarity 27.4%; Pred. No. 1.11e-12;
Matches 26; Conservative 20; Mismatches 46; Indels 3; Gaps 3;

```

```

Db 234 TENCYWEDGTYRGVAVNSVSGKPCRLRWLMKEISDP-ELIG-ONYCRNPGSVENSPW 291
QY 22 SGGCFWNGHLYREDQTSAPGLRCLNWLDAQSGNHSYCRNPDEDPGRGPW 81
Db 292 CFVDSRE-RRIELCDIPKCADKIWIATVGTAAI 325
QY 82 CYVSGEAGVPEKRCEDLRCPETTSQALPATTETI 116

RESULT 7
ENTRY A40332 #type complete
TITLE macrophage-stimulating protein 1 precursor - mouse
ALTERNATE_NAMES hepatocyte growth factor-like protein
ORGANISM #formal_name Mus musculus #common_name house mouse
DATE 17-Jul-1992 #sequence_revision 17-Jul-1992 #text_change
ACCESSIONS A40332; B40332
REFERENCE Degen, S.J.F.; Stuart, L.A.; Han, S.; Jamison, C.S.
#authors Biochemistry (1991) 30:9781-9791
#journal Characterization of the mouse cDNA and gene coding for a
#title hepatocyte growth factor-like protein: expression during
development.
#cross-references MUID:92002017
#accession A40332
#molecule_type DNA
#residues 1-716 #label DEG
#cross-references GB:M74180; NID:g193831; PID:g193832
#accession B40332
#molecule_type mRNA
#residues 1-18, 'P', 20-716 #label DEG2
#cross-references GB:M74181; NID:g193833; PID:g193834
GENETICS
#introns 18/1: 67/2; 105/1: 143/2; 189/1: 229/2; 269/1: 334/2; 378/1;
412/2; 458/1; 470/1: 506/2; 532/2; 581/2; 617/1; 663/3
COMPLEX disulfide-bonded heterodimer of chains derived from the same
precursor
CLASSIFICATION #superfamily hepatocyte growth factor; kringle homology;
trypsin homology
KEYWORDS duplication; glycoprotein; growth factor; kringle
FEATURE
1-31 #domain signal sequence #status predicted #label SIG\
19-488,489-716 #product macrophage-stimulating protein 1 #status
experimental #label MAT\
19-483 #domain alpha chain #status experimental #label ACH\
110-186 #domain kringle homology #label KR1\
191-268 #domain kringle homology #label KR2\
292-370 #domain kringle homology #label KR3\
379-457 #domain kringle homology #label KR4\
484-711 #domain beta chain #status experimental #label BCH\
489-709 #domain trypsin homology #label TRY\
72,173,305,620 #binding_site carbohydrate (Asn) (covalent) #status
predicted
SUMMARY #length 716 #molecular-weight 80619 #checksum 7627
Query Match 9.4%; Score 177; DB 1; Length 716;
Best Local Similarity 41.3%; Pred. No. 1,11e-12;
Matches 26; Conservative 9; Mismatches 26; Indels 2; Gaps 2;

Db 110 CIMDNGVSYRGTVARTAGGLPCQAWSRRFPNDHKVTPKNGLEENFCRNPDPGRGPWC 169
QY 25 CFVWNGHLYREDQTSAPGLRCLNWLDA-QSGLASAPVSGAG-NHSYCRNPDEDPGRGPWC 82
Db 170 YTT 172
QY 83 YVS 85

RESULT 8
ENTRY I46260 #type complete
TITLE plasmin (EC 3.4.21.7) precursor - western European hedgehog
ORGANISM #formal_name Erinaceus europaeus #common_name western

```

```

DATE European hedgehog
21-Feb-1997 #sequence_revision 21-Feb-1997 #text_change
17-Mar-1999
ACCESSIONS I46260
REFERENCE I46259
#authors Lawn, R.M.; Boonmark, N.W.; Schwartz, K.; Lindahl, G.E.;
Wade, D.P.; Byrne, C.D.; Fong, K.J.; Meer, K.; Pathy, L.
#journal J. Biol. Chem. (1995) 270:24004-24009
#title The recurring evolution of Lp(a): insights from cloning of
hedgehog apolipoprotein(a).
#cross-references MUID:96025778
#accession I46260
#status preliminary; translated from GB/EMBL/DBJ
#molecule_type mRNA
#residues 1-810 #label LAW
#cross-references EMBL:U33171; NID:g1046360; PID:g1046361
CLASSIFICATION #superfamily plasmin; kringle homology; plasminogen-related
protein precursor homology; trypsin homology
KEYWORDS hydrolase; serine proteinase
FEATURE
1-96 #domain plasminogen-related protein precursor homology
#label PLPH\
103-181 #domain kringle homology #label KR1\
185-262 #domain kringle homology #label KR2\
379-456 #domain kringle homology #label KR4\
582-803 #domain trypsin homology #label TRY
SUMMARY #length 810 #molecular-weight 90902 #checksum 2484
Query Match 9.3%; Score 176; DB 2; Length 810;
Best Local Similarity 32.9%; Pred. No. 1,64e-12;
Matches 26; Conservative 20; Mismatches 27; Indels 6; Gaps 6;

Db 107 NGKYRGTVSKTGTGLTCQKSAETPKPRFSEGLDQNYCRNPDPKGPWCYT 166
QY 29 NGHLYREDQTSAPGLRCLNW-LDA-QSG-LASAPVSGAG-NHSYCRNPDEDPGRGPWCIV 84
Db 167 M-DPEVRYEY-CEIIQCED 183
QY 85 SGEAGVPEKRRPCEDLRCP 103

RESULT 9
ENTRY B30848 #type complete
TITLE plasmin (EC 3.4.21.7) precursor - rhesus macaque
ORGANISM #formal_name Macaca mulatta #common_name rhesus macaque
DATE 31-Mar-1989 #sequence_revision 31-Mar-1989 #text_change
08-Sep-1997
ACCESSIONS B32869; B30848
REFERENCE A32869
#authors Tomlinson, J.E.; McLean, J.W.; Lawn, R.M.
#journal J. Biol. Chem. (1989) 264:5957-5965
#title Rhesus monkey apolipoprotein(a). Sequence, evolution, and
sites of synthesis.
#cross-references MUID:89174660
#accession B32869
#status preliminary
#molecule_type mRNA
#residues 1-810 #label TOM
#cross-references GB:J04697; NID:g342272; PID:g342273
CLASSIFICATION #superfamily plasmin; kringle homology; plasminogen-related
protein precursor homology; trypsin homology
KEYWORDS fibrinolysis; glycoprotein; hydrolase; kringle; serine
proteinase
FEATURE
1-96 #domain plasminogen-related protein precursor homology
#label PLPH\
103-181 #domain signal sequence #status predicted #label SIG\
185-262 #domain kringle homology #label KR1\
275-352 #domain kringle homology #label KR2\
377-454 #domain kringle homology #label KR3\
481-560 #domain kringle homology #label KR5\
581-803 #domain trypsin homology #label TRY\

```

[illegible]

#note	it is uncertain whether Met-1 or Met-8 is the initiator
REFERENCE	
#authors	A25835 Schaller, J.; Moser, P.W.; Danneegger-Muller, G.A.K.; Rossettel, S.J.; Kampfer, U.; Rickli, E.E. Eur. J. Biochem. (1985) 149:267-278 Complete amino acid sequence of bovine plasminogen. Comparison with human plasminogen.
#journal	
#title	
#cross-references	MUID:85203906
#accession	A25835
#molecule_type	protein
#residues	27-334,'D',336-515,'H',517-554,'L',556-812 ##label SCH
REFERENCE	
#authors	I45961 Malinowski, D.P.; Sadler, J.E.; Davie, E.W. Biochemistry (1984) 23:4243-4250 Characterization of a complementary deoxyribonucleic acid coding for human and bovine plasminogen.
#journal	
#title	
#cross-references	MUID:85023311
#accession	I45961
#status	translated from GB/EMBL/DDDBJ
#molecule_type	mRNA
#residues	706-743,'R',745-812 ##label MAL
#cross-references	GB:K02935; NID:g163551; PID:g163552
REFERENCE	
#authors	S03735 Brunisholz, R.A.; Lerch, P.G.; Schaller, J.; Rickli, E.E.; Lergier, W.; Manneberg, M.; Gillesen, D. Eur. J. Biochem. (1981) 114:465-470 Comparison of the primary structure of the N-terminal CNBR fragments of human, bovine and porcine plasminogen.
#journal	
#title	
#cross-references	MUID:81212097
#accession	S03735
#molecule_type	protein
#residues	27-83 ##label BRU
FUNCTION	
#description	dissolves the fibrin of blood clots; acts as a proteolytic factor in a variety of processes including embryonic development, tissue remodeling and tumor invasion; in ovulation it weakens the walls of the graafian follicle; also activates the urokinase-type plasminogen activator fibrinolysis
#pathway	
CLASSIFICATION	#superfamily plasmin; kringle homology; plasminogen-related protein precursor homology; trypsin homology duplication: fibrinolysis; glycoprotein; hydrolase; kidney; kringle; plasma; serine proteinase; zymogen
KEYWORDS	
FEATURE	
1-26	#domain signal sequence #status predicted #label SIG\
8-103	#domain plasminogen-related protein precursor homology #label PLPH\
27-812	#product plasminogen #status experimental #label PRO\
27-103	#domain activation peptide #status experimental #label APT\
104-583,584-812	#product plasmin #status experimental #label MAT\
104-583	#domain plasmin chain A #status experimental #label ACH\
104-588	#domain kringle homology #label KR1\
192-269	#domain kringle homology #label KR2\
282-359	#domain kringle homology #label KR3\
384-461	#domain kringle homology #label KR4\
485-564	#domain kringle homology #label KR5\
584-812	#domain plasmin chain B #status experimental #label BCH\
584-805	#domain trypsin homology #label TR1\
56-80,60-68, 110-188,131-171, 159-183,192-269, 195-323,213-252, 241-264,282-359, 303-342,331-354, 384-461,405-444, 433-456,485-564, 506-547,535-559, 570-687,580-588, 609-625,701-768, 731-747,758-786	#disulfide_bonds #status predicted\ #binding_site carbohydrate (Asn) (covalent) #status experimental\
315	

RESULT	13
ENTRY	JH0579 #type complete
TITLE	hepatocyte growth factor precursor - human
ALTERNATE_NAMES	hepatoietin A; scatter factor
ORGANISM	#formal_name Homo sapiens #common_name man
DATE	17-Aug-1992 #sequence_revision 17-Aug-1992 #text_change 18-Sep-1998
ACCESSIONS	JH0579; J00333; A41140; B36677; A36677; A33512; A39006; PH0114; A37796; S06794; I59214; SI5443
REFERENCE	JH0579
authors	Seki, T.; Hagiya, M.; Shimonishi, M.; Nakamura, T.; Shimizu, S.
#journal	Gene (1991) 102:213-219
#title	Organization of the human hepatocyte growth factor-encoding gene.
#cross-references	MUID:91340155
#accession	JH0579
#molecule_type	DNA
#residues	1-728 #label SEK
#cross-references	DBJ:D90318
#note	the authors translated the codon GAA for residue 662 as Gly
REFERENCE	JU0333
authors	Seki, T.; Hagiya, M.; Shimonishi, M.; Nakamura, T.; Shimizu, S.
#submission	submitted to JIPID, March 1991
#description	Organization of the human hepatocyte growth factor-encoding gene.
#accession	JU0333
#molecule_type	DNA
#residues	1-481,'RT',484-728 #label SE2
REFERENCE	A41140
authors	Weidner, K.M.; Arakaki, N.; Hartmann, G.; Vandekerckhove, J.; Weingart, S.; Rieder, H.; Fontatsch, C.; Tsubouchi, H.; Hishida, T.; Daikuhara, Y.; Birchmeier, W.
#journal	Proc. Natl. Acad. Sci. U.S.A. (1991) 88:7001-7005
#title	Evidence for the identity of human scatter factor and human hepatocyte growth factor.
#cross-references	MUID:91334393
#accession	A41140
#molecule_type	mRNA
#residues	1-728 #label WEI
#cross-references	GB:M73239; NID:g337935; PID:g337936
REFERENCE	A36677
authors	Seki, T.; Ihara, I.; Sugimura, A.; Shimonishi, M.; Nishizawa, I.; Asami, O.; Hagiya, M.; Nakamura, T.; Shimizu, S.
#journal	Biochem. Biophys. Res. Commun. (1990) 172:321-327
#title	Isolation and expression of cDNA for different forms of hepatocyte growth factor from human leukocyte.
#cross-references	MUID:91025062
#accession	B36677
#molecule_type	mRNA
#residues	1-728 #label SE3
#cross-references	GB:M60718; NID:gl84031; PID:gl84032
#accession	A36677
#molecule_type	mRNA
#residues	1-161,167-728 #label SE4
#cross-references	EMBL:X16323
#experimental_source	leukocyte
REFERENCE	A33512
authors	Miyazawa, K.; Tsubouchi, H.; Naka, D.; Takahashi, K.; Okizaki, M.; Arakaki, N.; Nakayama, H.; Hirono, S.; Sakiyama, O.; Takahashi, K.; Gohda, E.; Daikuhara, Y.; Kitamura, N.
#journal	Biochem. Biophys. Res. Commun. (1989) 163:967-973
#title	Molecular cloning and sequence analysis of cDNA for human hepatocyte growth factor.
#cross-references	MUID:89392017
#accession	A33512
#status	not compared with conceptual translation
#molecule_type	mRNA
#residues	1-728 #label MID
#cross-references	GB:M29145; NID:gl84041; PID:g306846


```

REFERENCE
#authors
A39006
Rubin, J.S.; Chan, A.M.L.; Bottaro, D.P.; Burgess, W.H.;
Taylor, W.G.; Cech, A.C.; Hirschfield, D.W.; Wong, J.;
Miki, T.; Finch, P.W.; Aaronson, S.A.
#journal
Proc. Natl. Acad. Sci. U.S.A. (1991) 88:415-419
#title
A broad-spectrum human lung fibroblast-derived mitogen is a
variant of hepatocyte growth factor.
#cross-references MUID:91110540
#accession
A39006
#molecule_type mRNA
#residues 1-161,167-728 #label RUB
##cross-references GB:M53379
##experimental_source embryonic lung
REFERENCE
#authors
PH0114
Yoshiyama, Y.; Arakaki, N.; Naka, D.; Takahashi, K.; Hirono,
S.; Kondo, J.; Nakayama, H.; Gohda, E.; Kitamura, N.;
Tsubouchi, H.; Ishii, T.; Hishida, T.; Daikuhara, Y.
#journal
Biochem. Biophys. Res. Commun. (1991) 175:660-667
#title
Identification of the N-terminal residue of the heavy chain
of both native and recombinant human hepatocyte growth
factor.
#cross-references MUID:91207365
#accession
PH0114
#molecule_type protein
#residues 32-43;53-58 #label YOS
##experimental_source plasma
REFERENCE
#authors
A37796
Weidner, K.M.; Behrens, J.; Vandekerckhove, J.; Birchmeier,
W.
#journal
J. Cell Biol. (1990) 111:2097-2108
#title
Scatter factor: molecular characteristics and effect on the
invasiveness of epithelial cells.
#cross-references MUID:91035621
#accession
A37796
#molecule_type protein
#residues 86-91;329-344;356-363,'XX',366-370;425-434;442-447,'X',
449-450;543-546,'X',548-553;563-565,'X',567-574
#label WE2
REFERENCE
S06794
Nakamura, T.; Nishizawa, T.; Hagiya, M.; Seki, T.;
Shimonishi, M.; Sugimura, A.; Tashiro, K.; Shimizu, S.
#journal
Nature (1989) 342:440-443
#title
Molecular cloning and expression of human hepatocyte growth
factor.
#cross-references MUID:90066576
#accession
S06794
#molecule_type mRNA
#residues 1-31,'HK',34-77,'N',79-292,'V',294-299,'W',301-316,'A',
318-335,'K',337-386,'N',388-415,'N',417-504,'V',
506-508,'I',510-557,'E',559-560,'R',562-594,'N',
596-728 #label NAK
##cross-references EMBL:X16323; NID:g32081; PID:g32082
##experimental_source liver
#note
the authors translated the codon CAG for residue 727 as
Glu
#note
part of this sequence, including the amino end of both
the alpha and beta chains, was confirmed by protein
sequencing
REFERENCE
I59214
Hartmann, G.; Naldini, L.; Weidner, K.M.; Sachs, M.; Vigna,
E.; Comoglio, P.M.; Birchmeier, W.
#journal
Proc. Natl. Acad. Sci. U.S.A. (1992) 89:11574-11578
#title
A functional domain in the heavy chain of scatter
factor/hepatocyte growth factor binds the c-Met receptor
and induces cell dissociation but not mitogenesis.
#cross-references MUID:93087571
#accession
I59214
#status
preliminary; translated from GB/EMBL/DBJ
#molecule_type mRNA
#residues 1-288,'ET' #label RES
##cross-references GB:I02931; NID:g184033; PID:g184034
#accession
S15443
Miyazawa, K.; Kitamura, A.; Naka, D.; Kitamura, N.
#journal
Eur. J. Biochem. (1991) 197:15-22
#title
An alternatively processed mRNA generated from human
hepatocyte growth factor gene.
#cross-references MUID:91200041
#accession
S15443
#status
preliminary
#molecule_type mRNA
#residues 1-288,'ET' #label M12
##cross-references EMBL:X57574; NID:g32083; PID:g32084
GENETICS
#gene
GDB:HGF
#map_position 7q21.1-7q21.1
#introns 30/1; 85/2; 123/1; 161/2; 209/1; 249/2; 289/1; 347/2; 390/1;
424/2; 469/1; 482/1; 514/2; 539/2; 586/2; 622/1; 670/3
#complex
disulfide-bonded heterodimer of chains derived from the same
precursor
#function
stimulates mitosis of hepatocytes and other cells
#note
does not have proteinase activity
#classification
#superfamily hepatocyte growth factor; kringle homology;
trypsin homology
#keywords
alternatively splicing; glycoprotein; growth factor;
heterodimer; kringle; pyroglutamic acid
#feature
1-31 #domain signal sequence #status predicted #label SIG\
32-494,495-728 #product hepatocyte growth factor #status experimental
#label MAT\
32-494 #domain alpha chain #status experimental #label ACH\
128-206 #domain kringle homology #label KR1\
211-288 #domain kringle homology #label KR2\
305-383 #domain kringle homology #label KR3\
391-469 #domain kringle homology #label KR4\
495-728 #domain beta chain #status experimental #label BCH\
32 #domain trypsin homology #label TRY\
#modified_site pyrrolidone carboxylic acid (Gln) (in
mature form) #status experimental\
294,402,566,653 #binding_site carbohydrate (Asn) (covalent) #status
predicted\
487-604 #disulfide_bonds #status predicted
#summary
#length 728 #molecular_weight 83133 #checksum 4163
Query Match 8.9%; Score 167; DB 1; Length 728;
Best Local Similarity 31.5%; Pred. No. 5.19e-11;
Matches 28; Conservative 22; Mismatches 33; Indels 6; Gaps 4;
Db 391 CYRGNKNTYGNLSQRTSLTCSMDKNDLHRHFWEPDASKLNEYCRNPDDAHGP 450
QY 25 CFWDNGLHYREDQTSAPGLRCLNW---LDA-QSGLASAPVSGAGNHSYCRNPDPRGP 80
Db 451 WCY-TGNPLIP-WDYCPISRCGDTTPTI 477
QY 81 WCIVSGEAGVPERPCEDLRCPTTSQAL 109
RESULT 14
ENTRY TBHU #type complete
TITLE thrombin (EC 3.4.21.5) precursor - human
ALTERNATE_NAMES coagulation factor II
CONTAINS prothrombin
ORGANISM Homo sapiens #common_name man
DATE 30-Nov-1980 #sequence_revision 22-Jul-1994 #text_change
20-Mar-1998
ACCESSIONS A29351; A00914; B00914; A37549; A37550; I51952
REFERENCE A29351
#authors Degen, S.J.F.; Davie, E.W.
#journal Biochemistry (1987) 26:6165-6177
#title Nucleotide sequence of the gene for human prothrombin.
#cross-references MUID:88077877
#accession A29351
#molecule_type DNA
#residues 1-622 #label DEG
##cross-references GB:M17262; GB:M33691; NID:g558069; PID:g339641

```

```

REFERENCE A00914
#authors Degen, S.J.F.; Macgillivray, R.T.A.; Davie, E.W.
#journal Biochemistry (1983) 22:2087-2097
#title Characterization of the complementary deoxyribonucleic acid
and gene coding for human prothrombin.
#cross-references MUID:83231469
#accession A00914
#molecule_type mRNA
#residues 8-163, 'N', 165-622 #label DE2
#cross-references GB:V00595; GB:J00307; NID:g37128; PID:e5121;
PID:g1335344
#accession B00914
#molecule_type DNA
#residues 188-311 #label DE3
REFERENCE A37549
#authors Walz, D.A.; Hewett-Emmett, D.; Seegers, W.H.
#journal Proc. Natl. Acad. Sci. U.S.A. (1977) 74:1969-1972
#cross-references MUID:77193964
#accession A37549
#molecule_type protein
#residues 44-118, 'N', 120, 'S', 122-163, 'I', 165-175, 'A', 177-182, 'T',
184-193, 'MV', 196-308, 'EE', 309-314 #label WAL
REFERENCE A37550
#authors Butkowski, R.J.; Elion, J.; Downing, M.R.; Mann, K.G.
#journal J. Biol. Chem. (1977) 252:4942-4957
#title Primary structure of human prothrombin 2 and alpha-thrombin.
#cross-references MUID:77207112
#accession A37550
#molecule_type protein
#residues 315-334, 'N', 336-348, 'N', 350-368, 'N', 370-397, 'N', 399-413,
'N', 415-484, 'N', 486-493, 'G', 495-503, 'Y', 505-508, 'S',
510, 'V', 512-513, 'D', 515-528, 'AL', 531, 'Q', 533-622
#label BUT
REFERENCE A37551
#authors Rabinet, M.J.; Blashill, A.; Furie, B.; Furie, B.C.
#journal J. Biol. Chem. (1986) 261:13210-13215
#cross-references MUID:87008532
#contents annotation; activation cleavages
REFERENCE I51952
#authors Macgillivray, R.T.; Irwin, D.M.; Guinto, E.R.; Stone, J.C.
#journal Ann. N.Y. Acad. Sci. (1986) 485:73-79
#title Recombinant genetic approaches to functional mapping of
thrombin.
#cross-references MUID:87182874
#accession I51952
#status translated from GB/EMBL/DBJ
#molecule_type mRNA
#residues 1-2, 'RI', 5-100 #label RES
#cross-references GB:M3031; NID:g190723; PID:g190724
COMMENT Thrombin, which cleaves bonds after Arg and Lys, converts
fibrinogen to fibrin and activates factors V, VIII, XIII, and, in
complex with thrombomodulin, protein C.
COMMENT Prothrombin is activated on the surface of a phospholipid membrane
that binds the amino end of prothrombin and factors Va and Xa in
calcium-dependent interactions. The activation peptide(s) can be
removed either by factor Xa or thrombin; the cleavage into light
and heavy chains is by factor Xa. It is not known whether one or
two smaller activation peptides, with additional cleavage after
314-Arg, are released in natural blood clotting.
COMMENT The cleavage after Arg-198, observed in vitro, does not occur in
plasma.
COMMENT The gamma-carboxyglutamyl residues bind calcium ions, result from
the carboxylation of glutamyl residues by microsomal vitamin
K-dependent carboxylase, and are necessary for calcium-dependent
interaction with the negatively charged phospholipid membrane
surface.
COMMENT The prothrombin precursor is synthesized in the liver.
GENETICS
#gene GDB:F2
#cross-references GDB:1119894; OMIM:176930
#map_position lip1-liq12
#introns 27/1; 80/3; 89/1; 106/1; 141/2; 187/1; 292/1; 335/1; 377/2;
433/2; 491/2; 552/1; 575/3
CLASSIFICATION #superfamily thrombin; Gla domain homology; kringle homology;
trypsin homology
KEYWORDS acute phase; blood coagulation; calcium binding;
carboxylglutamic acid; duplication; glycoprotein; hydrolase;
-kringle; liver; plasma; serine proteinase
FEATURE
1-24 #domain signal sequence #status predicted #label SIG\
25-43 #domain propeptide #status predicted #label PRO\
28-87 #domain Gla domain homology #label GLA\
44-622 #product prothrombin #status experimental #label MAT\
44-327 #domain activation peptide #status experimental #label
AP\
108-186 #domain kringle homology #label KR1\
213-291 #domain kringle homology #label KR2\
328-363 #product thrombin light chain #status experimental
#label LCH\
364-622 #product thrombin heavy chain #status experimental
#label HCH\
364-613 #domain trypsin homology #label TRY\
68,69,72,75 #modified_site gamma-carboxyglutamic acid (Glu) #status
experimental\
60-65,90-103,
108-186,129-169,
157-181,213-291,
234-274,262-286
121,143
336-482,536-550,
564-594
391-407
406,462
416
#disulfide_bonds #status predicted\
#disulfide_bonds #status experimental\
#active_site His, Asp #status predicted\
#binding_site carbohydrate (Asn) (covalent) #status
experimental\
568 #active_site Ser #status experimental
SUMMARY #length 622 #molecular-weight 70036 #checksum 3003
Query Match 8.8%; Score 165; DB 1; Length 622;
Best Local Similarity 37.7%; Pred. No. 1.11e-10;
Matches 26; Conservative 13; Mismatches 26; Indels 4; Gaps 3;
Db 213 CVPDRQQYQGRVAVTHGLPCLAWASQAQAKLSKHQDFNSAVOLVFQCRNPDGDEGV 272
| | | : : | | | | | : : : : | | | |
QY 25 CFWDNGHLRYEDQTSAPGLRCLNWLDAQS-GLASAP-VSGAGN--HSYCRNPDEDPG 80
| | | | |
Db 273 WCYVAGKPG 281
| | | | |
QY 81 WCYVSGEAG 89
RESULT 15
ENTRY A47136 #type complete
TITLE macrophage-stimulating protein 1 precursor - human
ORGANISM #formal_name Homo sapiens #common_name man
DATE 03-May-1994 #sequence_revision 14-Nov-1997 #text_change
11-Sep-1998
ACCESSIONS A40331; B40331; A47136; A61395
REFERENCE A40331
#authors Han, S.; Stuart, L.A.; Degen, S.J.F.
#journal Biochemistry (1991) 30:9768-9780
#title Characterization of the DNFI52 locus on human chromosome 3:
identification of a gene coding for four kringle domains
with homology to hepatocyte growth factor.
#cross-references MUID:92002016
#accession A40331
#molecule_type DNA
#residues 1-711 #label HA1
#cross-references GB:M74179
#accession B40331
#molecule_type mRNA
#residues 1-711 #label HA2
#cross-references GB:M74178; NID:g183976; PID:g183977
A47136
REFERENCE

```

Search completed: Fri Sep 17 18:26:39 1999
Job time : 50 secs.

W P S R E H

(TM)

Release 3.1A John F. Collins, Biocomputing Research Unit.
Copyright (c) 1993-1998 University of Edinburgh, U.K.
Distribution rights by Oxford Molecular Ltd

MPsrch_pp protein - protein database search, using Smith-Waterman algorithm

Run on: Fri Sep 17 18:26:56 1999; MasPar time 8.89 Seconds
Tabular output not generated. 835.926 Million cell updates/sec

Title: >US-09-084-491A-2
Description: (1-263) from US09084491A.pap
Perfect Score: 1883
Sequence: 1 MLLWVQAFVLVSNMLLAEAY.....PVDQEGSTPLMGAGTPGA 263

Scoring table: PAM 150
Gap 11

Searched: 77977 seqs, 28268293 residues

Post-processing: Minimum Match 0%
Listing first 45 summaries

Database: swiss-prot37
l:swissprot

Statistics: Mean 46.647; Variance 77.329; scale 0.603

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description	Pred. No.
1	204	10.8	169	1	PLMN_RAT PLASMINOGEN (EC 3.4.21	1.10e-20
2	184	9.8	812	1	PLMN_MOUSE PLASMINOGEN PRECURSOR	1.20e-16
3	183	9.7	4548	1	APOLIPOPROTEIN(A) PREC	1.89e-16
4	181	9.6	655	1	HEPATOCYTE GROWTH FACT	4.70e-16
5	177	9.4	716	1	HEPATOCYTE GROWTH FACT	2.88e-15
6	176	9.3	810	1	PLMN_ERIEU PLASMINOGEN PRECURSOR	4.53e-15
7	173	9.2	810	1	PLMN_MACMU PLASMINOGEN PRECURSOR	1.75e-14
8	171	9.1	790	1	PLMN_PIG PLASMINOGEN (EC 3.4.21	4.27e-14
9	172	9.1	812	1	PLMN_BOVIN PLASMINOGEN PRECURSOR	2.73e-14
10	168	8.9	728	1	HEPATOCYTE GROWTH FACT	1.62e-13
11	167	8.9	728	1	HEPATOCYTE GROWTH FACT	2.53e-13
12	165	8.8	622	1	PROTHROMBIN PRECURSOR	6.12e-13
13	166	8.8	711	1	HEPATOCYTE GROWTH FACT	3.94e-13
14	165	8.8	728	1	HEPATOCYTE GROWTH FACT	6.12e-13
15	164	8.7	625	1	PROTHROMBIN PRECURSOR	9.51e-13
16	163	8.7	1420	1	APOLIPOPROTEIN(A) (EC	1.48e-12
17	161	8.6	810	1	PLMN_HUMAN PLASMINOGEN PRECURSOR	3.54e-12
18	158	8.4	603	1	COAGULATION FACTOR XII	1.31e-11
19	156	8.3	431	1	URT2_DESRO SALIVARY PLASMINOGEN A	3.11e-11
20	156	8.3	477	1	URT2_DESRO TISSUE PLASMINOGEN A	3.11e-11
21	155	8.2	566	1	URT2_BOVIN TISSUE PLASMINOGEN ACT	4.79e-11
22	152	8.1	333	1	PLMN_CANFA PLASMINOGEN (EC 3.4.21	1.73e-10
23	152	8.1	433	1	UROK_PAPCY UROKINASE-TYPE PLASMIN	1.73e-10

24	152	8.1	434	1	UROK_CHICK UROKINASE-TYPE PLASMIN	1.73e-10
25	151	8.0	432	1	UROK_PIG UROKINASE-TYPE PLASMIN	2.68e-10
26	150	8.0	442	1	UROK_HUMAN TISSUE PLASMINOGEN ACT	4.07e-10
27	150	8.0	562	1	URT2_HUMAN COAGULATION FACTOR XII	6.22e-10
28	149	7.9	593	1	FA12_BOVIN PLASMINOGEN (EC 3.4.21	1.45e-09
29	147	7.8	343	1	PLMN_SHEEP SALIVARY PLASMINOGEN A	1.45e-09
30	147	7.8	394	1	URT2_DESRO UROKINASE-TYPE PLASMIN	2.21e-09
31	146	7.8	431	1	UROK_HUMAN UROKINASE-TYPE PLASMIN	2.21e-09
32	147	7.8	433	1	UROK_MOUSE PROTHROMBIN PRECURSOR	1.45e-09
33	146	7.8	617	1	THRB_RAT PROTHROMBIN PRECURSOR	5.10e-09
34	144	7.6	618	1	UROK_BOVIN UROKINASE-TYPE PLASMIN	1.78e-08
35	141	7.5	433	1	UROK_MOUSE TISSUE PLASMINOGEN ACT	1.78e-08
36	141	7.5	559	1	UROK_HUMAN COAGULATION FACTOR XII	9.20e-08
37	137	7.3	615	1	FA12_HUMAN PLASMINOGEN (EC 3.4.21	2.08e-07
38	135	7.2	325	1	PLMN_PETMA SALIVARY PLASMINOGEN A	3.11e-07
39	134	7.1	477	1	URT1_DESRO TISSUE PLASMINOGEN ACT	1.04e-06
40	131	7.0	559	1	UROK_RAT PLASMINOGEN (EC 3.4.21	7.53e-06
41	126	6.7	338	1	PLMN_HORSE CDP-DIACYLGLYCEROL--SE	1.89e-02
42	105	5.6	451	1	PSS_ECOLI GENERAL SECRETION PATH	1.06e-01
43	100	5.3	678	1	GSPD_AERHA LOW-DENSITY LIPOPROTEI	1.06e-01
44	99	5.3	678	1	GSPD_AERHA LOW-DENSITY LIPOPROTEI	1.06e-01
45	100	5.3	854	1	LDLR_CRIGR LOW-DENSITY LIPOPROTEI	1.06e-01

ALIGNMENTS

RESULT	1	STANDARD;	PRT;	169 AA.
ID	PLMN_RAT			
AC	Q01177;			
DT	01-APR-1993 (REL. 25, CREATED)			
DT	01-APR-1993 (REL. 25, LAST SEQUENCE UPDATE)			
DT	01-NOV-1995 (REL. 32, LAST ANNOTATION UPDATE)			
DE	PLASMINOGEN (EC 3.4.21.7) (FRAGMENT).			
GN	PLG.			
OS	RATTUS NORVEGICUS (RAT).			
OC	EUKARYOTA; METAZOA; CHORDATA; VERTEBRATA; MAMMALIA; EUTHERIA;			
OC	KODENTIA; SCIUROGNATHI; MURIDAE; MURINAE; RATTUS.			
RN	[1]			
RP	SEQUENCE FROM N.A.			
RC	TISSUE=LIVER;			
RX	MEDLINE; 91250378.			
RA	KANALAS J.J.; MARKER S.P.;			
RT	"Identification of the rat Heymann nephritis autoantigen (GP330) as a receptor site for plasminogen."			
RL	J. BIOL. CHEM. 266:10825-10829(1991).			
CC	!- FUNCTION: PLASMIN DISSOLVES THE FIBRIN OF BLOOD CLOTS AND ACTS AS A PROTEOLYTIC FACTOR IN A VARIETY OF OTHER PROCESSES INCLUDING EMBRYONIC DEVELOPMENT, TISSUE REMODELING, TUMOR INVASION, AND INFLAMMATION; IN OVULATION IT WEAKENS THE WALLS OF THE GRAAFIAN FOLLICLE. IT ACTIVATES THE UROKINASE-TYPE PLASMINOGEN ACTIVATOR, COLLAGENASES AND SEVERAL COMPLEMENT ZYMOGENS, SUCH AS C1 AND C5. IT CLEAVES FIBRIN, FIBRONECTIN, THROMBOSPONDIN, LAMININ AND VON WILLEBRAND FACTOR.			
CC	!- ENZYME REGULATION: CONVERTED INTO PLASMIN BY PLASMINOGEN ACTIVATORS, BOTH PLASMINOGEN AND ITS ACTIVATOR BEING BOUND TO FIBRIN. CANNOT BE ACTIVATED WITH STREPTOKINASE.			
CC	!- PLASMIN IS INACTIVATED BY ALPHA-2-ANTIPLASMIN IMMEDIATELY AFTER DISSOCIATION FROM THE CLOT.			
CC	!- SIMILARITY: CONTAINS 5 KRINGLE REGIONS.			
CC	!- SIMILARITY: BELONGS TO PEPTIDASE FAMILY S1; ALSO KNOWN AS THE TRYPSIN FAMILY. BELONGS TO THE PLASMINOGEN SUBFAMILY.			
CC	!- This SWISS-PROT entry is copyright. It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL outstation - the European Bioinformatics Institute. There are no restrictions on its use by non-profit institutions as long as its content is in no way modified and this statement is not removed. Usage by and for commercial entities requires a license agreement (See http://www.isb-sib.ch/announce/ or send an email to license@isb-sib.ch).			
CC	EMBL; M62832; G554488; -			
DR	PIR; A40522; A40522.			
DR	PROSITE; PS00134; TRYPSIN_HIS; PARTIAL.			

Db 492 KTAFTA 497
QY 140 RSEAAA 145

RESULT 3
ID APOA.HUMAN STANDARD; PRT; 4548 AA.
AC P08519;
DT 01-AUG-1988 (REL. 08, CREATED)
DT 01-AUG-1988 (REL. 08, LAST SEQUENCE UPDATE)
DE 01-OCT-1996 (REL. 34, LAST ANNOTATION UPDATE)
DE APOLOPOPROTEIN(A) PRECURSOR (EC 3.4.21.-) (APO(A)) (LP(A)).
GN LPA.
OS HOMO SAPIENS (HUMAN).
OC EUKARYOTA; METAZOA; CHORDATA; VERTEBRATA; MAMMALIA; EUTHERIA;
OC PRIMATES; CATARRHINI; HOMINIDAE; HOMO.
RN [1]
RN SEQUENCE FROM N.A.
RX MEDLINE; 88039109.
RA MCLEAN J.W., TOMLISON J.E., KUANG W.-J., EATON D.L., CHEN E.Y.,
RA FLESS G.M., SCANU A.M., LAWN R.M.;
RT "cDNA sequence of human apolipoprotein(a) is homologous to
RT plasminogen.";
RL NATURE 330:132-137(1987).
RN [2]
RN SERINE PROTEASE ACTIVITY.
RX MEDLINE; 90076123.
RA SALONEN E.-M., JAUHAINEN M., ZARDI L., VAHERI A., EHNHOLM C.;
RT "lipoprotein(a) binds to fibronectin and has serine proteinase
RT activity capable of cleaving it.";
RL EMBO J. 8:4035-4040(1989).
RN [3]
RN REVIEW.
RX MEDLINE; 90049223.
RA UTERMANN G.;
RT "The mysteries of lipoprotein(a).";
RL SCIENCE 246:904-910(1989).
RN [4]
RN X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 4121-4208.
RX MEDLINE; 96217891.
RA MIKOL V., LOGRASSO P.V., BOETTCHER B.R.;
RT "Crystal structures of apolipoprotein(a) kringle IV37 free and
RT complexed with 6-aminohexanoic acid and with p-aminomethylbenzoic
RT acid: existence of novel and expected binding modes.";
RL J. MOL. BIOL. 256:751-761(1996).
RN [5]
RN VARIANT ARG-4193.
RX MEDLINE; 95002201.
RA SCANU A.M., PFAFFINGER D., LEE J.C., HINMAN J.;
RT "A single point mutation (Trp72-->Arg) in human apo(a) kringle 4-37
RT associated with a lysine binding defect in Lp(a).";
RL BIOCHIM. BIOPHYS. ACTA 1227:41-45(1994).
CC -1- FUNCTION: APO(A) IS THE MAIN CONSTITUENT OF LIPOPROTEIN(A). APO(A)
CC CAN BIND TO FIBRONECTIN AND HAS SERINE PROTEINASE ACTIVITY CAPABLE
CC OF CLEAVING IT.
CC -1- SUBUNIT: APO(A) IS DISULFIDE LINKED TO APO-B100.
CC -1- DISEASE: CONCENTRATION OF LP(A) IN PLASMA IS CORRELATED WITH
CC ATHEROSCLEROSIS.
CC -1- SIMILARITY: CONTAINS 38 KRINGLE REGIONS.
CC -1- SIMILARITY: BELONGS TO PEPTIDASE FAMILY S1; ALSO KNOWN AS THE
CC TRYPSIN FAMILY. BELONGS TO THE PLASMINOGEN SUBFAMILY.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (see <http://www.isb-sib.ch/announce/>
CC or send an email to license@isb-sib.ch).
CC -----
CC ENBL; X06290; G28620; -
DR PIR; S00657; S00657.
DR MIM; 152200; -

DR PROSITE: PS00021; KRINGLE1; 38.
DR PROSITE: PS00134; TRYPSIN_HIS; 1.
DR PROSITE: PS00135; TRYPSIN_SER; 1.
DR PROSITE: PS00070; KRINGLE_2; 38.
DR PFAM: PF00051; kringle; 38.
DR PFAM: PF00089; trypsin; 1.
DR HSP: P00747; LPMK.
KW HYDROLASE; SERINE PROTEASE; LIPID TRANSPORT; PLASMA; GLYCOPROTEIN;
KW KRINGLE; DUPLICATION; REPEAT; ATHEROSCLEROSIS; SIGNAL; POLYMORPHISM.
FT SIGNAL 1 19
FT CHAIN 20 4548 APOLIPOPROTEIN(A).
FT DOMAIN 20 130 KRINGLE TYPE IV, 1.
FT DOMAIN 131 244 KRINGLE TYPE IV, 2.
FT DOMAIN 245 358 KRINGLE TYPE IV, 3.
FT DOMAIN 359 472 KRINGLE TYPE IV, 4.
FT DOMAIN 473 586 KRINGLE TYPE IV, 5.
FT DOMAIN 587 700 KRINGLE TYPE IV, 6.
FT DOMAIN 701 814 KRINGLE TYPE IV, 7.
FT DOMAIN 815 928 KRINGLE TYPE IV, 8.
FT DOMAIN 929 1042 KRINGLE TYPE IV, 9.
FT DOMAIN 1043 1156 KRINGLE TYPE IV, 10.
FT DOMAIN 1157 1270 KRINGLE TYPE IV, 11.
FT DOMAIN 1271 1384 KRINGLE TYPE IV, 12.
FT DOMAIN 1385 1498 KRINGLE TYPE IV, 13.
FT DOMAIN 1499 1612 KRINGLE TYPE IV, 14.
FT DOMAIN 1613 1726 KRINGLE TYPE IV, 15.
FT DOMAIN 1727 1840 KRINGLE TYPE IV, 16.
FT DOMAIN 1841 1954 KRINGLE TYPE IV, 17.
FT DOMAIN 1955 2068 KRINGLE TYPE IV, 18.
FT DOMAIN 2069 2182 KRINGLE TYPE IV, 19.
FT DOMAIN 2183 2296 KRINGLE TYPE IV, 20.
FT DOMAIN 2297 2410 KRINGLE TYPE IV, 21.
FT DOMAIN 2411 2524 KRINGLE TYPE IV, 22.
FT DOMAIN 2525 2638 KRINGLE TYPE IV, 23.
FT DOMAIN 2639 2752 KRINGLE TYPE IV, 24.
FT DOMAIN 2753 2866 KRINGLE TYPE IV, 25.
FT DOMAIN 2867 2980 KRINGLE TYPE IV, 26.
FT DOMAIN 2981 3094 KRINGLE TYPE IV, 27.
FT DOMAIN 3095 3208 KRINGLE TYPE IV, 28.
FT DOMAIN 3209 3322 KRINGLE TYPE IV, 29.
FT DOMAIN 3323 3436 KRINGLE TYPE IV, 30.
FT DOMAIN 3437 3550 KRINGLE TYPE IV, 31.
FT DOMAIN 3551 3664 KRINGLE TYPE IV, 32.
FT DOMAIN 3665 3770 KRINGLE TYPE IV, 33.
FT DOMAIN 3771 3884 KRINGLE TYPE IV, 34.
FT DOMAIN 3885 3998 KRINGLE TYPE IV, 35.
FT DOMAIN 3999 4112 KRINGLE TYPE IV, 36.
FT DOMAIN 4113 4226 KRINGLE TYPE IV, 37.
FT DOMAIN 4227 4327 KRINGLE TYPE V.
FT ACT_SITE 4328 4548 CATALYTIC.
FT ACT_SITE 4369 4369 CHARGE RELAY SYSTEM.
FT ACT_SITE 4412 4412 CHARGE RELAY SYSTEM.
FT ACT_SITE 4498 4498 CHARGE RELAY SYSTEM.
FT VARIANT 4193 W -> R (LOSS OF LYSINE-SEPHAROSE
FT BINDING).
SQ SEQUENCE 4548 AA; 501313 MW; 51F6509C CRC32;
Query Match 9.7%; Score 183; DB 1; Length 4548;
Best Local Similarity 27.5%; Pred. No. 1.89e-16;
Matches 36; Conservative 34; Mismatches 52; Indels 9; Gaps 8;
Db 3539 ILAPSLAEFF-EQALTEETPGVQDCVYHYGVSRYSTVTGRTCOAWSSMTPHOHSRT 3597
QY 1 MLLWQVALVSNMLAEAYGGSCFDWNGHLYREDQTSFAPGLRCLNW--LDA-OSGLA 57
Db 3598 PENYPNAGTRNYCRNPDAEIR-PWCYTM-DPSVR-WEYCNLTQCLVTSSVLATIV-V 3653
QY 58 SAPVSGAG-NHSCYCRNPDEDPRGPCVYSGEAGVPEKPCEDLRCPETTSQALPATTEI 116
Db 3654 PDPSTEASSEE 3664
QY 117 QEASEGPGADE 127

```

RESULT      4
ID HGFA_HUMAN STANDARD; PRT; 655 AA.
AC Q04756; Q14726;
DT 01-JUN-1994 (REL. 29, CREATED)
DT 01-JUN-1994 (REL. 29, LAST SEQUENCE UPDATE)
DT 01-NOV-1997 (REL. 35, LAST ANNOTATION UPDATE)
DE HEPATOCYTE GROWTH FACTOR ACTIVATOR PRECURSOR (EC 3.4.21.-) (HGF
DE ACTIVATOR).
OS HOMO SAPIENS (HUMAN).
OC EUKARYOTA; METAZOA; CHORDATA; VERTEBRATA; MAMMALIA; EUTHERIA;
OC PRIMATES; CATARRHINI; HOMINIDAE; HOMO.
RN [1]
RP SEQUENCE FROM N.A., AND PARTIAL SEQUENCE.
RC TISSUE=LIVER, AND SERUM;
RA MEDLINE: 93252878.
RA MIYAZAWA K., SHIMOMURA T., KITAMURA A., KONDO J., MORIMOTO Y.,
RA KITAMURA N.;
RT "Molecular cloning and sequence analysis of the cDNA for a human
RT serine protease responsible for activation of hepatocyte growth
RT factor. Structural similarity of the protease precursor to blood
RT coagulation factor XII.";
RL J. BIOL. CHEM. 268:10024-10028(1993).
RN [2]
RP SEQUENCE OF 40-655 FROM N.A.
RA ZHAO S., ODELL C.;
RL SUBMITTED (FEB-1996) TO EMBL/GENBANK/DBJ DATA BANKS.
CC -!- FUNCTION: ACTIVATES HEPATOCYTE GROWTH FACTOR (HGF) BY
CC CONVERTING IT FROM A SINGLE CHAIN TO A HETERODIMERIC FORM.
CC -!- SUBUNIT: DIMER OF A SHORT CHAIN AND A LONG CHAIN LINKED BY A
CC DISULFIDE BOND.
CC -!- SUBCELLULAR LOCATION: SECRETED AS AN INACTIVE SINGLE-CHAIN
CC PRECURSOR AND IS THEN ACTIVATED TO A HETERODIMERIC FORM.
CC -!- TISSUE SPECIFICITY: LIVER.
CC -!- SIMILARITY: CONTAINS 2 EGF-LIKE DOMAINS.
CC -!- SIMILARITY: CONTAINS 1 FIBRONECTIN TYPE-I DOMAIN.
CC -!- SIMILARITY: CONTAINS 1 FIBRONECTIN TYPE-II DOMAIN.
CC -!- SIMILARITY: CONTAINS 1 KRINGLE REGION.
CC -!- SIMILARITY: BELONGS TO PEPTIDASE FAMILY S1; ALSO KNOWN AS THE
CC TRYPSIN FAMILY.
CC -!- CAUTION: IT IS UNCERTAIN WHETHER MET-1 IS THE INITIATOR.
CC
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC
CC -----
CC EMBL; D14012; G219681; -
CC EMBL; Z69923; E225802; -
CC PIR; A46688; A46688.
CC DR PROSITE; PS00021; KRINGLE_1; 1.
CC DR PROSITE; PS00022; EGF_1; 2.
CC DR PROSITE; PS00023; FIBRONECTIN_2; 1.
CC DR PROSITE; PS00134; TRYPSIN_HIS; 1.
CC DR PROSITE; PS00135; TRYPSIN_SER; 1.
CC DR PROSITE; PS01186; EGF_2; 1.
CC DR PROSITE; PS01253; FIBRONECTIN_1; 1.
CC DR PROSITE; PS50070; KRINGLE_2; 1.
CC DR PFAM; PF00008; EGF; 2.
CC DR PFAM; PF00039; fn1; 1.
CC DR PFAM; PF00040; fn2; 1.
CC DR PFAM; PF00051; kringle; 1.
CC DR PFAM; PF00089; trypsin; 1.
CC DR HSSP; P00763; IDPO.
CC KW HYDROLASE; GLYCOPROTEIN; PLASMA; SERINE PROTEASE; KRINGLE; SIGNAL;
CC KW EGF-LIKE DOMAIN; REPEAT; ZIMOGEN.
CC FT SIGNAL 1 30
CC FT PROPEP 31 372 CLEAVED IN ACTIVE FORM.
CC FT CHAIN 373 407 HEPATOCYTE GROWTH FACTOR ACTIVATOR SHORT
CC FT CHAIN.

```

```

FT CHAIN 408 655 HEPATOCYTE GROWTH FACTOR ACTIVATOR LONG
FT DOMAIN 108 148 CHAIN.
FT DOMAIN 160 198 FIBRONECTIN TYPE-II.
FT DOMAIN 200 240 EGF-LIKE 1.
FT DOMAIN 241 279 FIBRONECTIN TYPE-I.
FT DOMAIN 286 367 EGF-LIKE 2.
FT DOMAIN 408 655 KRINGLE.
FT ACT_SITE 447 447 CATALYTIC.
FT ACT_SITE 497 497 CHARGE RELAY SYSTEM (BY SIMILARITY).
FT ACT_SITE 598 598 CHARGE RELAY SYSTEM (BY SIMILARITY).
FT DISULFID 108 133 BY SIMILARITY.
FT DISULFID 122 148 BY SIMILARITY.
FT DISULFID 164 175 BY SIMILARITY.
FT DISULFID 169 186 BY SIMILARITY.
FT DISULFID 188 197 BY SIMILARITY.
FT DISULFID 202 230 BY SIMILARITY.
FT DISULFID 228 237 BY SIMILARITY.
FT DISULFID 245 256 BY SIMILARITY.
FT DISULFID 250 267 BY SIMILARITY.
FT DISULFID 269 278 BY SIMILARITY.
FT DISULFID 286 367 BY SIMILARITY.
FT DISULFID 307 349 BY SIMILARITY.
FT DISULFID 338 362 BY SIMILARITY.
FT DISULFID 394 521 INTRACHAIN (BY SIMILARITY).
FT DISULFID 432 448 BY SIMILARITY.
FT DISULFID 440 510 BY SIMILARITY.
FT DISULFID 535 604 BY SIMILARITY.
FT DISULFID 567 583 BY SIMILARITY.
FT DISULFID 594 622 BY SIMILARITY.
FT CARBOHYD 48 48 POTENTIAL.
FT CARBOHYD 290 290 POTENTIAL.
FT CARBOHYD 468 468 POTENTIAL.
FT CARBOHYD 492 492 POTENTIAL.
FT CARBOHYD 546 546 POTENTIAL.
FT CONFLICT 644 644 R -> Q (IN REF. 2).
SQ SEQUENCE 655 AA; 70681 MW; BFE0842D CRC32;

Query Match 9.68; Score 181; DB 1; Length 655;
Best Local Similarity 40.5%; Pred. No. 4.70e-16;
Matches 30; Conservative 19; Mismatches 17; Indels 8; Gaps 4;

Db 286 CFLNGTGTGVSTASGLSLCLAWNSDLLYQELHVDVSGAAALLGLPHAYCRNPNDDE 345
QY 25 CFWDNHGHLREDQTSFAPGLRCLNW----L--DAQ-SGLASAPVSGAGNHSYCRNPDEP 77
Db 346 R-PWCYVVKDSALS 358
QY 78 RGPWCYVSGEAGVP 91

RESULT      5
ID HGFL_MOUSE STANDARD; PRT; 716 AA.
AC P26928;
DT 01-AUG-1992 (REL. 23, CREATED)
DT 01-AUG-1992 (REL. 23, LAST SEQUENCE UPDATE)
DT 15-JUL-1998 (REL. 36, LAST ANNOTATION UPDATE)
DE HEPATOCYTE GROWTH FACTOR-LIKE PROTEIN PRECURSOR (MACROPHAGE
DE STIMULATORY PROTEIN) (MSP).
GN HGFL.
OS MUS MUSCULUS (MOUSE).
OC EUKARYOTA; METAZOA; CHORDATA; VERTEBRATA; MAMMALIA; EUTHERIA;
OC RODENTIA; SCIUROGNATHI; MURIDAE; MURINAE; MUS.
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN-BALB/C; TISSUE=LIVER;
RX MEDLINE: 92002017.
RA PRIEZNER DEGEN S.J., STUART L.A., HAN S., JAMISON C.S.;
RT "Characterization of the mouse cDNA and gene coding for a hepatocyte
RT growth factor-like protein: expression during development.";
RL BIOCHEMISTRY 30:9781-9791(1991).
CC -!- FUNCTION: PROBABLY HAS NO PROTEOLYTIC ACTIVITY, SINCE CRUCIAL AA
CC CHARACTERISTIC OF SERINE PROTEASES CATALYTIC SITES ARE NOT

```

Db 170 YTT 172
I :
QY 83 YVS 85

RESULT 6 STANDARD; PRT; 810 AA.
ID PLMN_ERIEU
AC Q29485;
AD 01-NOV-1997 (REL. 35, CREATED)
DT 01-NOV-1997 (REL. 35, LAST SEQUENCE UPDATE)
DT 01-NOV-1997 (REL. 35, LAST ANNOTATION UPDATE)
DE PLASMINOGEN PRECURSOR (EC 3.4.21.7).
DN PLG.
GN ERINACEUS EUROPAEUS (WESTERN EUROPEAN HEDGEHOG).
OS EUKARYOTA; METAZOA; CHORDATA; VERTEBRATA; MAMMALIA; EUTHERIA;
OC INSECTIVORA; ERINACEIDAE; ERINACEINAE; ERINACEUS.
ON [1]
OR SEQUENCE FROM N.A.
RP TISSUE=LIVER;
RC MEDLINE; 96025778.
RX LAWN R.M., BOONMARK N.W., SCHWARTZ K., LINDAHL G.E., WADE D.P.,
RA BRYNE C.D., FONG K.J., MEER K., PATTY L.;
RT "The recurring evolution of lipoprotein(a). Insights from cloning of
RT hedgehog apolipoprotein(a).";
RT J. BIOL. CHEM. 270:24004-24009(1995).
RL [2]
RN REVISIONS.
RP
RA LAWN R.M.;
RL
CC -1- FUNCTION: PLASMIN DISSOLVES THE FIBRIN OF BLOOD CLOTS AND ACTS AS
CC A PROTEOLYTIC FACTOR IN A VARIETY OF OTHER PROCESSES INCLUDING
CC EMBRYONIC DEVELOPMENT, TISSUE REMODELING, TUMOR INVASION,
CC AND INFLAMMATION; IN OVULATION IT WEAKENS THE WALLS OF THE
CC GRAAFIAN FOLLICLE. IT ACTIVATES THE UROKINASE-TYPE PLASMINOGEN
CC ACTIVATOR, COLLAGENASES AND SEVERAL COMPLEMENT ZYMOGENS, SUCH
CC AS C1 AND C5. IT CLEAVES FIBRIN, FIBRONECTIN, THROMBOSPONDIN,
CC LAMININ AND VON WILLEBRAND FACTOR.
CC -1- ENZYME REGULATION: CONVERTED INTO PLASMIN BY PLASMINOGEN
CC ACTIVATORS, BOTH PLASMINOGEN AND ITS ACTIVATOR BEING BOUND TO
CC FIBRIN. CANNOT BE ACTIVATED WITH STREPTOKINASE.
CC -1- PLASMIN IS INACTIVATED BY ALPHA-2-ANTIPLASMIN IMMEDIATELY AFTER
CC DISSOCIATION FROM THE CLOT.
CC -1- SIMILARITY: CONTAINS 5 KRINGLE REGIONS.
CC -1- SIMILARITY: BELONGS TO PEPTIDASE FAMILY S1; ALSO KNOWN AS THE
CC TRYPSIN FAMILY. BELONGS TO THE PLASMINOGEN SUBFAMILY.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See <http://www.isb-sib.ch/announcement/>
CC or send an email to license@isb-sib.ch).
CC -----
CC EMBL; U33171; GI806583; -
DR PROSITE; PS00021; KRINGLE_1; 5.
DR PROSITE; PS00134; TRYPSIN_HIS; 1.
DR PROSITE; PS00135; TRYPSIN_SER; 1.
DR PROSITE; PS00070; KRINGLE_2; 5.
DR PFAM; PF00051; kringle; 5.
DR PFAM; PF00089; trypsin; 1.
DR HSP; PO0747; 1PMK.
KW HYDROLASE; SERINE PROTEASE; PLASMA; GLYCOPROTEIN; FIBRINOLYSIS;
KW TISSUE REMODELING; BLOOD COAGULATION; KRINGLE; ZYMOGEN; SIGNAL.
FT SIGNAL 1 19
FT CHAIN 20 810
FT CHAIN 20 582
FT CHAIN 583 810
FT CHAIN 583 810
FT DOMAIN 103 181
FT DOMAIN 185 262
FT DOMAIN 275 352
FT DOMAIN 379 456
FT DOMAIN 4.

FT	SIGNAL	1	19	BI PLASMINOGEN.
FT	CHAIN	20	810	HEAVY CHAIN A (BY SIMILARITY).
FT	CHAIN	20	582	LIGHT CHAIN B (BY SIMILARITY).
FT	CHAIN	583	810	CATALYTIC.
FT	DOMAIN	583	810	KRINGLE 1.
FT	DOMAIN	103	181	KRINGLE 2.
FT	DOMAIN	185	262	KRINGLE 3.
FT	DOMAIN	275	352	KRINGLE 4.
FT	DOMAIN	379	456	


```
FT DOMAIN 482 561 KRINGLE 5.
FT ACT_SITE 622 622 CHARGE RELAY SYSTEM.
FT ACT_SITE 665 665 CHARGE RELAY SYSTEM.
FT ACT_SITE 760 760 CHARGE RELAY SYSTEM.
FT CARBOHYD 339 339 POTENTIAL.
SQ SEQUENCE 810 AA; 90902 MW; ABFDC531 CRC32;

Query Match 9.3%; Score 176; DB 1; Length 810;
Best Local Similarity 32.9%; Pred. No. 4.53e-15;
Matches 26; Conservative 20; Mismatches 27; Indels 6; Gaps 6;

Db 107 NGKRYRGTSTKTKGTCQKWSAETPHKPRFSDENSEGLDQNYCNPNDPKGPCYIT 166
QY 29 NGHLREDQTSFAPGRLCLNW-JDA-QSG-LASAPVSGAG-NHSCYRNPDPDPRGWCYV 84

Db 167 M-DPEVRYEY-CEIIQEC 183
QY 85 SGEAGVPEKRPCEDLRCE 103

RESULT 7
ID PLMN MACMU STANDARD; PRT; 810 AA.
AC P12545:
DT 01-OCT-1989 (REL. 12, CREATED)
DT 01-OCT-1989 (REL. 12, LAST SEQUENCE UPDATE)
DT 01-NOV-1995 (REL. 32, LAST ANNOTATION UPDATE)
DE PLASMINOGEN PRECURSOR (EC 3.4.21.7).
GN PLG.
OS MACACA MULATTA (RHESUS MACAQUE).
OC EUKARYOTA; METAZOA; CHORDATA; VERTEBRATA; MAMMALIA; EUTHERIA;
OC PRIMATES; CATARRHINI; CERCOPITHECIDAE; CERCOPITHECINAE; MACACA.
RN [1]
RP MEDLINE: 89174660.
RA TOMLINSON J.E., MCLEAN J.W., LAMN R.M.;
RT "Rhesus monkey apolipoprotein(a). Sequence, evolution, and sites of
synthesis.";
RL J. BIOL. CHEM. 264:5957-5965(1989).
CC A PROTEOLYTIC FACTOR IN A VARIETY OF OTHER PROCESSES INCLUDING
EMBRYONIC DEVELOPMENT, TISSUE REMODELING, TUMOR INVASION,
AND INFLAMMATION; IN OVULATION IT WEAKENS THE WALLS OF THE
GRAAFIAN FOLLICLE. IT ACTIVATES THE UROKINASE-TYPE PLASMINOGEN
ACTIVATOR, COLLAGENASES AND SEVERAL COMPLEMENT ZYMOGENS, SUCH
AS C1 AND C5. IT CLEAVES FIBRIN, FIBRONECTIN, THROMBOSPONDIN,
LAMININ AND VON WILLEBRAND FACTOR.
CC ENZYME REGULATION: CONVERTED INTO PLASMIN BY PLASMINOGEN
ACTIVATORS, BOTH PLASMINOGEN AND ITS ACTIVATOR BEING BOUND TO
FIBRIN. ACTIVATED WITH CATALYTIC AMOUNTS OF STREPTOKINASE.
CC PLASMIN IS INACTIVATED BY ALPHA-2-ANTIPLASMIN IMMEDIATELY AFTER
DISSOCIATION FROM THE CLOT.
CC IN THE PRESENCE OF THE INHIBITOR, THE ACTIVATION INVOLVES ONLY
CLEAVAGE AFTER ARG-580, RESULTING IN 2 CHAINS HELD TOGETHER BY 2
DISULFIDE BONDS. WITHOUT THE INHIBITOR, THE ACTIVATION INVOLVES
ALSO REMOVAL OF THE ACTIVATION PEPTIDE.
CC SIMILARITY: CONTAINS 5 KRINGLE REGIONS.
CC SIMILARITY: BELONGS TO PEPTIDASE FAMILY S1; ALSO KNOWN AS THE
TRYPSIN FAMILY. BELONGS TO THE PLASMINOGEN SUBFAMILY.
-----
This SWISS-PROT entry is copyright. It is produced through a collaboration
between the Swiss Institute of Bioinformatics and the EMBL outstation -
the European Bioinformatics Institute. There are no restrictions on its
use by non-profit institutions as long as its content is in no way
modified and this statement is not removed. Usage by and for commercial
entities requires a license agreement (see http://www.isb-sib.ch/announcement/
or send an email to license@isb-sib.ch).
-----
CC EMBL: J04697; G342273; -.
CC PIR: B30848; B30848.
CC PIR: B32869; B32869.
CC PROSITE: PS00021; KRINGLE_1; 5.
CC PROSITE: PS00134; TRYPSIN_HIS; 1.
CC PROSITE: PS00135; TRYPSIN_SER; 1.
```

```
DR PROSITE: PS50070; KRINGLE_2; 5.
DR PFAM: PF00031; kringle; 5.
DR PFAM: PF00089; trypsin; 1.
DR HSP: P00747; IPMK.
KW HYDROLASE; SERINE PROTEASE; PLASMA; GLYCOPROTEIN; FIBRINOLYSIS;
KW TISSUE REMODELING; BLOOD COAGULATION; KRINGLE; ZYMOGEN; SIGNAL.
FT SIGNAL 1 19
FT CHAIN 20 810 PLASMINOGEN.
FT CHAIN 20 580 HEAVY CHAIN A.
FT PEPTIDE 20 96 ACTIVATION PEPTIDE.
FT CHAIN 97 580 SHORT FORM OF CHAIN A.
FT CHAIN 581 810 LIGHT CHAIN B.
FT DOMAIN 103 181 KRINGLE 1.
FT DOMAIN 184 262 KRINGLE 2.
FT DOMAIN 275 352 KRINGLE 3.
FT DOMAIN 377 454 KRINGLE 4.
FT DOMAIN 481 560 KRINGLE 5.
FT DOMAIN 581 810 CATALYTIC.
FT ACT_SITE 622 622 CHARGE RELAY SYSTEM.
FT ACT_SITE 665 665 CHARGE RELAY SYSTEM.
FT BINDING 136 136 OMEGA-AMINOCARBOXYLIC ACIDS.
FT BINDING 158 158 OMEGA-AMINOCARBOXYLIC ACIDS.
FT BINDING 172 172 OMEGA-AMINOCARBOXYLIC ACIDS.
FT BINDING 432 432 OMEGA-AMINOCARBOXYLIC ACIDS.
FT BINDING 445 445 OMEGA-AMINOCARBOXYLIC ACIDS.
FT BINDING 134 134 FIBRIN.
FT BINDING 136 136 FIBRIN.
FT DISULFID 49 73 BY SIMILARITY.
FT DISULFID 53 61 BY SIMILARITY.
FT DISULFID 103 181 BY SIMILARITY.
FT DISULFID 124 164 BY SIMILARITY.
FT DISULFID 152 176 BY SIMILARITY.
FT DISULFID 185 262 BY SIMILARITY.
FT DISULFID 188 316 BY SIMILARITY.
FT DISULFID 206 245 BY SIMILARITY.
FT DISULFID 234 257 BY SIMILARITY.
FT DISULFID 275 352 BY SIMILARITY.
FT DISULFID 296 335 BY SIMILARITY.
FT DISULFID 324 347 BY SIMILARITY.
FT DISULFID 377 454 BY SIMILARITY.
FT DISULFID 398 437 BY SIMILARITY.
FT DISULFID 426 449 BY SIMILARITY.
FT DISULFID 481 560 BY SIMILARITY.
FT DISULFID 502 543 BY SIMILARITY.
FT DISULFID 531 555 BY SIMILARITY.
FT DISULFID 567 685 BY SIMILARITY.
FT DISULFID 577 585 BY SIMILARITY.
FT DISULFID 607 623 BY SIMILARITY.
FT DISULFID 699 766 BY SIMILARITY.
FT DISULFID 729 745 BY SIMILARITY.
FT DISULFID 756 784 BY SIMILARITY.
FT CARBOHYD 365 365 BY SIMILARITY.
SQ SEQUENCE 810 AA; 90255 MW; B5AA0F07 CRC32;

Query Match 9.2%; Score 173; DB 1; Length 810;
Best Local Similarity 24.8%; Pred. No. 1.75e-14;
Matches 31; Conservative 41; Mismatches 43; Indels 10; Gaps 9;

Db 377 CYHGDGSGYRGTSTTTTGGKQCQSWSSMTPHWHEKTPENFFNAGLTMMYCRNPAD-KGP 435
QY 25 CFWDNGHLYREDQTSFAPGLRCLNW-LDAQ-SGLASAPVSGAG-NHSCYRNPDPDPRG 80
Db 436 WCFTT-DPSVR-WYCNLKKCSGTGEGVAAAPPVLAQLPDA-ETPSEDC-MFGNGKGVRG 491
QY 81 WCYVSGEAGVPEKRPCEDLRCPET-TSQALPAFTTIOEASEGPGAEVQVFAPANALPA 139
Db 492 KKATT 496
QY 140 RSEAA 144

RESULT 8
```

```

ID      PLMN_PIG      STANDARD;      PRT;      790 AA.
AC      P06867;
AD      01-JAN-1988 (REL. 06, CREATED)
AE      01-FEB-1991 (REL. 17, LAST SEQUENCE UPDATE)
AF      01-OCT-1996 (REL. 34, LAST ANNOTATION UPDATE)
AG      PLASMINOGEN (EC 3.4.21.7).
AH      SUS SCROFA (PIG).
AI      EUKARYOTA; METAZOA; CHORDATA; VERTEBRATA; MAMMALIA; EUTHERIA;
AJ      ARTHRODACTYLA; SUIFORMES; SUINA; SUIDAE; SUS.
AK      (1)
AL      SEQUENCE OF 1-560.
AM      SCHALLER J., MARTI T., ROESSELET S.J., KAEMPFER U., RICKLI E.E.;
AN      "Amino acid sequence of the heavy chain of porcine plasmin. Comparison
AO      of the carbohydrate attachment sites with the human and bovine
AP      species.";
AQ      FIBRINOLYSIS 1:91-102(1987).
AR      (2)
AS      SEQUENCE OF 450-790.
AT      MEDLINE: 85203907.
AU      MARTI T., SCHALLER J., RICKLI E.E.;
AV      "Determination of the complete amino-acid sequence of porcine
AW      miniplasminogen.";
AX      EUR. J. BIOCHEM. 149:279-285(1985).
AY      C-!- FUNCTION: PLASMIN DISSOLVES THE FIBRIN OF BLOOD CLOTS AND ACTS AS
AZ      A PROTEOLYTIC FACTOR IN A VARIETY OF OTHER PROCESSES INCLUDING
BA      EMBRYONIC DEVELOPMENT, TISSUE REMODELING, TUMOR INVASION,
BB      AND INFLAMMATION; IN OVULATION IT WEAKENS THE WALLS OF THE
BC      GRAAFIAN FOLLICLE. IT ACTIVATES THE UROKINASE-TYPE PLASMINOGEN
BD      ACTIVATOR. COLLAGENASES AND SEVERAL COMPLEMENT ZYMOGENS, SUCH
BE      AS C1 AND C5. IT CLEAVES FIBRIN, FIBRONECTIN, THROMBOSPONDIN,
BF      LAMININ AND VON WILLEBRAND FACTOR.
BG      C-!- ENZYME REGULATION: CONVERTED INTO PLASMIN BY PLASMINOGEN
BH      ACTIVATORS, BOTH PLASMINOGEN AND ITS ACTIVATOR BEING BOUND TO
BI      FIBRIN. CANNOT BE ACTIVATED WITH STREPTOKINASE.
BJ      C-!- PLASMIN IS INACTIVATED BY ALPHA-2-ANTIPLASMIN IMMEDIATELY AFTER
BK      DISSOCIATION FROM THE CLOT.
BL      C-!- SIMILARITY: CONTAINS 5 KRINGLE REGIONS.
BM      C-!- SIMILARITY: BELONGS TO PEPTIDASE FAMILY S1; ALSO KNOWN AS THE
BN      TRYPSIN FAMILY. BELONGS TO THE PLASMINOGEN SUBFAMILY.
BO      PIR: A25834; A25834.
BP      PIR: S03733; S03733.
BQ      PROSITE: PS00134; TRYPSIN_HIS; FALSE_NEG.
BR      PROSITE: PS00021; KRINGLE_1; 5.
BS      PROSITE: PS00135; TRYPSIN_SER; 1.
BT      PROSITE: PS50070; KRINGLE_2; 5.
BU      PFAM: PF00051; kringle; 5.
BV      PFAM: PF00089; trypsin; 1.
BW      HSP: P00747; SHBG.
BX      KW HYDROLASE; SERINE PROTEASE; PLASMA; GLYCOPROTEIN; FIBRINOLYSIS;
BY      TISSUE REMODELING; BLOOD COAGULATION; KRINGLE; ZYMOGEN.
BZ      FT CHAIN 1 560
BA      FT CHAIN 1 560
BB      FT CHAIN 561 790
BC      FT DOMAIN 561 790
BD      FT DOMAIN 84 162
BE      FT DOMAIN 156 243
BF      FT DOMAIN 256 333
BG      FT DOMAIN 358 435
BH      FT DOMAIN 461 540
BI      FT ACT_SITE 602 602
BJ      FT ACT_SITE 645 645
BK      FT ACT_SITE 740 740
BL      FT CARBOHYD 249 249
BM      SQ SEQUENCE 790 AA; 88592 MW; EE597814 CRC32;

Query Match      9.1%; Score 171; DB 1; Length 790;
Best Local Similarity 26.4%; Pred. No. 4.27e-14;
Matches      34; Conservative      36; Mismatches 49; Indels 10; Gaps
db      358 CYRGNGESYRGSSFTITGRKCSQWVSTPRHREKTPGCFNAGLTWNYCRNPAD-KSP 416
      |...|||...|||...|||...|||...|||...|||...|||...|||...|||...|||
      25 CFWDNGHLTYREDQTPAGPLRCNLNW--LDAQS-GLASAPVSGAG-NHSYCRNPDPRGP 80
db      417 WCYTT-DPRVR-WEYCNLKKKSET-EQOVTNFPALQAVPSVEDLSEDC-MFGNGKRYRG 472

```

[illegible]

RA ARAKAI N., NAKAYAMA H., HIRONO S., SAKIYAMA O., TAKAHASHI K.,
 RA GOHDA E., DAIKUHARA Y., KITAMURA N.;
 RT "Molecular cloning and sequence analysis of cDNA for human hepatocyte
 RT growth factor.";
 RL BIOCHEM. BIOPHYS. RES. COMMUN. 163:967-973(1989).
 RN [3]
 RP SEQUENCE FROM N.A.
 RC TISSUE=LEUKOCYTE;
 RX MEDLINE; 91025062;
 RA SEKI T., IHARA I., SUGIMURA A., SHIMONISHI M., NISHIZAWA T.,
 RA ASAMI O., HAGIYA M., NAKAMURA T., SHIMIZU S.;
 RT "Isolation and expression of cDNA for different forms of hepatocyte
 RT growth factor from human leukocyte.";
 RL BIOCHEM. BIOPHYS. RES. COMMUN. 172:321-327(1990).
 RN [4]
 RP SEQUENCE FROM N.A., AND SEQUENCE OF 55-73 AND 495-520.
 RC TISSUE=LIVER;
 RX MEDLINE; 90066676;
 RA NAKAMURA T., NISHIZAWA T., HAGIYA M., SEKI T., SHIMONISHI M.,
 RA SUGIMURA A., TASHIRO K., SHIMIZU S.;
 RT "Molecular cloning and expression of human hepatocyte growth factor.";
 RL NATURE 342:440-443(1989).
 RN [5]
 RP SEQUENCE FROM N.A.
 RC TISSUE=EMBRYONIC FIBROBLAST;
 RX MEDLINE; 91334393;
 RA WEIDNER K.M., ARAKAI N., HARTMANN G., VANDEKERCKHOVE J., WEINGART S.,
 RA RIEDER H., FONATSCHE C., TSUBOUCHI H., HISHIDA T., DAIKUHARA Y.,
 RA BIRCHMEIER W.;
 RT "Evidence for the identity of human scatter factor and human
 RT hepatocyte growth factor.";
 RL PROC. NATL. ACAD. SCI. U.S.A. 88:7001-7005(1991).
 RN [6]
 RP SIGNAL SEQUENCE CLEAVAGE SITE.
 RX MEDLINE; 91207365;
 RA YOSHIIYAMA Y., ARAKAI N., NAKA D., TAKAHASHI K., HIRONO S., KONDO J.,
 RA NAKAYAMA H., GOHDA E., KITAMURA N., TSUBOUCHI H., ISHII T.,
 RA HISHIDA T., DAIKUHARA Y.;
 RT "Identification of the N-terminal residue of the heavy chain of both
 RT native and recombinant human hepatocyte growth factor.";
 RL BIOCHEM. BIOPHYS. RES. COMMUN. 175:660-667(1991).
 RN [7]
 RP CARBOHYDRATE-BINDING SITE 476.
 RX MEDLINE; 93129192;
 RA SHIMIZU N., HARA H., SOGABE T., SAKAI H., IHARA I., INOUE H.,
 RA NAKAMURA T., SHIMIZU S.;
 RT "Hepatocyte growth factor is linked by O-glycosylated oligosaccharide
 RT on the alpha chain.";
 RL BIOCHEM. BIOPHYS. RES. COMMUN. 189:1329-1335(1992).
 RN [8]
 RP MUTAGENESIS.
 RX MEDLINE; 92331602;
 RA LOKKER N.A., MARK M.R., LUIS E.A., BENNETT G.L., ROBBINS K.A.,
 RA BAKER J.B., GODOWSKI P.J.;
 RT "Structure-function analysis of hepatocyte growth factor:
 RT Identification of variants that lack mitogenic activity yet retain
 RT high affinity receptor binding.";
 RL EMBO J. 11:2503-2510(1992).
 RN [9]
 RP STRUCTURE BY NMR OF 31-127.
 RX MEDLINE; 98154323;
 RA ZHOU H., MAZZULLA M.J., KAUFMAN J.D., STAHL S.J., WINGFIELD P.T.,
 RA RUBIN J.S., BOTTARO D.P., BYRD R.A.;
 RT "The solution structure of the N-terminal domain of hepatocyte growth
 RT factor reveals a potential heparin-binding site.";
 RL STRUCTURE 6:109-116(1998).
 RN [10]
 RP X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 35-210.
 RX MEDLINE; 99036858;
 RA ULTSCH M., LOKKER N.A., GODOWSKI P.J., DE VOS A.M.;
 RT "Crystal structure of the N1 fragment of human hepatocyte growth
 RT factor at 2.0-A resolution.";
 RL STRUCTURE 6:1383-1393(1998).

CC -!- FUNCTION: HGF IS A POTENT MITOGEN FOR MATURE PARENCHYMAL
 CC HEPATOCYTE CELLS. SEEMS TO BE AN HEPATOTROPIC FACTOR, AND ACTS
 CC AS GROWTH FACTOR FOR A BROAD SPECTRUM OF TISSUES AND CELL TYPES.
 CC IT HAS NO DETECTABLE PROTEASE ACTIVITY.
 CC -!- SUBUNIT: DIMER OF AN ALPHA CHAIN AND A BETA CHAIN LINKED BY A
 CC DISULFIDE BOND.
 CC -!- SIMILARITY: CONTAINS 4 KRINGLE REGIONS.
 CC -!- SIMILARITY: BELONGS TO PEPTIDASE FAMILY S1; ALSO KNOWN AS THE
 CC TRYPSIN FAMILY. BELONGS TO THE PLASMINOGEN SUBFAMILY.
 CC -----
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non-profit institutions as long as its content is in no way
 CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (See [http://www.isb-sib.ch/](http://www.isb-sib.ch/announce/)
 CC or send an email to license@isb-sib.ch).
 CC -----
 DR EMBL; D90334; G219700;
 DR EMBL; D90318; G219700; JOINED.
 DR EMBL; D90319; G219700; JOINED.
 DR EMBL; D90320; G219700; JOINED.
 DR EMBL; D90322; G219700; JOINED.
 DR EMBL; D90323; G219700; JOINED.
 DR EMBL; D90324; G219700; JOINED.
 DR EMBL; D90325; G219700; JOINED.
 DR EMBL; D90326; G219700; JOINED.
 DR EMBL; D90327; G219700; JOINED.
 DR EMBL; D90328; G219700; JOINED.
 DR EMBL; D90329; G219700; JOINED.
 DR EMBL; D90330; G219700; JOINED.
 DR EMBL; D90331; G219700; JOINED.
 DR EMBL; D90332; G219700; JOINED.
 DR EMBL; D90333; G219700; JOINED.
 DR EMBL; M29145; G306846;
 DR EMBL; M60718; G184032;
 DR EMBL; X16323; G32082;
 DR EMBL; M73239; G337936;
 DR EMBL; M73240; G337938;
 DR PIR; JH0579; JH0579.
 DR PIR; S06794; S06794.
 DR PDB; 2HGF; 24-JUN-98.
 DR PDB; 1BHT; 18-NOV-98.
 DR MIM; 142409;
 DR PROSITE; PS00021; KRINGLE_1; 4.
 DR PROSITE; PS00070; KRINGLE_2; 4.
 DR PFAM; PF00051; kringle; 4.
 DR PFAM; PF00089; trypsin; 1.
 KW GROWTH FACTOR; KRINGLE; GLYCOPROTEIN; SERINE PROTEASE HOMOLOG;
 KW SIGNAL; 3D-STRUCTURE.
 FT SIGNAL 1 31
 FT CHAIN 32 494
 FT CHAIN 495 728
 FT MOD_RES 32 32
 FT DOMAIN 32 127
 FT DOMAIN 128 206
 FT DOMAIN 211 288
 FT DOMAIN 305 383
 FT DOMAIN 391 469
 FT DOMAIN 495 728
 FT DISULFID 70 96
 FT DISULFID 74 84
 FT DISULFID 128 206
 FT DISULFID 149 189
 FT DISULFID 177 201
 FT DISULFID 487 604
 FT CARBOHYD 294 294
 FT CARBOHYD 402 402
 FT CARBOHYD 476 476
 FT CARBOHYD 566 566
 FT CARBOHYD 653 653
 FT CONFLICT 32 33
 FT CONFLICT 78 78
 INTERCHAIN (BY SIMILARITY).
 POTENTIAL.
 POTENTIAL.
 POTENTIAL.
 OR -> HK (IN REF. 4).
 K -> N (IN REF. 4).

The refined 1.9 Å crystal structure of human alpha-thrombin: interaction with D-Phe-Pro-Arg chloromethylketone and significance of the Tyr-Pro-Pro-Tip insertion segment.; EMBO J. 8:3467-3475(1989).

[7]

RN X-RAY CRYSTALLOGRAPHY (2.3 ÅNGSTROMS).

RX MEDLINE; 90327074.

RA RYDEL T.J., RAVICHANDRAN K.G., TULINSKY A., BODE W., HUBER R., ROITSCH C., FENTON J.W. II.

RT "The structure of a complex of recombinant hirudin and human alpha-thrombin.;"

RL SCIENCE 249:277-280(1990).

[8]

RN X-RAY CRYSTALLOGRAPHY (2.5 ÅNGSTROMS).

RX MEDLINE; 94350942.

RA RYDEL T.J., YIN M., PADMANABHAN K.P., BLANKENSHIP D.T., CARDIN A.D., CORREA P.E., FENTON J.W. II, TULINSKY A.;

RT "Crystallographic structure of human gamma-thrombin.;"

RL J. BIOL. CHEM. 269:22000-22006(1994).

[9]

RN X-RAY CRYSTALLOGRAPHY (2.3 ÅNGSTROMS).

RX MEDLINE; 97357286.

RA VAN DE LOCHT A., BODE W., HUBER R., LE BONNIEC B.F., STONE S.R., ESMON C.T., STUBBS M.T.;

RT "The thrombin E192Q-BPTI complex reveals gross structural rearrangements: implications for the interaction with antithrombin and thrombomodulin.;"

RL EMBO J. 16:2977-2984(1997).

[10]

RN VARIANT BARCELONA.

RX MEDLINE; 87033739.

RA RABET M.-J., FURIE B.C., FURIE B.;

RT "Molecular defect of prothrombin Barcelona. Substitution of cysteine for arginine at residue 273.;"

RL J. BIOL. CHEM. 261:15045-15048(1986).

[11]

RN VARIANT FRANKFURT.

RX MEDLINE; 95313001.

RA DEGEN S.J.F., MCDOWELL S.A., SPARKS L.M., SCHARRER I.;

RT "Prothrombin Frankfurt: a dysfunctional prothrombin characterized by substitution of Glu-466 by Ala.;"

RL THROMB. HAEMOST. 73:203-209(1995).

[12]

RN VARIANTS HIMI-1 AND HIMI-2.

RX MEDLINE; 93043342.

RA MORISHITA E., SAITO M., KUMABASHIRI I., ASAKURA H., MATSUDA T., YAMAGUCHI K.;

RT "Prothrombin Himi: a compound heterozygote for two dysfunctional prothrombin molecules (Met-337-->Thr and Arg-388-->His).;"

RL BLOOD 80:2275-2280(1992).

[13]

RN VARIANT PADUA-1.

RX MEDLINE; 95169898.

RA JAMES H.L., KIM D.J., ZHENG D.-Q., GIROLAMI A.;

RT "Prothrombin Padua I: incomplete activation due to an amino acid substitution at a factor Xa cleavage site.;"

RL BLOOD COAGUL. FIBRINOLYSIS 5:841-844(1994).

[14]

RN VARIANT QUICK-1.

RX MEDLINE; 89207504.

RA HENRIKSEN R.A., MANN K.G.;

RT "Identification of the primary structural defect in the dysfibrinogen Quick I: substitution of cysteine for arginine-382.;"

RL BIOCHEMISTRY 27:9160-9165(1988).

[15]

RN VARIANT QUICK-2.

RX MEDLINE; 89247398.

RA HENRIKSEN R.A., MANN K.G.;

RT "Substitution of valine for glycine-558 in the congenital dysfibrinogen Quick II alters primary substrate specificity.;"

RL BIOCHEMISTRY 28:2078-2082(1989).

[16]

RN VARIANT SALAKTA.

RX MEDLINE; 89247398.

RA HENRIKSEN R.A., MANN K.G.;

RT "Substitution of valine for glycine-558 in the congenital dysfibrinogen Quick II alters primary substrate specificity.;"

RL BIOCHEMISTRY 28:2078-2082(1989).

[17]

RN VARIANT SALAKTA.

RX MEDLINE; 89247398.

RA HENRIKSEN R.A., MANN K.G.;

RT "Substitution of valine for glycine-558 in the congenital dysfibrinogen Quick II alters primary substrate specificity.;"

RL BIOCHEMISTRY 28:2078-2082(1989).

[18]

RN VARIANT SALAKTA.

RX MEDLINE; 89247398.

RA HENRIKSEN R.A., MANN K.G.;

RT "Substitution of valine for glycine-558 in the congenital dysfibrinogen Quick II alters primary substrate specificity.;"

RL BIOCHEMISTRY 28:2078-2082(1989).

[19]

RN VARIANT SALAKTA.

RX MEDLINE; 89247398.

RA HENRIKSEN R.A., MANN K.G.;

RT "Substitution of valine for glycine-558 in the congenital dysfibrinogen Quick II alters primary substrate specificity.;"

RL BIOCHEMISTRY 28:2078-2082(1989).

[20]

RN VARIANT SALAKTA.

RX MEDLINE; 89247398.

RA HENRIKSEN R.A., MANN K.G.;

RT "Substitution of valine for glycine-558 in the congenital dysfibrinogen Quick II alters primary substrate specificity.;"

RL BIOCHEMISTRY 28:2078-2082(1989).

[21]

RN VARIANT SALAKTA.

RX MEDLINE; 89247398.

RA HENRIKSEN R.A., MANN K.G.;

RT "Substitution of valine for glycine-558 in the congenital dysfibrinogen Quick II alters primary substrate specificity.;"

RL BIOCHEMISTRY 28:2078-2082(1989).

[22]

RN VARIANT SALAKTA.

RX MEDLINE; 89247398.

RA HENRIKSEN R.A., MANN K.G.;

RT "Substitution of valine for glycine-558 in the congenital dysfibrinogen Quick II alters primary substrate specificity.;"

RL BIOCHEMISTRY 28:2078-2082(1989).

[23]

RN VARIANT SALAKTA.

RX MEDLINE; 89247398.

RA HENRIKSEN R.A., MANN K.G.;

RT "Substitution of valine for glycine-558 in the congenital dysfibrinogen Quick II alters primary substrate specificity.;"

RL BIOCHEMISTRY 28:2078-2082(1989).

[24]

RN VARIANT SALAKTA.

RX MEDLINE; 89247398.

RA HENRIKSEN R.A., MANN K.G.;

RT "Substitution of valine for glycine-558 in the congenital dysfibrinogen Quick II alters primary substrate specificity.;"

RL BIOCHEMISTRY 28:2078-2082(1989).

[25]

RN VARIANT SALAKTA.

RX MEDLINE; 89247398.

RA HENRIKSEN R.A., MANN K.G.;

RT "Substitution of valine for glycine-558 in the congenital dysfibrinogen Quick II alters primary substrate specificity.;"

RL BIOCHEMISTRY 28:2078-2082(1989).

[26]

RN VARIANT SALAKTA.

RX MEDLINE; 89247398.

RA HENRIKSEN R.A., MANN K.G.;

RT "Substitution of valine for glycine-558 in the congenital dysfibrinogen Quick II alters primary substrate specificity.;"

RL BIOCHEMISTRY 28:2078-2082(1989).

[27]

RN VARIANT SALAKTA.

RX MEDLINE; 89247398.

RA HENRIKSEN R.A., MANN K.G.;

RT "Substitution of valine for glycine-558 in the congenital dysfibrinogen Quick II alters primary substrate specificity.;"

RL BIOCHEMISTRY 28:2078-2082(1989).

[28]

RN VARIANT SALAKTA.

RX MEDLINE; 89247398.

RA HENRIKSEN R.A., MANN K.G.;

RT "Substitution of valine for glycine-558 in the congenital dysfibrinogen Quick II alters primary substrate specificity.;"

RL BIOCHEMISTRY 28:2078-2082(1989).

[29]

RN VARIANT SALAKTA.

RX MEDLINE; 89247398.

RA HENRIKSEN R.A., MANN K.G.;

RT "Substitution of valine for glycine-558 in the congenital dysfibrinogen Quick II alters primary substrate specificity.;"

RL BIOCHEMISTRY 28:2078-2082(1989).

[30]

RN VARIANT SALAKTA.

RX MEDLINE; 89247398.

RA HENRIKSEN R.A., MANN K.G.;

RT "Substitution of valine for glycine-558 in the congenital dysfibrinogen Quick II alters primary substrate specificity.;"

RL BIOCHEMISTRY 28:2078-2082(1989).

[31]

RN VARIANT SALAKTA.

RX MEDLINE; 89247398.

RA HENRIKSEN R.A., MANN K.G.;

RT "Substitution of valine for glycine-558 in the congenital dysfibrinogen Quick II alters primary substrate specificity.;"

RL BIOCHEMISTRY 28:2078-2082(1989).

[32]

RN VARIANT SALAKTA.

RX MEDLINE; 89247398.

RA HENRIKSEN R.A., MANN K.G.;

RT "Substitution of valine for glycine-558 in the congenital dysfibrinogen Quick II alters primary substrate specificity.;"

RL BIOCHEMISTRY 28:2078-2082(1989).

[33]

RN VARIANT SALAKTA.

RX MEDLINE; 89247398.

RA HENRIKSEN R.A., MANN K.G.;

RT "Substitution of valine for glycine-558 in the congenital dysfibrinogen Quick II alters primary substrate specificity.;"

RL BIOCHEMISTRY 28:2078-2082(1989).

[34]

RN VARIANT SALAKTA.

RX MEDLINE; 89247398.

RA HENRIKSEN R.A., MANN K.G.;

RT "Substitution of valine for glycine-558 in the congenital dysfibrinogen Quick II alters primary substrate specificity.;"

RL BIOCHEMISTRY 28:2078-2082(1989).

[35]

RN VARIANT SALAKTA.

RX MEDLINE; 89247398.

RA HENRIKSEN R.A., MANN K.G.;

RT "Substitution of valine for glycine-558 in the congenital dysfibrinogen Quick II alters primary substrate specificity.;"

RL BIOCHEMISTRY 28:2078-2082(1989).

[36]

RN VARIANT SALAKTA.

RX MEDLINE; 89247398.

RA HENRIKSEN R.A., MANN K.G.;

RT "Substitution of valine for glycine-558 in the congenital dysfibrinogen Quick II alters primary substrate specificity.;"

RL BIOCHEMISTRY 28:2078-2082(1989).

[37]

RN VARIANT SALAKTA.

RX MEDLINE; 89247398.

RA HENRIKSEN R.A., MANN K.G.;

RT "Substitution of valine for glycine-558 in the congenital dysfibrinogen Quick II alters primary substrate specificity.;"

RL BIOCHEMISTRY 28:2078-2082(1989).

[38]

RN VARIANT SALAKTA.

RX MEDLINE; 89247398.

RA HENRIKSEN R.A., MANN K.G.;

RT "Substitution of valine for glycine-558 in the congenital dysfibrinogen Quick II alters primary substrate specificity.;"

RL BIOCHEMISTRY 28:2078-2082(1989).

[39]

RN VARIANT SALAKTA.

RX MEDLINE; 89247398.

RA HENRIKSEN R.A., MANN K.G.;

RT "Sub

RX MEDLINE: 92378975.
 RA MIYATA T., ARUGA R., UMEYAMA H., BEZEAUD A., GUILLIN M.-C.,
 RA IWANAGA S.;
 RT "Prothrombin Salakta: substitution of glutamic acid-466 by alanine
 RL reduces the fibrinogen clotting activity and the esterase activity.";
 RN BIOCHEMISTRY 31:7457-7462(1992).
 [17]
 RP VARIANT TOKUSHIMA.
 RX MEDLINE: 87185407.
 RA MIYATA T., MORITA T., INOMOTO T., KAWAUCHI S., SHIRAKAMI A.,
 RA IWANAGA S.;
 RT "Prothrombin Tokushima, a replacement of arginine-418 by tryptophan
 RL that impairs the fibrinogen clotting activity of derived thrombin
 RN Tokushima.";
 RN BIOCHEMISTRY 26:1117-1122(1987).
 [18]
 RP VARIANT TOKUSHIMA.
 RX MEDLINE: 87101511.
 RA INOMOTO T., SHIRAKAMI A., KAWAUCHI S., SHIGEKIYO T., SAITO S.,
 RA MIYOSHI K., MORITA T., IWANAGA S.;
 RT "Prothrombin Tokushima: characterization of dysfunctional thrombin
 RL derived from a variant of human prothrombin.";
 RN BLOOD 69:565-569(1987).
 [19]
 RP VARIANT TOKUSHIMA.
 RX MEDLINE: 92256895.
 RA IWAHANA H., YOSHIMOTO K., SHIGEKIYO T., SHIRAKAMI A., SAITO S.,
 RA ITAKURA M.;
 RT "Detection of a single base substitution of the gene for prothrombin
 RL Tokushima. The application of PCR-SSCP for the genetic and molecular
 RN analysis of dysprothrombinemia.";
 RN INT. J. HEMATOL. 55:93-100(1992).
 [20]
 RP VARIANT TYPE-3.
 RX MEDLINE: 83204687.
 RA BOARD P.G., SHAW D.C.;
 RT "Determination of the amino acid substitution in human prothrombin
 RL type 3 (157 Glu leads to Lys) and the localization of a third
 RN thrombin cleavage site.";
 RN BR. J. HAEMATOL. 54:245-254(1983).
 CC -!- FUNCTION: THROMBIN, WHICH CLEAVES BONDS AFTER ARG & LYS, CONVERTS
 CC FIBRINOGEN TO FIBRIN AND ACTIVATES FACTORS V, VII, VIII, XIII,
 CC AND IN COMPLEX WITH THROMBOMODULIN, PROTEIN C.
 CC -!- SUBCELLULAR LOCATION: EXTRACELLULAR.
 CC -!- TISSUE SPECIFICITY: SYNTHESIZED IN THE LIVER; FOUND IN PLASMA.
 CC -!- RESULT FROM THE CARBOXYLATION OF GLUTAMYL RESIDUES BY A MICROSOXAL
 CC ENZYME, THE VITAMIN K-DEPENDENT CARBOXYLASE. THE MODIFIED RESIDUES
 CC ARE NECESSARY FOR THE CA-DEPENDENT INTERACTION WITH A NEGATIVELY
 CC CHARGED PHOSPHOLIPID SURFACE, WHICH IS ESSENTIAL FOR THE CONVERSION
 CC OF PROTHROMBIN TO THROMBIN.
 CC -!- DISEASE: DEFECTS IN F2 ARE THE CAUSE OF VARIOUS FORMS OF
 CC DYSPROTHROMBINEMIA.
 CC -!- PROTHROMBIN IS ACTIVATED ON THE SURFACE OF A PHOSPHOLIPID
 CC MEMBRANE THAT BINDS THE AMINO END OF PROTHROMBIN & FACTORS VA & XA
 CC IN CA-DEPENDENT INTERACTIONS; FACTOR XA REMOVES THE ACTIVATION
 CC PEPTIDE & CLEAVES THE REMAINING PART INTO LIGHT & HEAVY CHAINS.
 CC THE ACTIVATION PROCESS STARTS SLOWLY BECAUSE FACTOR V ITSELF HAS
 CC TO BE ACTIVATED BY THE INITIAL, SMALL AMOUNTS OF THROMBIN.
 CC -!- IT IS NOT KNOWN WHETHER 1 OR 2 SMALLER ACTIVATION PEPTIDES, WITH
 CC ADDITIONAL CLEAVAGE AFTER 314-ARG, ARE RELEASED IN NATURAL BLOOD
 CC CLOTTING.
 CC -!- THROMBIN CAN ITSELF CLEAVE THE AMINO TERMINAL FRAGMENT (FRAGMENT
 CC 1) OF THE PROTHROMBIN, PRIOR TO ITS ACTIVATION BY FACTOR XA.
 CC -!- THE CLEAVAGE AFTER R-198, OBSERVED IN VITRO, DOES NOT OCCUR IN
 CC PLASMA.
 CC -!- SIMILARITY: CONTAINS 2 KRINGLE REGIONS.
 CC -!- SIMILARITY: BELONGS TO PEPTIDASE FAMILY S1; ALSO KNOWN AS THE
 CC TRYPSIN FAMILY.
 CC -----
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
 CC the European Bioinformatics Institute. There are no restrictions on its

CC use by non-profit institutions as long as its content is in no way
 CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
 CC or send an email to license@isb-sib.ch).
 CC -----
 DR EMBL: M17262; G339641; -
 DR EMBL: V00595; E5121; -
 DR PIR: A00914; TBHU.
 ...
 Note: remainder of annotations omitted.
 Query Match 8.8%; Score 165; DB 1; Length 622;
 Best Local Similarity 37.7%; Pred. No. 6.12e-13;
 Matches 26; Conservative 13; Mismatches 26; Indels 4; Gaps 3;
 Db 213 CVPDRGOYQGRGLAVTTHGLPCLAWASQAQAKLSKHDFNSAVQVFNFCRNPDGDEGV 272
 QY 25 CFWDNGHLYREDQTSPPAGRLCLNWLDAQS-GLASAP-VSGAGN--HSYCNPDDEPRGP 80
 Db 273 WCYVAGKPG 281
 QY 81 WCYVSGEAG 89
 RESULT 13
 ID HGFL_HUMAN STANDARD; PRT; 711 AA.
 AC P26927;
 DT 01-AUG-1992 (REL. 23, CREATED)
 DT 01-AUG-1992 (REL. 23, LAST SEQUENCE UPDATE)
 DT 01-NOV-1995 (REL. 32, LAST ANNOTATION UPDATE)
 DE HEPATOCYTE GROWTH FACTOR-LIKE PROTEIN PRECURSOR (MACROPHAGE
 DE STIMULATORY PROTEIN) (MSP) (MACROPHAGE STIMULATING PROTEIN).
 GN MST1 OR HGFL.
 OS HOMO SAPIENS (HUMAN).
 OC EUKARYOTA; METAZOA; CHORDATA; VERTEBRATA; MAMMALIA; EUTHERIA;
 OC PRIMATES; CATARRHINI; HOMINIDAE; HOMO.
 RN [1]
 RP SEQUENCE FROM N.A.
 RC TISSUE=LIVER;
 RX MEDLINE: 92002016.
 RA HAN S., STUART L.A., FRIEZNER DEGEN S.J.;
 RT "Characterization of the DNFI52 locus on human chromosome 3:
 RT identification of a gene coding for four kringle domains with
 RT homology to hepatocyte growth factor.";
 RL BIOCHEMISTRY 30:9768-9780(1991).
 CC -!- FUNCTION: PROBABLY HAS NO PROTEOLYTIC ACTIVITY, SINCE CRUCIAL AA
 CC CHARACTERISTIC OF SERINE PROTEASES CATALYTIC SITES ARE NOT
 CC CONSERVED.
 CC -!- PTM: MAY BE CLEAVED AFTER AA 484, TO YIELD A TWO-CHAIN MOLECULE
 CC HELD TOGETHER BY DISULFIDE BONDS, OR TWO SEPARATE POLYPEPTIDES.
 CC -!- SIMILARITY: CONTAINS 4 KRINGLE REGIONS.
 CC -!- SIMILARITY: BELONGS TO PEPTIDASE FAMILY S1; ALSO KNOWN AS THE
 CC TRYPSIN FAMILY. BELONGS TO THE PLASMINOGEN SUBFAMILY.
 CC -----
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non-profit institutions as long as its content is in no way
 CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
 CC or send an email to license@isb-sib.ch).
 CC -----
 DR EMBL: M74178; G183977; -
 DR EMBL: M74179; G183979; -
 DR PIR: A40331; A40331.
 DR MIM: 142408; -
 DR PROSITE: PS00021; KRINGLE_1; 4.
 DR PROSITE: PS50070; KRINGLE_2; 4.
 DR PFAM: PF00051; kringle; 4.
 DR PFAM: PF00089; trypsin; 1.
 DR HSSP: P00763; 1SLW.
 KW KRINGLE; GLYCOPROTEIN; SERINE PROTEASE HOMOLOG; SIGNAL;
 KW POLYMORPHISM.

```

FT SIGNAL 1 31
FT CHAIN 32 711
FT DOMAIN 32 109
FT DOMAIN 110 186
FT DOMAIN 191 268
FT DOMAIN 283 361
FT DOMAIN 370 448
FT DOMAIN 484 711
FT DISULFID 56 78
FT DISULFID 60 66
FT DISULFID 110 186
FT DISULFID 131 169
FT DISULFID 157 181
FT DISULFID 191 268
FT DISULFID 194 324
FT DISULFID 212 251
FT DISULFID 240 263
FT DISULFID 283 361
FT DISULFID 304 343
FT DISULFID 332 355
FT DISULFID 370 448
FT DISULFID 391 431
FT DISULFID 419 443
FT DISULFID 468 588
FT DISULFID 507 523
FT DISULFID 602 667
FT DISULFID 632 646
FT DISULFID 657 685
FT CARBOHYD 72 72
FT CARBOHYD 296 296
FT CARBOHYD 615 615
FT VARIANT 13 13
FT VARIANT 212 212
SQ SEQUENCE 711 AA; 80379 MW; C9978F05 CRC32;

Query Match 8.8%; Score 166; DB 1; Length 711;
Best Local Similarity 32.5%; Pred. No. 3.94e-13;
Matches 27; Conservative 17; Mismatches 35; Indels 4; Gaps 4;

Db 110 CIMNGVYRGTMATYVGLPCQAWSHKFPNDHKYPTLRNGLEENFCRNPDPGGPWC 169
QY 25 CFWNDGHLRYEDQTSAPGLRCLNWLDA-QSGLASAPVSGAG-NHSCYCRNPDEDPGGPWC 82

Db 170 YTT-DPAVRF-QSCGIRKSCREA 190
QY 83 YVSGAGVPEKPCEDLRCPETT 105

RESULT 14
ID HGF_RAT STANDARD; PRT; 728 AA.
AC P17945;
DT 01-NOV-1990 (REL. 16, CREATED)
DT 01-NOV-1990 (REL. 16, LAST SEQUENCE UPDATE)
DT 15-JUL-1998 (REL. 36, LAST ANNOTATION UPDATE)
DE HEPATOCYTE GROWTH FACTOR PRECURSOR (SCATTER FACTOR) (SF)
DE (HEPATOPOEITIN A).
GN HGF
OS RATTUS NORVEGICUS (RAT).
OC EUKARYOTA; METAZOA; CHORDATA; VERTEBRATA; MAMMALIA; EUTHERIA;
OC RODENTIA; SCIUROGNATHI; MURIDAE; MURINAE; RATTUS.
RN [1]
RP SEQUENCE FROM N.A., AND PARTIAL SEQUENCE.
RC STRAIN=WISTAR; TISSUE=LIVER;
RX MEDLINE; 90222197.
RA SHIMIZU S., NAKAMURA T.;
RA SHIMIZU K., HAGIYA M., NISHIZAWA T., SEKI T., SHIMONISHI M.,
RT "Deduced primary structure of rat hepatocyte growth factor and
RT expression of the mRNA in rat tissues."
RL PROC. NATL. ACAD. SCI. U.S.A. 87:3200-3204(1990).
RN [2]
RP SEQUENCE FROM N.A.
RC STRAIN=WISTAR; TISSUE=LIVER;
RX MEDLINE; 91031482.

```

```

RA OKAJIMA A., MIYAZAWA K., KITAMURA N.;
RT "Primary structure of rat hepatocyte growth factor and induction of
RT its mRNA during liver regeneration following hepatic injury.";
RL EUR. J. BIOCHEM. 193:375-381(1990).
CC 1- FUNCTION: HGF IS A POTENT MITOGEN FOR MATURE PARENCHYMAL
CC HEPATOCYTE CELLS, SEEMS TO BE AN HEPATOTROPIC FACTOR, AND ACTS
CC AS GROWTH FACTOR FOR A BROAD SPECTRUM OF TISSUES AND CELL TYPES.
CC IT HAS NO DETECTABLE PROTEASE ACTIVITY.
CC 1- SUBUNIT: DIMER OF AN ALPHA CHAIN AND A BETA CHAIN LINKED BY A
CC DISULFIDE BOND.
CC 1- SIMILARITY: CONTAINS 4 KRINGLE REGIONS.
CC 1- SIMILARITY: BELONGS TO PEPTIDASE FAMILY S1; ALSO KNOWN AS THE
CC TRYPSIN FAMILY. BELONGS TO THE PLASINOGEN SUBFAMILY.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC -----
DR EMBL; D90102; G320767; --
DR EMBL; X54400; G56354; --
DR PIR; S13211; S13211.
DR PIR; A35644; A35644.
DR PROSITE; PS00021; KRINGLE_1; 4.
DR PROSITE; PS50070; KRINGLE_2; 4.
DR PFAM; PF00051; Kringle; 4.
DR PFAM; PF00089; trypsin; 1.
DR HSSP; P14210; 2HGF.
KW GROWTH FACTOR; KRINGLE; GLYCOPROTEIN; SERINE PROTEASE HOMOLOG;
KW SIGNAL.
FT SIGNAL 1 32 BY SIMILARITY.
FT CHAIN 33 495 HEPATOCYTE GROWTH FACTOR ALPHA CHAIN.
FT CHAIN 496 728 HEPATOCYTE GROWTH FACTOR BETA CHAIN.
FT MOD_RES 33 33 PYRROLIDONE CARBOXYLIC ACID
FT (BY SIMILARITY).
FT DOMAIN 33 128 PAP.
FT DOMAIN 129 207 KRINGLE 1.
FT DOMAIN 212 289 KRINGLE 2.
FT DOMAIN 306 384 KRINGLE 3.
FT DOMAIN 392 470 KRINGLE 4.
FT DOMAIN 496 728 SERINE PROTEASE-LIKE.
FT DISULFID 71 97 BY SIMILARITY.
FT DISULFID 75 85 BY SIMILARITY.
FT DISULFID 488 607 INTERCHAIN (BY SIMILARITY).
FT CARBOHYD 295 295 POTENTIAL.
FT CARBOHYD 403 403 POTENTIAL.
FT CARBOHYD 569 569 POTENTIAL.
FT CARBOHYD 656 656 POTENTIAL.
SQ SEQUENCE 728 AA; 82905 MW; 0285098A CRC32;

Query Match 8.8%; Score 165; DB 1; Length 728;
Best Local Similarity 31.9%; Pred. No. 6.12e-13;
Matches 30; Conservative 22; Mismatches 35; Indels 7; Gaps 5;

Db 387 SSGDCYRGNGKNYGNLSKTRSGLTCSMDKNMEDLHRHIFWEPDASKLTKNYCRNPD 446
QY 21 GSG-GCFWDNGHLRYEDQTSAPGLRCLNWLDA-QSGLASAPVSGAGNHSCYCRNPDE 75

Db 447 DAHGPWCY-TGNPLVP-WDYCPISRCEDTPTI 478
QY 76 DPRGPWCYVSGAGVPEKPCEDLRCPETT 109

RESULT 15
ID THRB_BOVIN STANDARD; PRT; 625 AA.
AC P00735;
DT 21-JUL-1986 (REL. 01, CREATED)
DT 01-APR-1990 (REL. 14, LAST SEQUENCE UPDATE)
DT 15-DEC-1998 (REL. 37, LAST ANNOTATION UPDATE)
DE PROTHROMBIN PRECURSOR (EC 3.4.21.5).

```



```
FT SITE 199 200
FT SITE 317 318
FT SITE 366 367
FT ACT_SITE 409 409
FT ACT_SITE 465 465
FT ACT_SITE 571 571
FT MOD_RES 50 50
FT MOD_RES 51 51
FT MOD_RES 58 58
FT MOD_RES 60 60
FT MOD_RES 63 63
FT MOD_RES 64 64
FT MOD_RES 69 69
FT MOD_RES 70 70
FT MOD_RES 73 73
FT MOD_RES 76 76
FT CARBOHYD 120 120
FT CARBOHYD 144 144
FT CARBOHYD 419 419
FT DISULFID 61 66
FT DISULFID 91 104
FT DISULFID 109 187
FT DISULFID 130 170
FT DISULFID 158 182
FT DISULFID 214 292
FT DISULFID 235 275
FT DISULFID 263 287
FT DISULFID 339 485
FT DISULFID 394 410
FT DISULFID 539 553
FT DISULFID 567 597
FT VARIANT 600 600
FT CONFLICT 231 231
FT CONFLICT 249 249
FT CONFLICT 288 288
FT CONFLICT 353 353
FT CONFLICT 355 355
FT CONFLICT 549 550
FT HELIX 50 52
FT HELIX 57 62
FT HELIX 68 73
FT TURN 74 75
FT HELIX 79 89
FT TURN 90 93
FT HELIX 99 103
FT TURN 106 107
FT STRAND 110 110
FT TURN 112 114
...
Note: remainder of annotations omitted.
```

CLEAVAGE (BY THROMBIN).
CLEAVAGE (BY FACTOR XA).
CLEAVAGE (BY FACTOR XA).
CHARGE RELAY SYSTEM.
CHARGE RELAY SYSTEM.
CHARGE RELAY SYSTEM.
CHARGE RELAY SYSTEM.
GAMMA-CARBOXYGLUTAMIC ACID.
GAMMA-CARBOXYGLUTAMIC ACID.
GAMMA-CARBOXYGLUTAMIC ACID.
GAMMA-CARBOXYGLUTAMIC ACID.
GAMMA-CARBOXYGLUTAMIC ACID.
GAMMA-CARBOXYGLUTAMIC ACID.
GAMMA-CARBOXYGLUTAMIC ACID.
GAMMA-CARBOXYGLUTAMIC ACID.
GAMMA-CARBOXYGLUTAMIC ACID.
GAMMA-CARBOXYGLUTAMIC ACID.
GAMMA-CARBOXYGLUTAMIC ACID.
GAMMA-CARBOXYGLUTAMIC ACID.

INTERCHAIN.

D -> N.
S -> H (IN REF. 2).
D -> H (IN REF. 2).
D -> N (IN REF. 3).
Q -> E (IN REF. 3).
E -> Q (IN REF. 3).
DN -> ND (IN REF. 3).

```
Query Match 8.7%; Score 164; DB 1; Length 625;
Best Local Similarity 36.2%; Pred. No. 9.51e-13;
Matches 25; Conservative 14; Mismatches 26; Indels 4; Gaps 4;

Db 214 CVPDRGREYRGLAVTTSGSRCLAWSSEQAALSKDQDFNPVLAENFCRNPDGDEGA 273
QY 25 CFWDNGHLYREDQTSPPAGLRLCNWLDAQS-GLASAP-VSGA-G-NHSYCRNPDEDPRGP 80
| | | | | : : : | | | | | : : : | | : : : | | : : : | | : : : | | : : : |
| | | | | : : : | | | | | : : : | | : : : | | : : : | | : : : | | : : : |
Db 274 WCYVADQPG 282
| | | | | : : :
QY 81 WCYVSGEAG 89
```

Search completed: Fri Sep 17 18:27:21 1999
Job time : 25 secs.

(TM)

Release 3.1A John F. Collins, Biocomputing Research Unit.
Copyright (c) 1993-1998 University of Edinburgh, U.K.
Distribution rights by Oxford Molecular Ltd

MPSrch_pp protein - protein database search, using Smith-Waterman algorithm

Run on: Fri Sep 17 18:27:37 1999; MasPar time 17.87 Seconds
803.257 Million cell updates/sec

Tabular output not generated.

Title: >US-09-084-491A-2

Description: (1-263) from US09084491A.pep

Perfect Score: 1883

Sequence: 1 MLLAWVQAFVSNMLLAAY.....PVDPOEGSTPLMGQAGTPGA 263

Scoring table: PAM 150

Gap 11

Searched: 179066 seqs, 54579741 residues

Post-processing: Minimum Match 0%

Listing first 45 summaries

Database: sprenb19

1:sp-archaea 2:sp-bacteria 3:sp-fungi 4:sp-human

5:sp-invertebrate 6:sp-mammal 7:sp-mhc 8:sp-organelle

9:sp-phage 10:sp-plant 11:sp-rodent 12:sp-unclassified

13:sp-vertebrate 14:sp-virus

Statistics: Mean 45.193; Variance 75.818; scale 0.596

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description	Pred. No.
1	1881	99.9	263	4	000318 PUTATIVE PROTEIN.	0.00e+00
2	193	10.2	420	13	090504 THROMBIN.	2.18e-18
3	184	9.8	704	13	090855 HEPATOCYTE GROWTH FACT	1.37e-16
4	178	9.5	716	11	P70521 HEPATOCYTE GROWTH FACT	2.09e-15
5	177	9.4	685	5	Q24488 NEUROTHROPIC RECEPTOR	3.28e-15
6	172	9.1	717	13	P70006 HEPATOCYTE GROWTH FACT	3.10e-14
7	169	9.0	728	11	Q64007 HEPATOCYTE GROWTH FACT	1.18e-13
8	168	8.9	748	11	Q61662 HEPATOCYTE GROWTH FACT	1.84e-13
9	168	8.9	806	6	Q18783 PLASMINOGEN.	1.84e-13
10	165	8.8	597	11	Q35727 FACTOR XII.	6.95e-13
11	166	8.8	711	4	Q14870 MACROPHAGE-STIMULATING	4.47e-13
12	166	8.8	711	4	Q13350 HEPATOCYTE GROWTH FACT	4.47e-13
13	161	8.6	810	4	Q15146 PLASMINOGEN PRECURSOR.	4.02e-12
14	156	8.3	334	6	Q46507 PLASMINOGEN (FRAGMENT)	3.54e-11
15	157	8.3	716	13	Q91691 GROWTH FACTOR LIVERIN	2.29e-11
16	155	8.2	567	4	Q13208 HEPATOCYTE GROWTH FACT	5.44e-11
17	151	8.0	943	4	Q01974 PROTEIN-TYROSINE KINAS	3.03e-10
18	147	7.8	385	5	Q25101 SERINE PROTEINASE.	1.66e-09
19	146	7.8	411	4	Q15844 UROKINASE-TYPE PLASMIN	2.52e-09
20	146	7.8	431	4	Q16618 UROKINASE (EC 3.4.99.2	2.52e-09

21	141	7.5	454	6	046506 APOLIPOPROTEIN A (FRAG	2.04e-08
22	141	7.5	607	13	Q91001 THROMBIN.	2.04e-08
23	142	7.5	710	13	Q91402 HEPATOCYTE GROWTH FACT	1.35e-08
24	139	7.4	323	5	P91823 T22A3.6 PROTEIN.	4.67e-08
25	129	6.9	145	6	Q28911 APOLIPOPROTEIN(A (FRAG	2.70e-06
26	130	6.9	202	13	Q09675 TISSUE-TYPE PLASMINOGE	1.81e-06
27	130	6.9	946	13	Q07153 TYROSINE KINASE RECEPT	1.81e-06
28	126	6.7	215	13	Q42341 HGF ALPHA-CHAIN (FRAGM	8.89e-06
29	124	6.6	132	4	Q16609 (APOARGC).	1.95e-05
30	124	6.6	560	4	Q14520 HGF ACTIVATOR LIKE PRO	1.95e-05
31	125	6.6	726	13	Q09078 HEPATOCYTE GROWTH FACT	1.32e-05
32	122	6.5	210	4	Q13494 HGF AGONIST/ANTAGONIST	4.25e-05
33	122	6.5	290	4	Q02935 HEPATOCYTE GROWTH FACT	4.25e-05
34	122	6.5	296	4	Q14519 COMPETITIVE HGF ANTAGO	4.25e-05
35	121	6.4	111	6	Q77688 PROTHROMBIN PRECURSOR	6.25e-05
36	118	6.3	937	4	Q01973 PROTEIN-TYROSINE KINAS	1.98e-04
37	119	6.3	2869	6	Q28398 APOLIPOPROTEIN (FRAGME	1.35e-04
38	117	6.2	806	5	Q17576 KIN-8 PROTEIN.	2.89e-04
39	115	6.1	211	11	Q55027 HEPATOCYTE GROWTH FACT	6.14e-04
40	114	6.1	714	5	Q02001 NEUROSPECIFIC RECEPTOR	8.93e-04
41	115	6.1	761	11	Q08762 PROTEASE, SERINE, 12 N	6.14e-04
42	111	5.9	412	11	Q63611 TUMOR-ASSOCIATED ANTIG	2.72e-03
43	105	5.6	458	2	P78256 CDP-DIACYLGLYCEROL--SE	2.38e-02
44	102	5.4	1074	5	Q94046 T13F2.3 PROTEIN.	6.84e-02
45	98	5.2	1003	5	Q21977 CODED FOR BY C. ELEGAN	2.70e-01

ALIGNMENTS

RESULT 1
ID O00318 PRELIMINARY; PRT; 263 AA.
AC O00318;
DT 01-JUL-1997 (TREMBLREL. 04, CREATED)
DT 01-JUL-1997 (TREMBLREL. 04, LAST SEQUENCE UPDATE)
DT 01-AUG-1998 (TREMBLREL. 07, LAST ANNOTATION UPDATE)
DE PUTATIVE PROTEIN.
OS HOMO SAPIENS (HUMAN).
OC EUKARYOTA; METAZOA; CHORDATA; VERTEBRATA; MAMMALIA; EUTHERIA; PRIMATES;
OC CATARRHINI; HOMINIDAE; HOMO.
RN [1]
RP SEQUENCE FROM N.A.
RA DU Z., SCHEET P., HARPER M.;
RL SUBMITTED (MAY-1997) TO EMBL/GENBANK/DBJ DATA BANKS.
RN [2]
RP SEQUENCE FROM N.A.
RA WATERSTON R.;
RL SUBMITTED (MAY-1997) TO EMBL/GENBANK/DBJ DATA BANKS.
DR EMBL; AC002073; G2078470; -;
SQ SEQUENCE 263 AA; 28248 MW; 220695EC CRC32;

Query Match 99.9%; Score 1881; DB 4; Length 263;
Best Local Similarity 99.6%; Pred. No. 0.00e+00;
Matches 262; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Db	1	MLLAWVQAFVSNMLLAAYGGCGFWDNGHLYREDQTSAPGLRCLNWLDAQSLASAP	60
QY	1	MLLAWVQAFVSNMLLAAYGGCGFWDNGHLYREDQTSAPGLRCLNWLDAQSLASAP	60
Db	61	VSGAGNSHCNRPDEDPGRPCWCVYSGEAGVPEKPCEDLRCPETTSQALPAFTTIEQAS	120
QY	61	VSGAGNSHCNRPDEDPGRPCWCVYSGEAGVPEKPCEDLRCPETTSQALPAFTTIEQAS	120
Db	121	EGPDADEVQVFPANALPARSEAAVQVIGISQVRNNSKEKKDLGILGYVLGTMMVI	180
QY	121	EGPDADEVQVFPANALPARSEAAVQVIGISQVRNNSKEKKDLGILGYVLGTMMVI	180
Db	181	IIATGAGIILGYSYKRGKDLKEQHDQKVCEREMORITPLSAFTNPTCEIVDEKTVVVHT	240
QY	181	IIATGAGIILGYSYKRGKDLKEQHDQKVCEREMORITPLSAFTNPTCEIVDEKTVVVHT	240
Db	241	SQTPVDPQEGTTPLMGQAGTPGA	263
QY	241	SQTPVDPQEGTTPLMGQAGTPGA	263

QY	25	CFTWNGHLHREDQTSPAPGLRCLNWLDAQSLA-S-A-PVSGAGNHSCYNRPDDEPRGPW	81
Db	438	CY 439 	
QY	82	CY 83	
RESULT	7		
ID	Q64007	PRELIMINARY; PRT; 728 AA.	
AC	Q64007;		
DT	01-NOV-1996 (TREMBLREL. 01, CREATED)		
DT	01-NOV-1996 (TREMBLREL. 01, LAST SEQUENCE UPDATE)		
DT	01-NOV-1998 (TREMBLREL. 08, LAST ANNOTATION UPDATE)		
DE	HEPATOCYTE GROWTH FACTOR.		
GN	HGF.		
OS	MUS MUSCULUS (MOUSE).		
OC	EUKARYOTA; METAZOA; CHORDATA; VERTEBRATA; MAMMALIA; EUTHERIA; RODENTIA;		
OC	SCIUROGNATHI; MURIDAE; MURINAE; MUS.		
RN	[1]		
RP	SEQUENCE FROM N.A.		
RX	MEDLINE; 94363381.		
RA	LEE C.C., KOZAK C.A., YAMADA K.M.;		
RT	"Structure, genetic mapping, and expression of the mouse Hgf/scatter		
RT	factor gene.";		
RL	CELL ADHES. COMMUN. 1:101-111(1993).		
DR	EMBL; S71816; G632774; -		
DR	MGD; MG1:96079; HGF.		
DR	PFAM; PF00051; kringle; 4.		
DR	PFAM; PF00089; trypsin; 1.		
SQ	SEQUENCE 728 AA; 82972 MW; E5876030 CRC32;		
Query Match	9.0%; Score 169; DB 11; Length 728;		
Best Local Similarity	33.7%; Pred. No. 1.18e-13;		
Matches	32; Conservative 22; Mismatches 33; Indels 8; Gaps 6;		
Db	387	SSGDCYTRNGKNTGMNLKSTRSLGTCSMDKNMDELHRHFIEPDSKLNKYCRNPDD	446
QY	21	GSG-GCFWDNGHLYREDQTSAPGLRCILNW---LDA-QSGLASAPVSGAGNHSCYNRPDE	75
Db	447	DAGHPWCY-TGNPLIP-WDYCPISRCGGDTPTTL	479
QY	76	DPRGPCVSGEAGVEPKPCEDLRCP-ETTSQAL	109
RESULT	8		
ID	Q61662	PRELIMINARY; PRT; 748 AA.	
AC	Q61662;		
DT	01-NOV-1996 (TREMBLREL. 01, CREATED)		
DT	01-NOV-1996 (TREMBLREL. 01, LAST SEQUENCE UPDATE)		
DT	01-NOV-1998 (TREMBLREL. 08, LAST ANNOTATION UPDATE)		
DE	HEPATOCYTE GROWTH FACTOR (FRAGMENT).		
GN	HGF.		
OS	MUS MUSCULUS (MOUSE).		
OC	EUKARYOTA; METAZOA; CHORDATA; VERTEBRATA; MAMMALIA; EUTHERIA; RODENTIA;		
OC	SCIUROGNATHI; MURIDAE; MURINAE; MUS.		
RN	[1]		
RP	SEQUENCE FROM N.A.		
RC	STRAIN-B6SJLF1/J; TISSUE=LIVER;		
RX	MEDLINE; 94060105.		
RA	LIU Y., MICHALOPOULOS G.K., ZARNEGAR R.;		
RT	"Molecular cloning and characterization of cDNA encoding mouse		
RT	hepatocyte growth factor.";		
RL	BIOCHIM. BIOPHYS. ACTA 1216:299-303(1993).		
DR	EMBL; X72307; G433431; -		
DR	MGD; MG1:96079; HGF.		
DR	PFAM; PF00051; kringle; 4.		
DR	PFAM; PF00089; trypsin; 1.		
FT	NON_TER	1	
SQ	SEQUENCE 748 AA; 85200 MW; 24AE0820 CRC32;		
Query Match	8.9%; Score 168; DB 11; Length 748;		
Best Local Similarity	31.9%; Pred. No. 1.84e-13;		
Matches	30; Conservative 23; Mismatches 34; Indels 7; Gaps 5;		

Db 217

```

RC TISSUE=LIVER.
RRA COX L.A., JETT C., HIXSON J.E.;
RRL SUBMITTED (OCT-1997) TO EMBL/GENBANK/DDBJ DATA BANKS.
RDR EMBL; AF029692; G2815618; -
RFT NON TER
RFS SEQUENCE 334 AA; 36791 MW; B29A3EA3 CRC32;
RFSQ

Query Match 8.38; Score 156; DB 6; Length 334;
Best Local Similarity 37.98; Pred. NO. 3.54e-11;
Matches 25; Conservative 11; Mismatches 25; Indels 5; Gaps

Ddb 5 CMFNGKRYRGKATVTVGTCQEWAAKPHSHLIFTPTTPRAGLEKXNYCRNPDGVGG 64
      | | | | | : | | | | | : | | | | | : | | | | | : | | | | |
QY 25 CFWDNGHLYREDQTSAPAGRLCLNWL--DAQSGLASAPVS-G-AG-NHSYCRNPDEPRG 79
      | | | | | : | | | | | : | | | | | : | | | | | : | | | | |
Ddb 65 PWCYTT 70
      | | | | |
QY 80 PWCYVS 85
      | | | | |

RESULT 15
ID Q91691 PRELIMINARY; PRT; 716 AA.
AC Q91691;
DT 01-NOV-1996 (TREMBLREL. 01, CREATED)
DT 01-NOV-1996 (TREMBLREL. 01, LAST SEQUENCE UPDATE)
DT 01-NOV-1998 (TREMBLREL. 08, LAST ANNOTATION UPDATE)
DE GROWTH FACTOR LIVERTINE.
OS XENOPUS LAEVIS (AFRICAN CLAWED FROG).
OC EUKARYOTA; METAZOA; CHORDATA; VERTEBRATA; AMPHIBIA; BATRACHIA; ANURA;
OC MESOBATRACHIA; PIPOIDEA; PIPIDAE; XENOPODINAE; XENOPUS.
RN [1]
RP SEQUENCE FROM N.A.
RP I ALTABA A.; THERY C.;
RRL SUBMITTED (MAY-1996) TO EMBL/GENBANK/DDBJ DATA BANKS.
DR EMBL; U57455; GI399751; -
DR PFAM; PF00051; kringie; 4.
DR PFAM; PF00089; trypsin; 1.
RFSQ SEQUENCE 716 AA; 81971 MW; 14BE3913 CRC32;

Query Match 8.38; Score 157; DB 13; Length 716;
Best Local Similarity 37.18; Pred. NO. 2.29e-11;
Matches 23; Conservative 12; Mismatches 24; Indels 3; Gaps

Ddb 377 CYHNGELYSGRVSKTKGKICRRWEEKRNDLELSLDQPLVPLEENYCRNPDSDHGPW 436
      | | | | | : | | | | | : | | | | | : | | | | | : | | | | |
QY 25 CFWDNGHLYREDQTSAPAGRLCLNWLDAQSGLA-S-A-PVSGAGNHSYCRNPDEPRGPW 81
      | | | | | : | | | | | : | | | | | : | | | | | : | | | | |
Ddb 437 CY 438
      | |
QY 82 CY 83

Search completed: Fri Sep 17 18:28:51 1999
Job time : 74 secs.

```